WO2009099597A1 - Multi-site atrial electrostimulation - Google Patents

Multi-site atrial electrostimulation Download PDF

Info

Publication number
WO2009099597A1
WO2009099597A1 PCT/US2009/000693 US2009000693W WO2009099597A1 WO 2009099597 A1 WO2009099597 A1 WO 2009099597A1 US 2009000693 W US2009000693 W US 2009000693W WO 2009099597 A1 WO2009099597 A1 WO 2009099597A1
Authority
WO
WIPO (PCT)
Prior art keywords
electrostimulation
wireless
heart
electrode assembly
electrostimulation electrode
Prior art date
Application number
PCT/US2009/000693
Other languages
French (fr)
Inventor
Roger Hastings
John A. Becker
Michael J. Pikus
Daniel M. Lafontaine
Kevin D. Edmunds
Original Assignee
Cardiac Pacemakers, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiac Pacemakers, Inc. filed Critical Cardiac Pacemakers, Inc.
Publication of WO2009099597A1 publication Critical patent/WO2009099597A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/378Electrical supply
    • A61N1/3787Electrical supply from an external energy source
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • A61N1/0565Electrode heads
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • A61N1/057Anchoring means; Means for fixing the head inside the heart
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/05Electrodes for implantation or insertion into the body, e.g. heart electrode
    • A61N1/056Transvascular endocardial electrode systems
    • A61N1/057Anchoring means; Means for fixing the head inside the heart
    • A61N1/0573Anchoring means; Means for fixing the head inside the heart chacterised by means penetrating the heart tissue, e.g. helix needle or hook
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/368Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
    • A61N1/3684Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium
    • A61N1/36842Multi-site stimulation in the same chamber
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37205Microstimulators, e.g. implantable through a cannula
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37217Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
    • A61N1/37223Circuits for electromagnetic coupling
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/37211Means for communicating with stimulators
    • A61N1/37217Means for communicating with stimulators characterised by the communication link, e.g. acoustic or tactile
    • A61N1/37223Circuits for electromagnetic coupling
    • A61N1/37229Shape or location of the implanted or external antenna
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/372Arrangements in connection with the implantation of stimulators
    • A61N1/375Constructional arrangements, e.g. casings
    • A61N1/3756Casings with electrodes thereon, e.g. leadless stimulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3621Heart stimulators for treating or preventing abnormally high heart rate
    • A61N1/3622Heart stimulators for treating or preventing abnormally high heart rate comprising two or more electrodes co-operating with different heart regions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/3621Heart stimulators for treating or preventing abnormally high heart rate
    • A61N1/3624Heart stimulators for treating or preventing abnormally high heart rate occurring in the atrium, i.e. atrial tachycardia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/18Applying electric currents by contact electrodes
    • A61N1/32Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/362Heart stimulators
    • A61N1/365Heart stimulators controlled by a physiological parameter, e.g. heart potential
    • A61N1/368Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions
    • A61N1/3684Heart stimulators controlled by a physiological parameter, e.g. heart potential comprising more than one electrode co-operating with different heart regions for stimulating the heart at multiple sites of the ventricle or the atrium

Definitions

  • Electrostimulation can be used to treat acute and chronic patient conditions, such as to elicit or inhibit heart muscle contractions, for example, using a cardiac rhythm management device.
  • Cardiac rhythm management devices can include, for example, implantable pacemakers, implantable cardiac re-synchronization therapy devices, and implantable cardioverter defibrillators, among others.
  • Cardiac rhythm management devices can be used to treat conditions such as atrial or ventricular tachycardia, atrial or ventricular fibrillation, bradycardia, and congestive heart failure, among other diseases.
  • An example of a cardiac rhythm management device can include a battery-operated electronics unit implanted under the skin, such as in the pectoral region, connected to one or more implantable flexible intravascular leads implanted using a catheter-based delivery system, such as to reach a location within a heart chamber or one or more coronary blood vessels.
  • Such leads can include one or more exposed electrodes to directly electrostimulate cardiac tissue, or to sense potentials at the tissue (e.g., for sensing intrinsic cardiac activity, or sensing an evoked response to the application of electrostimulus).
  • Tissue growth can encapsulate the electrode. This can reduce a required electrostimulus threshold energy to achieve a desired response, but can also present a challenge if lead re-positioning or removal is needed. This may preclude using multiple leads in certain locations. Epicardial electrostimulus locations can also be used, such as when acute pacing therapy is desired and pericardial cavity access is available.
  • Atrial electrostimulation e.g., pacing, or one or more other forms of electrical stimulation
  • electrostimulation can be used to depolarize tissue near one or more wireless electrostimulation electrode assemblies (e.g., including one or more electrodes that are not "tethered” by an intravascular leadwire to a CRM device electronics unit), such as to disrupt a "circus" depolarization wavefront, such as to terminate a tachyarrhythmia.
  • electrostimulation can be used to spatially coordinate or resynchronize contractions within or between the left and right atria, hi certain examples, this can help improve atrial hemodynamics or reduce the risk of stroke, such as due to a blood clot (e.g., a thrombus) forming in stagnant blood in one or more heart chambers.
  • a blood clot e.g., a thrombus
  • Example 1 describes an apparatus.
  • the apparatus can include a first wireless electrostimulation electrode assembly including an electrostimulation circuit, a wireless receiver configured to receive wireless energy and configured to provide at least some of the received wireless energy to the electrostimulation circuit, a first expandable support mechanically coupled to the electrostimulation circuit and the wireless receiver and configured to conform to, and at least partially encircle, a ring formed by an annulus of a mitral valve of a heart.
  • the electrostimulation circuit can be configured to deliver at least some of the received wireless energy as an electrostimulation to the heart
  • the first wireless electrostimulation electrode assembly can be configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart
  • the first wireless electrostimulation electrode assembly can be configured to fit entirely within the heart.
  • Example 2 the wireless energy of Example 1 optionally includes magnetically-coupled energy, and the wireless receiver can be optionally configured to receive the magnetically-coupled energy.
  • Example 3 the apparatus of any one or more of Examples 1-2 optionally includes a transmitter configured to provide the magnetically-coupled energy, and the transmitter is optionally sized and shaped to be located subcutaneously within a patient, or outside a patient body.
  • Example 4 the electrostimulation circuit of any one or more of
  • Examples 1-3 can be optionally configured to deliver an electrostimulation including enough of the received wireless energy to depolarize cardiac tissue near the wireless electrostimulation electrode assembly.
  • the first expandable support of any one or more of Examples 1-4 optionally includes a shape memory material configured to provide an expansion force, and the first expandable support can be optionally configured to anchor the first wireless electrostimulation electrode assembly at the implant location at the annulus of the mitral valve at least in part using the expansion force when the first wireless electrostimulation electrode assembly is delivered to the implant location.
  • the first wireless electrostimulation electrode assembly of any one or more of Examples 1-5 optionally includes one or more extending tines configured to controllably extend into tissue when the first wireless electrostimulation electrode assembly is delivered to the implant location at the annulus of the mitral valve of the heart.
  • the apparatus of any one or more of Examples 1-6 optionally includes a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a blood vessel and configured to provide an electrostimulation to the heart near the blood vessel, and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
  • Example 8 the blood vessel of any one or more of Examples 1-7 can be optionally selected from a list including a pulmonary vein, a coronary sinus, or a vena cava.
  • Example 9 the apparatus of any one or more of Examples 1-8 optionally includes a second electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart, and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
  • a second electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart
  • a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
  • the atrial appendage of the heart of any one or more of Examples 1-9 can optionally be a left atrial appendage
  • the second electrostimulation electrode assembly optionally includes a second expandable support configured to at least partially block the opening to the left atrial appendage of the heart
  • the second expandable support can be optionally configured to anchor the second electrostimulation electrode assembly at the opening of the left atrial appendage when the second expandable support is expanded.
  • Example 11 the apparatus of any one or more of Examples 1-10 optionally includes a plurality of separate wireless electrostimulation electrode assemblies, each optionally configured to be intravascularly delivered to a respective implant location and each configured to provide an electrostimulation to the heart at the respective implant location, a controller communicatively coupled to the plurality of separate wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location, and the plurality of separate wireless electrostimulation electrode assemblies optionally including the first wireless electrostimulation electrode assembly.
  • the plurality of separate wireless electrostimulation electrode assemblies of any one or more of Examples 1-11 optionally includes one or more wireless electrostimulation electrode assemblies selected from a list including a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial septum of the heart and configured to provide an electrostimulation to the heart, a third wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart, a fourth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a pulmonary vein and configured to provide an electrostimulation to the heart, a fifth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a vena cava and configured to provide an electrostimulation to the heart, a sixth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a coronary sinus and configured to provide an electrostimulation the
  • the controller can be communicatively coupled to each corresponding wireless electrostimulation electrode assembly and the controller can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location by each respective wireless electrostimulation electrode assembly.
  • the controller of any one or more of Examples 1-12 optionally includes an arrhythmia detector configured to detect an arrhythmia, and the controller can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia in response to information provided by the arrhythmia detector.
  • the arrhythmia of any one or more of Examples 1-13 can optionally include an atrial tachyarrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
  • an atrial tachyarrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
  • Example 15 the controller of any one or more of Examples 1-14 can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia without exceeding a pain threshold of a patient.
  • Example 16 describes a method. In this example, the method includes receiving wireless energy using a first wireless electrostimulation electrode assembly, delivering at least some of the received wireless energy as an electrostimulation to a heart, mechanically supporting the first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of the heart, wherein the first wireless electrostimulation electrode assembly can be configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart, and the first wireless electrostimulation electrode assembly can be configured to fit entirely within the heart.
  • Example 17 the method of Example 16 optionally includes receiving wireless energy using a plurality of separate wireless electrostimulation electrode assemblies, the plurality optionally including the first wireless electrostimulation electrode assembly, and the plurality of separate wireless electrostimulation electrode assemblies can each be optionally configured to be intravascularly delivered to a respective implant location, delivering one or more coordinated electrostimulations to the heart at the respective implant location using at least one of the plurality of electrostimulation electrode assemblies and using at least some of the received wireless energy.
  • Example 18 the method of any one or more of Examples 16-17 optionally includes detecting an arrhythmia, terminating the detected arrhythmia using the delivering one or more coordinated electrostimulations and using information provided by the detecting the arrhythmia, the delivering one or more coordinated electrostimulations optionally includes delivering enough received wireless energy to depolarize cardiac tissue at each respective implant location where the one or more coordinate electrostimulations are delivered.
  • Example 19 the detecting the arrhythmia of any one or more of Examples 16-18 optionally includes detecting an atrial arrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
  • Example 20 the terminating the arrhythmia using the delivering the one or more coordinated electrostimulations of any one or more of Examples 16- 19 optionally includes depolarizing enough cardiac tissue to terminate the arrhythmia without exceeding a pain threshold of a patient.
  • FIG. 1 illustrates generally an example of an apparatus including a wireless electrostimulation electrode assembly at a mitral valve annulus location.
  • FIG. 2 illustrates generally an example of a schematic of a controller, transmitter, and a wireless electrostimulation electrode assembly.
  • FIG. 3 illustrates generally an example of an apparatus including a plurality of wireless electrostimulation electrode assemblies at respective implant locations within a heart and within respective blood vessels.
  • FIGS. 4A-D illustrate generally section views of an example of a system including a delivery catheter, actuator, and a wireless electrostimulation electrode assembly including an expandable mechanical support.
  • FIG. 5A-B illustrate generally examples of a wireless electrostimulation electrode assembly at a mitral valve annulus location.
  • FIGS. 6A-B illustrates generally section views of an example of a system including a delivery catheter, and a wireless electrostimulation electrode assembly including an expandable mechanical support and multiple extending tines.
  • FIG. 7 illustrates generally an example of a system including a delivery catheter, actuator, inflation balloon, and wireless electrostimulation electrode assembly.
  • FIG. 8 illustrates generally an example of an apparatus including an external device including a transmitter and a controller, and multiple wireless electrostimulation electrode assemblies.
  • FIG. 9 illustrates generally an example of an apparatus including an implantable device including a subcutaneous transmitter and a controller, and multiple wireless electrostimulation electrode assemblies.
  • FIG. 10 illustrates generally an example of a wireless electrostimulation electrode assembly including a loop-shaped mechanical support coupled to one or more mechanical struts, the mechanical struts at least partially encircling and supported by a mitral valve annulus.
  • FIG. 11 illustrates generally an example of a method including receiving wireless energy and delivering at least a portion of the received wireless energy as an electrostimulation to a heart.
  • FIG. 12 illustrates generally an example of a method including receiving wireless energy, detecting an arrhythmia, and delivering at least a portion of the received wireless energy as an electrostimulation to a heart in order to terminate the arrhythmia.
  • FIGS. 13 A-B illustrate generally examples of a stent- like wireless electrostimulation electrode assembly.
  • FIG. 14 illustrates generally a section view of at least a portion of a wireless electrostimulation electrode assembly.
  • Atrial tachyarrhythmias can be uni-focal, multi-focal, or unfocused. They can originate in a left or right atrium, or elsewhere, involving one or more conduction pathways through atrial heart tissue.
  • a uni-focal atrial tachyarrhythmia can involve an ectopic focus in the atrium, and can result in a "circus" depolarization wavefront, such as within one or both atria.
  • a multifocal atrial tachyarrhythmia can involve multiple ectopic foci in one or both atria, and can result in multiple "circus" wavefronts.
  • coordinated electrostimulation can be delivered to multiple atrial wireless electrostimulation electrode implant locations, such as to depolarize cardiac tissue to disrupt the one or more "circus" wavefronts to terminate the arrhythmia, whether uni-focal or multi-focal.
  • atrioventricular tachyarrhythmias such as AV nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia (AVRT), or atrial flutter, may be terminated or regulated (e.g., controlled by high-rate pacing, or one or more other electrostimulations).
  • the likelihood of disrupting a pathway used by a reentrant depolarization (and thus terminating the arrhythmia) can increase as the energy used for electrostimulation increases or as the number of electrostimulation sites increases.
  • the present inventors have recognized, among other things, that providing at least one electrostimulation electrode assembly in the left atrium (e.g., such as anchored to a mitral valve annulus) can increase the likelihood of converting a tachyarrhythmia as compared to using only a single unipolar or bipolar electrode assembly in the right atrium (such as provided by a pacemaker using a "tethered" intravascular lead system). More electrostimulation sites can more readily disrupt the one or more conduction pathways followed by a reentrant depolarization waveform, since such pathways are more likely to be near one of the multiple electrostimulation sites.
  • the present inventors have recognized, among other things, that using a plurality of electrostimulation electrodes dispersed at various locations about the left or right atria, or both, can help increase the likelihood of inhibiting, preventing, regulating, or terminating an SVT, and may enable pain-free cardioversion of SVTs.
  • Such cardioversion might be pain free by keeping the energy delivered to each electrostimulation location below a pain threshold of a patient while still achieving a sufficient electric field intensity across a region of cardiac tissue to cause a depolarization throughout the region, in bulk.
  • ablation or other surgical procedures can be performed, such as to reduce an occurrence of or eliminate one or more atrial arrhythmias.
  • such surgeries can permanently impair conduction through regions that have been incised or ablated.
  • certain patients can have damaged conduction paths within one or both atria, such as due to scarring around or within tissue that has experienced a previous myocardial infarction.
  • the present inventors have recognized, among other things, that the one or more electrostimulation electrode assemblies can be used to provide one or more atrial pacing therapies such as bradyarrhythmia therapy or atrial resynchronization therapy.
  • Such resynchronization therapy can include delivering one or more electrostimulations to multiple sites in the left or right atrium, or both, simultaneously or nearly simultaneously to spatially coordinate the depolarization such as to provide a more uniform depolarization wavefront.
  • a uniform depolarization can disrupt, inhibit, or prevent one or more "circus” or reentrant wavefronts, thereby reducing a likelihood of atrial tachyarrhythmia (e.g., inhibiting or preventing an arrhythmia from developing).
  • Such pacing therapies can be called "atrial resynchronization therapy," and can improve or restore more normal atrial conduction and contractile behavior for patients with one or more damaged conduction pathways. This can help improve atrial hemodynamics (e.g., improving atrial fill, reducing a risk of clotting due to stagnant blood in the left atrium, etc.).
  • Wireless electrostimulation assemblies can eliminate the need for the wired connection between the pulse generator assembly and an electrode assembly at a pacing site.
  • pacing energy can be wirelessly supplied to the site from a tiny rechargeable battery located in the body of the wireless pacing electrode. This can enable an autonomous pacing assembly, but size considerations can result in frequent (e.g., daily) battery recharge, such as via wireless magnetic induction.
  • the present apparatus can provide electrostimulation at patient implant locations where using intravascular lead-wires is problematic, or to electrostimulate at multiple sites that are separate and distinct from the location of a controller that transmits wireless energy to wireless electrostimulation apparatuses at the sites.
  • MRI magnetic resonance imaging
  • the present wireless electrostimulation apparatus can, in certain examples, also improve the range of wireless coupling, such as for wireless power transmission, or for wireless communication of information.
  • range can be several centimeters for electrostimulation applications. This can involve using one or more inductor core materials having lower relative magnetic permeability than ferrite or using a tuned receiver design, or both.
  • multiple wireless electrostimulation electrode assemblies can wirelessly receive energy used for electrostimulations from a common transmitter of magnetically-coupled energy (e.g., an inductive transmitter) with limited loss in efficiency as compared to using a single wireless electrostimulation assembly.
  • the wireless electrostimulation power transmitter can be located either subcutaneously within the patient, or included as part of an external device, such as a hospital bed, operating table, hand-held device, physician programmer, hat or clothing, or in one or more other locations.
  • an external device such as a hospital bed, operating table, hand-held device, physician programmer, hat or clothing, or in one or more other locations.
  • explanting the controller/transmitter unit can permit replacing a battery in the controller/transmitter, without explanting the separate wireless electrostimulation electrode assemblies.
  • Enhanced efficiency of wireless coupling of electrostimulation energy such as from resonant coupling between the controller/transmitter and the one or more receiving wireless electrostimulation assemblies can increase the time between rechargings or battery replacements.
  • distance between the controller/transmitter and the one or more receiving wireless electrostimulation electrode assemblies can be increased, such as using resonant coupling to transmit electrostimulation energy therebetween.
  • the wireless electrostimulation electrode assemblies can be implanted at or near a cardiac location (e.g., such as within one or more blood vessels, or entirely within a heart chamber), and can include an expandable inductive loop antenna.
  • the expandable loop can be initially collapsed, folded, or compressed, such as to allow easier implant (such as via a delivery catheter through an intravascular route), and then unfolded, expanded, opened, or uncompressed to achieve a larger loop area, and hence greater coupling to the inductive transmit antenna.
  • an inductive transmit antenna can be incorporated into a cardiac lead system, and can be configured to expand, unfold, or open when implanted at a desired location, such as in the right side of the heart (e.g., in the right atrium or the right ventricle at or near a location accessible by a pacemaker or defibrillator intravascular lead).
  • a wireless electrostimulation electrode assembly can be configured to be implanted in a heart at a mitral valve annulus.
  • the wireless electrostimulation electrode assemblies can include one or more electrode assemblies including an expandable mechanical support and an electrostimulation circuit.
  • the expandable mechanical support can be sized and shaped to anchor an associated wireless electrostimulation electrode assembly in a blood vessel, such as a pulmonary vein, a vena cava (inferior or superior), a coronary sinus, or one or more other blood vessels.
  • FIG. 1 illustrates generally an example of a sectional view of a heart 102, showing an example of a wireless electrostimulation apparatus 100 including a wireless electrostimulation electrode assembly 110 implanted within the heart 102 at a mitral valve annulus, where an anterior leaflet 178 A and a posterior leaflet 178B terminate in the left atrium 174.
  • the wireless electrostimulation electrode assembly 110 can include an electrostimulation circuit 140 electrically connected to one or more electrically conductive electrodes, such as a first electrode 150 and a second electrode 160 located at or near cardiac tissue of the heart 102 to electrostimulate the tissue.
  • the first electrode 150 can be an anode and the second electrode 160 can be a cathode, such as to form a closed electrostimulation circuit conductively coupled to cardiac tissue
  • one or more forms of wireless energy can be provided, such as wireless energy from a location within the heart 114 A, or wireless energy from a location outside the heart 114B, and at least some of the wireless energy 114A-B can be received by the electrostimulation assembly 1 10.
  • at least some of the wireless energy 114A-B can be provided as an electrostimulation to the heart 102, such as using the first electrode 150 and the second electrode 160, and the electrostimulation circuit 140.
  • the wireless energy from a location within the heart 114A can be provided by one or more other implantable assemblies contained entirely within the heart, such as a battery-operated controller and transmitter.
  • the wireless energy from a location within the heart 114A can be provided by a transmitter located on a cardiac rhythm management device lead system, such as located within a right atrium 170, a right ventricle 172, a location within a left ventricle 176, a coronary sinus near the left ventricle 176, or from one or more other locations.
  • the wireless energy from a location outside the heart 114B can be provided from a subcutaneous location, such as from a subcutaneous lead system or transmitter attached to or part of a cardiac rhythm management device, or provided by a transmitter located outside the patient body, or from one or more other locations.
  • the wireless energy from a location within the heart 114A or from a location outside the heart 114B can include acoustic energy (e.g., ultrasonic energy), optical energy, electromagnetic energy (e.g., electric field energy, magnetic field energy, or an electromagnetic wave), or one or more other forms of energy.
  • a body of the wireless electrostimulation electrode assembly 110 can include an expandable mechanical support that is sized, shaped, or otherwise configured to anchor the assembly 110 at the mitral valve annulus.
  • FIG. 2 illustrates generally an example of a schematic of a wireless electrostimulation apparatus 200 including a controller / transmitter 220, and a wireless electrostimulation electrode assembly 210.
  • the example in FIG. 2 shows a controller / transmitter 220 that can include a battery 226, a voltage regulator 225, and a microprocessor 224.
  • the microprocessor 224 comprises an input-output (I/O).
  • a switch 228 can be coupled to the microprocessor 224 using the input-output, such as to control current flow from the battery 226 or an optional energy storage device such as a capacitor 227 to an inductive antenna 206.
  • the inductive antenna can include a wire loop inductor 208.
  • the inductive antenna 206 can include multiple wire loops, at least some of which can be configured to be offset from each other or otherwise configured or arranged to generate two or more magnetic fields that can be spatially orthogonal to one another, such as to reduce orientation sensitivity of wireless energy transmission or wireless information communication using the inductive antenna 206.
  • a tuning element 229 can be included, such as to allow a range of frequencies to be selected at which magnetically-coupled energy 214 will be generated by the inductive antenna 206.
  • the resulting inductance-capacitance (LC) circuit can form a resonant "tank" circuit, which can have an operable range of resonant frequencies selected from a range of 300 KHz to 10 MHz, but selected below the self-resonant frequency of the inductor 208 comprising the inductive antenna 206.
  • the tuning element 229 can include, but are not restricted to, a capacitor, a variable-capacitance diode (e.g., "varicap” diode), an active circuit modeling a capacitor of a selected value, or the like.
  • the switch 228 and the tuning element 229 can be replaced, such as by a combination of a voltage-controlled oscillator and power amplifier coupled to directly drive the inductive antenna 206, such as to generate the magnetically- coupled energy 214 at a specified range of frequencies.
  • the switch 228 can be implemented either mechanically, such as using a microminiature relay, or as solid-state device (e.g., FET, BJT, IGBT, SCR, thyristor, or the like).
  • the regulator 225, the microprocessor 224, the sensing circuit 223, and the switch 228 can be co-integrated in a single integrated circuit or multi-chip module package.
  • the "microprocessor” can include, among other things, a microcontroller including one or more of a volatile or non- volatile memory, multiple input/output channels, an analog-to-digital converter, a power supply, a digital-to-analog converter, or one or more other circuits, modules, or components that, in an example, can be co-integrated in a single integrated circuit, a single circuit package, a multi-chip module package, a hybrid, a polyimide flex-circuit assembly, or the like.
  • the initiation, timing, duration, or frequency range of the magnetically-coupled energy 214 can be controlled by the microprocessor 224, which can be provided with input from a sensing circuit 223.
  • the sensing circuit 223 can be coupled to one or more electrodes 204A, 204B in contact with tissue, or implanted subcutaneously, such as within or near cardiac tissue 202A.
  • the wireless energy transmission source can be external to the body, and the electrodes 204A, 204B can be coupled to the skin of the patient (e.g., to measure an electrocardiogram).
  • the controller / transmitter 220 can be included in an implantable cardiac rhythm management device that can include one or more sense electrodes 222A, 222B coupled to the sensing circuit.
  • the one or more of the sense electrodes 222 A, 222B can be disposed on the housing of the controller / transmitter 220.
  • the controller / transmitter 220 can include an arrhythmia detector (such as using the microprocessor 224) configured to use information provided by the one or more sense electrodes 222A, 222B or other sensing information, such as to detect an arrhythmia.
  • such information can be used to control one or more wireless electrostimulation electrode assemblies 210, such as to provide coordinated electrostimulation to inhibit, terminate, or regulate the detected arrhythmia.
  • the magnetically-coupled energy 214 can be generated for either (or both) transferring the operating or electrostimulation energy 214A to the wireless electrostimulation electrode assembly 210, or information communication 214B with the wireless electrostimulation electrode assembly 210.
  • a first range of frequencies can be established for wireless energy transfer, and a second range of frequencies can be established for commanding the wireless electrostimulation electrode assembly 210 to deliver an electrostimulus).
  • a filter 209 can be configured to discriminate between the operating energy 214A and the information communication 214B.
  • the filter 209 can be configured to detect a particular range of frequencies included in the communication 214B captured by the wireless electrostimulation electrode assembly 210, such as by using an inductive pickup 212.
  • the filter 209 can be coupled to stimulus control logic 216.
  • the logic 216 can be configured to inhibit or to initiate tissue electrostimulation, such as in response to the filter 209 detecting one or more specified signals.
  • the filter 209 can include, in certain examples, a bandpass filter, which can be coupled to a threshold comparator.
  • the filter 209 can include a digital demodulator.
  • communication 214B can be encoded digitally and can include (or be transmitted concurrently to) operating energy 214A being wirelessly communicated to the wireless electrostimulation electrode assembly 210.
  • Examples of digital encoding of communication 214B can include, but are not restricted to, on-off keying, amplitude-shift keying, phase-shift keying, frequency-shift keying, or the like.
  • the combined capacitance of the tuning element 229 and actual or parasitic capacitances of the inductive antenna 206 can vary when the wireless energy transmission source is implanted in or near tissue 202E.
  • the effect of tissue interaction with the system can be reduced by at least partially surrounding the inductive antenna 206 or the inductive pickup 212 with a protective material or encapsulant (e.g., silicone or one or more other encapsulating compounds).
  • Such encapsulation can inhibit or prevent tissue 202E or liquid (e.g., blood or one or more other bodily fluids) from penetrating into the cavities between individual turns of the windings of the inductive pickup 212 or the inductive antenna 206, which would otherwise increase the effective relative dielectric constant seen by the pickup 212, or the antenna 206.
  • tissue 202E or liquid e.g., blood or one or more other bodily fluids
  • the microprocessor 224 can be configured to adjust the capacitance of the tuning element 229, or to adjust the frequency of a corresponding voltage-controlled oscillator, such as to achieve a desired level of efficiency in coupling to the wireless electrostimulation electrode assembly 210.
  • a cardiac pacing electrostimulus can be applied, such as using electrodes 250 and 260, and the evoked response can be observed, such as using the sensing electrodes 205 A, 205B, the leads 222A, 222B, an external electrocardiogram sensing apparatus, or one or more other sources of physiologic information.
  • the tuning element 229 can be adjusted by the microprocessor 224, such as to vary the generated range of frequencies of magnetically-coupled energy 214, for example, until a desired or reliable "capture,” (e.g., activation of cardiac tissue resulting from electrostimulation) is observed.
  • a desired or reliable "capture” e.g., activation of cardiac tissue resulting from electrostimulation
  • the wireless electrostimulation electrode assembly 210 can include an inductive pickup 212 and an optional discrete tuning element 211.
  • the value of the capacitance of the tuning element 211 can be selected before implanting the wireless electrostimulation electrode assembly, such as to achieve a desired resonant frequency when implanted, such as when surrounded by blood or muscle tissue, hi certain examples, to reduce the size of the wireless electrostimulation electrode assembly 210, a discrete capacitor, such as used for tuning element 211, can be omitted, and the capacitance used to achieve resonance of the inductive pickup 212 can be provided by the parasitic capacitance of the physical coil structure of the inductive pickup 212 (for example, the inter-winding capacitance), or one or more other sources of distributed capacitance.
  • the magnetically-coupled energy 214A can be rectified, such as by a full-wave rectifier 213, as shown in the example in FIG. 2, or by a half- wave rectifier, which can save space by reducing the number of diode components used in the wireless electrostimulation electrode assembly 210.
  • Rectified energy can be stored in an optional capacitor 215, such as shown in the example in FIG. 2.
  • the capacitor 215 can act like a filter capacitor, such as to help suppress ripple voltage.
  • Stimulus control logic 216 can be coupled to a switch 217.
  • the switch 217 can include a solid-state device (e.g., FET, BJT, IGBT, SCR, thyristor, etc.).
  • one or more of the filter 209, the logic 216, the switch 217, or the rectifier 213, or one or more other circuits, components, or modules can be co-integrated into a single integrated circuit package, or for example, into a multi-chip module or the like similar to that described above for the controller / transmitter 220.
  • multiple storage devices 215 and switches 217 can be used, such as to arrange stored voltages in a desired series, parallel, or series- parallel combination, for example, such as to achieve an electrostimulus peak voltage in excess of the maximum voltage stored on a single capacitor 215 using operating energy 214A.
  • a direct-current (DC) blocking device 218 can be used to inhibit a DC-stimulus component from being coupled to the electrostimulus electrodes 250, 260.
  • the electrostimulus electrodes 250, 260 can be conductively coupled to the muscle tissue 202E to be electrostimulated (e.g., myocardial tissue).
  • the electrode 250 can be used as the cathode and the electrode 260 can be used as the anode.
  • the blocking device 218 and the shunt device 219 can form a high-pass network configured such that the upper cutoff frequency (or resulting time- domain pulse shape) can be selected or even programmably adjusted, such as to form or shape a desired electrostimulus waveform.
  • the blocking device 218 can be selected as a capacitor having a capacitance of about 1 microFarad
  • the shunt device 219 can be selected as an approximately 5 kiloOhm resistor, such as to achieve a desired cardiac tissue electrostimulation pacing pulse.
  • tissue and body fluid can absorb and disperse inductive energy, and that such absorption and dispersive effects can rapidly increase at frequencies greater than 100 KHz. These effects can severely limit the range and maximum achievable efficiency of typical magnetic coupling schemes.
  • One technique for decreasing such losses can be to substantially or completely surround the inductive antenna 206 or inductive pickup 212 with a high relative permeability magnetic material, such as an iron-powder core, a ferrite material, or the like. Such materials can effectively magnify the magnetically-coupled energy density experienced by a nearby winding structure, at a given incident magnetic field intensity.
  • the high relative magnetic permeability of such materials can render the resultant implantable device assemblies incompatible with magnetic resonance imaging (MRI) equipment.
  • MRI magnetic resonance imaging
  • Locally-induced forces or torques (e.g., induced in single components) associated with the strong bias field present near operating MRI equipment could result in mechanical damage to the inductive antenna 206 or the inductive pickup 212 assemblies if they incorporate a high relative magnetic permeability material.
  • MRI equipment can also induce large voltages, across the terminals of the inductive antenna 206 or the inductive pickup 212, and large currents. This can induce an internal temperature rise. This can damage (e.g., by electrical short-circuiting or dielectric failure) inductors or other components electrically coupled thereto, or can thermally damage surrounding tissue 202E.
  • one or more protection devices e.g., discharge tubes, gaps, solid-state transient-suppression devices
  • a small wireless electrostimulation electrode assembly 210 is generally desired (e.g., to allow intravascular introduction and placement) and such additional protection devices can use additional space and may not mitigate the MRI- induced forces and torques.
  • ferrite core materials can also have other limitations.
  • internal loss mechanisms can preclude using ferrite as core material for highly-tuned inductors at frequencies above a few MHz. This can prevent the resonant "tank circuit" in the inductive transmit network or inductive receiver network from achieving high power coupling efficiencies, since the quality factors ("Q") of both networks are limited by the resistive damping effects of increasing losses within the ferrite core material.
  • the core materials or mechanical supports surrounding the inductive antenna 206 or the inductive pickup 212 can include one or more materials other than ferrites, such as one or more materials having a relative magnetic permeability less than 1.1.
  • the inductive antenna 206 or the inductive pickup 212 can be surrounded by, encompassed by, or located near a material or a mechanical support having a relative magnetic permeability substantially equal to 1, such as air, one or more bodily tissues (e.g., muscle, fat, bone, etc.), or one or more bodily fluids such as blood.
  • an effective relative magnetic permeability seen by the inductive antenna 206 or the inductive pickup 212 can be substantially equal to 1, such as such as representing an inhomogeneous medium around the inductive antenna 206 or the inductive pickup 212.
  • Shape-memory Nickel-Titanium (NiTi or Nitinol) compounds are effectively non-ferromagnetic and can have other beneficial mechanical properties.
  • the shape-memory property can be used to provide self-expansion (e.g., after implant) of the loop antenna 206 or the inductive pickup 212. Increasing or maximizing the area of a loop forming an inductive antenna 206, or inductive pickup 212, can enhance the mutual coupling of two nearby such inductive devices.
  • such a shape-memory material can be used as a mechanical support, such as to provide an expansion force to expand a wound coil that is configured to be used as either an inductive transmit antenna (e.g., inductive antenna 206) or as an inductive receiver (e.g. inductive pickup 212).
  • an inductive transmit antenna e.g., inductive antenna 206
  • an inductive receiver e.g. inductive pickup 212
  • Such materials can also help mitigate ferrite efficiency loss and allow more efficient coupling of time-varying magnetic flux through tissue, such as at frequencies up to several MHz.
  • air core can be used to describe inductive transmitter 208 and inductive pickup 212 structures that do not have a ferrite core within a wound loop of such structures, even though the actual construction of such devices might include non- ferromagnetic metallic support structures and, when implanted, tissue or bodily fluid may be present within the core of the inductive transmitter 208 or inductive pickup 212.
  • a mathematical analysis of a simplified combination of the controller / transmitter 220 and wireless electrostimulation electrode assembly 210 can be used to estimate power coupling efficiency, r ⁇ , and electrostimulus output voltage magnitude,
  • the combination of the switch 228, and the battery 226 can be represented as an AC voltage source operating at angular frequency ⁇ , and peak output voltage V 0 .
  • the inductive antenna 206 can be modeled as a combination of an ideal inductor, L, 208 in series with a transmit circuit resistance R.
  • the tuning element 229 can be modeled as a capacitor, C.
  • C l/ ⁇ 2 L
  • Z R.
  • the imaginary components due to the reactances of the capacitor and inductor, can cancel each other (unity power factor).
  • the inductor 212 can be modeled as Li , and its corresponding loss as resistance "r" in series with Li .
  • the tuning element 211 can be modeled as a parallel capacitor Ci, and the tissue load 202E appearing across electrostimulus electrodes 250, 260 can be modeled as R L .
  • the total parallel impedance Z 2 r + R L / ( 1 + (G)R L C 1 ) 2 ) + i [ ⁇ Li - ⁇ R L 2 Ci / / ( 1 + ( ⁇ R L Ci) 2 ].
  • 1 + (G)R L C,) 2 R L 2 C, / L 1
  • the wireless electrostimulation electrode assembly 210 receiver resonant frequency and quality factor Qi can vary depending on the specific implant configuration of the inductive pickup 212, and the resulting tissue and blood proximity effects on the electrical response of the inductive pickup 212.
  • the controller / transmitter 220 transmitter resonant frequency can be varied, such as to compensate for changes in the wireless electrostimulation electrode assembly 210 receiver resonant frequency or to control electrostimulus amplitude or energy achieved at electrodes 250, 260.
  • the receiver can have a broader "tuning envelope" than the transmitter.
  • the transmitter tuning element 229 can be adjusted more easily (e.g., less precisely) to provide an operating frequency at resonance corresponding the resonant frequency of the receiver in the wireless electrostimulation electrode assembly 210 (e.g., the transmitter can be tuned to be more sharply "peaked” at resonance than the receiver, and transmitter resonant frequency can then be swept until centered on receiver resonant frequency).
  • varying the resonant frequency of the transmitter by changing the capacitance of the tuning element 229 can also control the magnitude of the electrostimulus voltage coupled to the tissue load 202E.
  • Selecting a value for the tuning element 229 that shifts the resonant frequency of the controller / transmitter 220 away from the resonant frequency of the wireless electrostimulation electrode assembly 210 can result in decreasing maximum voltage, I V L
  • the operating energy 214A can be limited in duration or maximum amplitude such as to avoid tissue heating or regulatory limits for average or instantaneous power transmitted through tissue.
  • the resulting rectified energy can be integrated or otherwise accumulated by, for example, the capacitor 215.
  • VJ can, for instance, be established by a series- or shunt-regulation component such as a Zener diode 230.
  • the Zener diode 230 can be used to simplify or eliminate the stimulus control logic 216 and the switch 217 when a pulse-width modulation (PWM) scheme is used at the controller / transmitter 220.
  • PWM pulse-width modulation
  • a microprocessor, state machine, timing logic, and the like can be omitted from the wireless electrostimulation electrode assembly 210 to reduce complexity, physical volume, etc.
  • the stimulus control logic 216 can still be used to inhibit electrostimulation delivery to the tissue load 202E (e.g., by opening the switch 217 when an intrinsic event is sensed), but is not required to control the level of electrostimulation energy content delivered to the tissue load 202E.
  • the operating energy 214A can be established at a specific burst duration (e.g., a burst can be a square pulse envelope commencing a sequence of multiple resonant oscillations).
  • the duration or pulse width of the burst of operating energy 214A can be related to the energy content delivered to the tissue load 202E when the diode 230 is clamping the voltage across the capacitor 215.
  • , can be achieved using a resonant frequency of 1 MHz.
  • the load capacitor can be represented effectively as a short circuit, and the AC resistance of the model cardiac tissue load 202E is equal to around 500 ohms (1 kiloOhm in parallel with 1 kiloOhm).
  • the burst duration of the operating energy 214A can be controlled by the microprocessor 224 and the switch 228 at the controller / transmitter 220 to achieve a desired energy content coupled to the tissue load 202E.
  • V CAP A theoretical voltage delivered across a cardiac tissue capacitance, V CAP , can be represented as:
  • VcAP VcLAMp [ l - e- w/ r L C L ] (4)
  • V CLAMP represents the voltage clamping threshold of the diode
  • V CAP V CAP
  • V CA P VCLAMP [W/ ⁇ LCL] for w « r L C L (5)
  • V CAP can be computed as approximately 3 Volts.
  • w can be 1250 microseconds, and V CAP can be computed as approximately 4 Volts.
  • the volume occupied by wireless electrostimulation electrode assembly 210 can be decreased by limiting the total energy stored, for example, the capacitor 215. An estimate of the desired stored energy for various electrostimulation pulses can be made.
  • a square-wave pulse of duration T 0.4 milliseconds can correspond to a stored electrostimulation energy of T
  • 2 / R L 5 microJoules.
  • the energy stored in the capacitor 215 can be represented as ⁇ A C S
  • 2 , divided by the electrostimulation energy consumed by a single electrostimulation cycle delivered to the tissue impedance T
  • 2 / RL- Thus, the number of cycles that capacitor 215 can supply can be represented as R L C S /2T.
  • the capacitor 215 value Cs, load resistance R L and, for example, pulse width can be made between the capacitor 215 value Cs, load resistance R L and, for example, pulse width, to achieve a desired wireless electrostimulation electrode assembly 210 volume and a desired electrostimulation duration, for instance, during an interval when the inductive operating energy 214A is absent or insufficient.
  • a low voltage 1.6 ⁇ F capacitor 215 can be small (e.g., sub-millimeter dimensions on each axis).
  • back-up storage can be desired for patient protection (e.g., to provide continued electrostimulation for a limited duration in the temporary absence of the operating energy 214A).
  • the size of the capacitor to store a corresponding amount of energy can be represented,
  • Cs 2THRT s t O red/RL-
  • a compromise between the capacitor 215 value Cs and the physical size of the capacitor 215 can be made.
  • 2.5 volts.
  • the capacitor 215 can also be specified to accommodate the quiescent power consumed by, for example, the stimulus control logic 216 comprising a microprocessor, which can be very small depending upon the device used, but in some cases can be comparable to, or larger than, the average pacing power.
  • the power consumed by the wireless electrostimulation electrode assembly 210 can be reduced if the stimulus control logic 216 and the filter 209 are omitted and the switch 217 is permanently closed or omitted.
  • the sensing circuitry 232 can be coupled to the cardiac tissue 202E to provide physiologic information to stimulus control logic 216 in response to sensed potentials detected by the sensing circuitry 232. Signaling to the stimulus control logic 216 by the sensing circuitry 232 can occur in response to intrinsic tissue activity (e.g., the sensing circuitry 232 establishes a threshold level or window and intrinsic activity can cause a voltage fluctuation exceeding a threshold level or window resulting in a threshold crossing signal to the stimulus control logic). The stimulus control logic 216 can inhibit electrostimulation using the switch 217 in response to, for example, detection of sensed events provided by the sensing circuitry 232.
  • a shunt device 219 can also provide charge neutralization.
  • Charge neutralization can include providing a path between the electrostimulus electrodes 250, 260 to slowly discharge an afterpotential occurring during or after an electrostimulation, resulting in a net neutral charge delivered by the electrostimulation electrodes 250, 260.
  • charge neutralization can be observed as a smaller amplitude negative-phase pulse of longer duration following the positive-phase cardiac tissue electrostimulation pulse.
  • the wireless electrostimulation electrode assembly 210 can include multiple electrostimulation output blocks electrically connected to multiple electrostimulation electrodes 250, 260.
  • one or more capacitors 215, can be coupled to one or more respective cathode electrodes 250, such as through one or more respective switches 217.
  • the one or more cathode electrodes 250 can use a commonly-shared anode electrode 260.
  • FIG. 3 illustrates generally an example of an apparatus 300 including a plurality of wireless electrostimulation electrode assemblies at respective implant locations within a heart 302 and within respective blood vessels.
  • a first wireless electrostimulation electrode assembly 310 can be located within a heart 302 at a mitral valve 378 annulus, as shown and discussed above in FIG. 1.
  • a controller / transmitter 320 can include one or more wireless couplings to one or more wireless electrostimulation electrode assemblies, such as a wireless coupling 314E to the first assembly 310.
  • the first assembly 310 can receive operating energy or communicate (e.g., control information, sensing information, a signal to initiate an electrostimulation, or one or more other forms of information) using the wireless coupling 314E.
  • one or more additional wireless electrostimulation electrode assemblies can be implanted at other locations within the heart, or within one or more blood vessels, resulting in a plurality of wireless electrostimulation electrode assemblies available to deliver one or more coordinated electrostimulations, such as to locations within a right atrium 379, a left atrium 374, or a left ventricle 376.
  • an apparatus including the plurality of wireless electrostimulation electrode assemblies can also include one or more intravascularly-introduced endocardial leads, such as to provide electrostimulation to the right ventricle 372, the right atrium 379, or one or more other locations.
  • a second wireless electrostimulation electrode assembly 315 can be located at or near an ostium of left atrial appendage 375. Such a second assembly 315 can also be used, for example, to partially or completely occlude or block the opening to the left atrial appendage 375.
  • the second assembly 315 can include an expandable mesh, or screen, or other semi-permeable or impermeable structure to prevent a blood clot or other debris within the left atrial appendage 375 from being released elsewhere into the heart 302, or vasculature (e.g., see FIG. 7).
  • a third wireless electrostimulation electrode assembly can be located at a right atrial appendage.
  • the third wireless electrostimulation electrode assembly can be configured to occlude or block the opening to the right atrial appendage.
  • one or more wireless electrostimulation electrode assemblies can be located in one or more pulmonary veins, such as a fourth wireless electrostimulation electrode assembly 31 IA located within a right pulmonary vein 379A, or a fifth wireless electrostimulation electrode assembly 31 IB located within a left pulmonary vein 379B.
  • the fourth or fifth assemblies 311 A, 311B can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314A, 314C.
  • one or more wireless electrostimulation electrode assemblies can be located in the vena cava, such as a sixth wireless electrostimulation electrode assembly 311C located in a superior vena cava 392, or a seventh wireless electrostimulation electrode assembly 31 ID located in an inferior vena cava 391.
  • the sixth or seventh assemblies 311 C, 311D can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314H, 3141.
  • a body of one or more intravascularly-introduced endocardial leads can occupy a vena cava after a sixth or seventh assembly 311 C, or 311 D is implanted, since the sixth or seventh assembly 311 C, or 31 ID can be stent-like and need not occupy a large portion of a cross section of the vena cava.
  • an eighth wireless electrostimulation electrode assembly 31 IE can be located in a coronary sinus, hi an example, the eighth assembly 31 IE can receive operating energy or communicate with the controller / transmitter 320 using a wireless coupling 314J.
  • the eighth assembly 31 IE is located within the coronary sinus as closely as possible to the ostium of the coronary sinus, such as to place one or more electrostimulation electrodes in electrical contact with a muscle sleeve portion of the coronary sinus, hi certain examples, if an ablation procedure has been performed near or around the ostium of the coronary sinus, the eighth assembly 31 IE can be used to terminate or control a reentrant arrhythmia having a focus or conduction pathway near the ostium of the coronary sinus, hi certain examples, one or more wireless electrostimulation electrode "seed" assemblies can be implanted partially or completely within the myocardium of the heart 302, such as in left atrium 374, or in the left ventricle 376 where intravascularly-introduced endocardial leads are contra- indicated, hi an example, the eighth assembly 313 can receive operating energy or communicate with the controller / transmitter 320 using a wireless coupling 314B.
  • a ninth wireless electrostimulation electrode assembly 313 can be located in the atrial septal region of the heart 302.
  • a tenth or an eleventh wireless electrostimulation electrode assembly 317A, 317B can be located partially or completely within myocardial tissue in the left ventricle 376.
  • the tenth or eleventh assemblies 317A, 317B can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314F, 314G.
  • one or more of the wireless couplings 314A- J can use magnetically-coupled energy, such as inductive coupling, between the controller / transmitter 320 and one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B to provide operating energy to, or to communicate with, the one or more wireless electrostimulation electrode assemblies 310, 311 A-E, 313, 315, 317A-B.
  • one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include circuitry or components similar to the wireless electrostimulation electrode assembly 210 shown in FIG. 2.
  • the transmitter / controller 320 can be a subcutaneous implantable medical device such as a cardiac rhythm management device.
  • the transmitter / controller 320 can include circuitry or components similar to the controller / transmitter 220 shown in FIG. 2.
  • one or more of the wireless electrostimulation electrode assemblies 310, 31 IA- E, 313, 315, 317A-B can be delivered into the heart or into the one or more blood vessels using an intravascular, transluminal route, such as through one or more delivery catheters.
  • one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include one or more expandable mechanical supports configured to fold, collapse, or contract during delivery to an implant location, allowing the one or more wireless electrostimulation electrode assemblies to pass through the lumen of a delivery catheter when the delivery catheter is passed through one or more blood vessels.
  • the wireless electrostimulation electrode assemblies 31 IA-E can be stent-like, as shown in FIG.
  • one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include multiple electrodes coupled to an electrostimulation circuit included as a portion, part or component of each of the respective assemblies 310, 31 IA-E, 313, 315, 317A-B.
  • the multiple electrodes can be multiple cathode electrodes included on a portion of the one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B.
  • the multiple cathode electrodes can be located closer to the heart 302, such as contacting the muscle sleeve near the opening or ostium of the one or more blood vessels.
  • the multiple cathode electrodes can share a common anode electrode.
  • the controller / transmitter 320 can include an arrhythmia detector 324.
  • the arrhythmia detector can detect, identify, or categorize one or more arrhythmias and can provide communication or operating energy to one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B, such as to provide one or more coordinated electrostimulations to regulate, control or terminate the arrhythmia.
  • the arrhythmia detector 324 can detect one or more arrhythmias using physiologic information, such as provided by one or more electrocardiogram sensing electrodes.
  • the arrhythmia detector 324 can include one or more timers or comparators, such as to detect a shortened QRS duration, a shortened P-wave to QRS duration, multiple P-waves or one or more other arrhythmic indications derived from information from the one or more electrocardiogram sensing electrodes, or from other physiologic sensors.
  • the arrhythmia detector can be a portion, part or component of a microprocessor, microcontroller, multi-chip module, or one or more other circuits or modules, such as shown in the controller / transmitter 220 in FIG. 2.
  • one or more conduction pathways of the heart 302 can be damaged, such as due to previous myocardial infarct, disease, or one or more other acute or chronic causes or conditions.
  • Intravascularly-introduced endocardial pacemaker or defibrillator lead systems can be incapable of use at locations near such damaged pathways.
  • intravascular leads can be contra-indicated for use at many locations where such conduction pathway damage can occur (e.g., the left heart, or within one or more blood vessels near or within the heart.)
  • the present inventors have recognized that a likelihood that an arrhythmia can be detected, prevented, or terminated can be increased when endocardially-implanted or vascularly-implanted wireless electrostimulation electrode assemblies are used since a greater variety of implant locations can be available compared to intravascularly "tethered" conductive electrostimulation lead systems, and such wireless assemblies can be compact and can fit entirely within a chamber of the heart or within one or more blood vessels.
  • Atrial fibrillation triggers can prevent or reduce an incidence of atrial fibrillation or other atrial arrhythmias.
  • one or more locations in each of the left and right atria can be paced simultaneously to provide "atrial resynchronization therapy.”
  • tissue can be depolarized before the arrival of an arrhythmic depolarization wavefront, and such tissue can be in a refractory period, thus breaking the propagation of the arrhythmic depolarization wavefront (e.g., preventing the depolarization wavefront from activating tissue that has been previously electrostimulated, since such tissue is in a refractory period).
  • the one or more electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can be used to defibrillate the heart 302.
  • multi-site or distributed defibrillation as distinct from pacing therapies, can require less total energy as compared to two pole defibrillation (e.g., defibrillation using only two electrodes).
  • a threshold electric field intensity can be determined when two electrodes are placed across the heart (or atria in the case of AFIB). In this example, the two electrodes can reliably defibrillate the heart 302 when the threshold electric field intensity can be exceeded.
  • the electric field in tissue can be reduced in proportion to the inverse square of the distance from a defibrillation electrode.
  • the threshold electric field can be represented as the electric field needed to fully depolarize tissue that is farthest from an electrode.
  • Tissue of the heart 302 can be modeled a as spherical shell of radius R, and two defibrillation electrodes can be separated by a distance 7iR.
  • R spherical shell of radius
  • a minimum electric field needed to depolarize tissue midway between the array of electrodes can be proportional to the inverse square of their separation, and thus the ratio of minimum electric field needed for N electrodes compared to the minimum electric field needed two electrodes can be represented as 2/N.
  • Defibrillation energy can be proportional to the square of the electric field, so a ratio of defibrillation energy to be delivered between any pair of electrodes in the array as compared to two electrodes alone can be represented as 4/N 2 .
  • the total energy delivered to the array to provide defibrillation, divided by the total energy needed if only two electrodes are used can be represented as 2/N.
  • a clinical requirement for painless atrial defibrillation can be that no more than one Joule total energy can be delivered to the tissue to avoid pain.
  • a typical defibrillation between only two implanted electrodes is 4 Joules, then a painless, one Joule, shock can be delivered using 8 distributed electrodes, with 0.25 Joules delivered between respective electrode pairs.
  • FIGS. 4A-D illustrate generally section views of an example of a system including an elongate delivery catheter 480, actuator 482, a pull wire 483, and a wireless electrostimulation electrode assembly 401 including an expandable mechanical support, and including an electrostimulation circuit 440.
  • the delivery catheter 480 can be steered, introduced, advanced, or otherwise navigated to a location within the heart or within a blood vessel, near a desired implant location 402, such as a blood vessel location, or some other constraining location within the heart (e.g. an atrial appendage, an aorta, a mitral valve annulus, or one or more other locations).
  • the delivery catheter may be introduced into the interior of a heart via a subclavian or transfemoral approach as is used for various minimally-invasive procedures such as pacemaker or defibrillator lead implantation, or such as used for percutaneous coronary interventional procedures, hi the example of FIG. 4, the actuator can be attached to the electrostimulation assembly 401, such as by forcing, displacing or constraining a portion of the electrostimulation assembly 401 into a channel within the actuator 482, and holding the electrostimulation assembly 401 captive in the channel using the pull wire 483.
  • the actuator 482, electrostimulation assembly 401, and pull wire 483 can together be translated, rotated, or pushed through the lumen 481 formed by the elongate delivery catheter 480.
  • the delivery catheter 480 can be further steered or advanced into the implant location 402.
  • the actuator 482, electrostimulation assembly 401, and pull wire 483 can together be translated, rotated, or pushed out of the lumen 481 formed by the elongate delivery catheter 480, exiting the delivery catheter 480.
  • the delivery catheter 480 can be retracted, leaving the actuator 482, pull wire 483, and electrostimulation assembly 401 in place at the implant location 402.
  • one or more additional actuators or manipulators can be included within the lumen 481 of the delivery catheter 480, such as to expand, rotate, move, or assemble the electrostimulation assembly 440.
  • one or more additional actuators or manipulators e.g., one or more pusher tubes, push rods, push or pull wires, or one or more other actuators
  • the lumen 481 of the delivery catheter 480 can be included within the lumen 481 of the delivery catheter 480, such as to expand, rotate, move, or assemble the electrostimulation assembly 440.
  • the wireless electrostimulation assembly 440 can include a portion, part or component, such as a mechanical support or body, made of a shape-memory material such as stainless steel, NiTi (nickel titanium), a polymer material, or one or more other biocompatible materials, hi an example, when the electrostimulation assembly 440 is constrained by the delivery catheter 480, the electrostimulation assembly 440 can be in a folded, compressed, or collapsed configuration, and can occupy less area, length, width, or height.
  • a shape-memory material such as stainless steel, NiTi (nickel titanium), a polymer material, or one or more other biocompatible materials
  • the electrostimulation assembly 440 when the electrostimulation assembly 440 is no longer constrained by the delivery catheter 480, the electrostimulation assembly 440 can expand, unfold, open, or decompress to possess a larger area, length, width, or height, such as constrained by an implant location 402.
  • an expansion force can be provided by the electrostimulation assembly 440, such as imparted by a shape memory material, and the expansion force can anchor the electrostimulation assembly 440 to the implant location, such as to prevent the electrostimulation assembly 440 from dislodging or moving away from the implant location 402.
  • one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3 can be delivered, manipulated, assembled or moved using, for example, a portion, part, or component of the system of FIGS. 4A-D.
  • FIGS. 5A-5B illustrate generally examples of a wireless electrostimulation electrode assembly 500 at a mitral valve annulus location within the left atrium of a heart 502.
  • An expandable mechanical support 501 can conform to and at least partially encircle a ring formed by the mitral valve annulus, such as just above the anterior and posterior leaflets 578A, 578B.
  • a portion, part, or component of the mechanical support 501 can be made from a shape memory material to provide an expansion force to anchor the electrostimulation assembly 500 at the mitral valve location.
  • the electrode assembly 500 of FIGS. 5A-B can be delivered, assembled, manipulated, or moved using a transluminal, intravascular, catheter-based approach such as shown in FIGS 4A-D.
  • the cross-section or shape of the expandable mechanical support 501 can include a circular cross section (e.g., including a wire shape or tubular shape, etc.), an elliptical cross section, a rectangular cross section, or one or more other shapes, such as to provide a flexible mechanical support including at least a portion configured to conform to the ring of the mitral valve annulus.
  • the expandable mechanical support 501 can be fabricated using extrusion, laser cutting, stamping, molding, lithographic etching, or using one or more other techniques, methods, or processes.
  • the electrode assembly 500 can include one or more electrostimulation electrodes 550, 560, 561 coupled to cardiac tissue of the heart 502.
  • a fibrous tissue layer at the annulus can inhibit electrostimulation or raise a threshold needed to evoke a depolarization, reducing the efficiency of the electrostimulation,
  • the electrostimulation electrode assembly 500 can include electrodes having a spine, a tine, a helix, a barb or one or more other features to penetrate into the fibrous layer and through to a myocardial tissue layer in order to provide electrostimulation to the myocardial tissue directly, such as shown in FIGS. 6A-B.
  • the electrode 550 can be an anode electrode
  • the electrode 560 can be a cathode electrode
  • the electrostimulation assembly 500 can include multiple cathode electrodes, such as, for example, electrodes 560-561, and a commonly shared anode, such as electrode 550.
  • an electrostimulation circuit 540 can be coupled to electrodes 550, 560, and 561 using conductive connections 503A, 503C, and 503B, respectively, hi an example, the electrostimulation assembly 540 can include one or more parts, components, or circuits such as shown in the wireless electrostimulation electrode assembly 210 of FIG. 2.
  • the electrostimulation assembly 540 can be similar to or the same as the wireless electrostimulation electrode assembly 110 shown in FIG. 1.
  • the electrostimulation assembly 500 can include one or more inductive pickups 512A, 512B to receive magnetically-coupled energy from a location within or outside the heart 502, such as from a controller / transmitter 220, 320 as shown in FIGS. 2-3.
  • the one or more inductive pickups 512A, 512B can be one or more inductive coils wrapped around or on one or more sides of the mechanical support 501.
  • the one or more inductive pickups 512A, 512B can be configured to receive or transmit magnetic fields in a spatially orthogonal manner to minimize sensitivity to a particular orientation of the electrostimulation assembly 500, such as when the electrostimulation assembly transmits or receives magnetically-coupled energy.
  • the expandable mechanical support 501 need not completely encircle the ring formed by the annulus of the mitral valve.
  • patients can have annulus shapes and sizes that can vary, such as for an individual patient over time, or between different patients. In certain examples, such as shown in FIGS.
  • a gap 507 along the circumference of the expandable mechanical support 501 can allow the expandable mechanical support 501 to flex or bend to occupy a larger or smaller ring size, and to conform to the shape of the ring formed by the mitral valve annulus.
  • diagnostic imaging such CT, PET, fluoroscopic imaging, ultrasonic imaging, or one or more other forms of imaging can be used to non-invasively assess a size of the ring formed by the mitral valve annulus, and a corresponding expandable mechanical support 501 can be selected for a particular patient at a particular time (such as shortly after imaging, the support 501 sized and shaped to fit the particular patient), hi certain examples, a wireless electrostimulation electrode assembly 500 such as shown in FIGS.
  • one or more inductive pickups 512 can include one or more turns of wire, for example, included on one or more faces of the electrostimulation assembly 500, such as, for example, to receive or transmit magnetic energy over a cross sectional area including a substantial portion of a cross section of the mitral valve annulus.
  • the gap 507 can be crossed by a flexible portion of the inductive pickup 512, such as, for example, to better allow the inductive pickup and the mechanical support 501 to adjust or conform to the anatomy of the mitral valve annulus of the particular patient.
  • FIGS. 6 A-B illustrates generally section views of an example of a system 600 including a delivery catheter 680, and a wireless electrostimulation electrode assembly 601 including an expandable mechanical support and one or more extending tines 655A-D.
  • a delivery system similar to FIG. 5 can be used to move, manipulate, assemble, or rotate the electrostimulation assembly 601 at or near the mitral valve annulus 678 above the anterior and posterior leaflets 678A, 678B in the left atrium of a heart 602.
  • the one or more extending tines 655A-D can be in a collapsed, folded, or retracted position such that the electrostimulation assembly 601 can be freely moved, translated, or rotated within the delivery catheter 680.
  • the one or more extending tines 655A-D can be extended into tissue at or near the mitral valve annulus 678 to anchor the electrostimulation assembly 601 to the annulus 678 within the heart.
  • the extending tines can include a portion, part, or component made of a shape memory material, such that when the delivery catheter 680 is retracted, the extending tines can automatically extend, unfold, pop out of a cavity, or otherwise deploy into cardiac tissue such as to anchor the electrostimulation assembly 601.
  • the one or more extending tines 655A-D can provide one or more electrostimulation sites penetrating through a fibrous layer at the mitral valve annulus 678.
  • one or more of the extending tines 655A-D can be an electrode coupled to an electrostimulation circuit included as a portion, part or component of the wireless electrostimulation electrode assembly 601.
  • one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3 can include a spine, a tine, a helix, a barb or one or more other features to penetrate into cardiac tissue, such as the extending tines of FIGS. 6A-6B, such as to anchor the one or more wireless electrostimulation electrode assemblies, or to penetrate into the myocardium from within a heart or within a blood vessel.
  • FIG. 7 illustrates generally an example of a system 700 including a delivery catheter 780, an inflation balloon 786, and wireless electrostimulation electrode assembly 715 located at a left atrial appendage 775.
  • a transfemoral approach can be used to guide the delivery catheter through the vasculature to the inferior vena cava 791, into a right atrium of a heart 702, and then through the atrial septal region, such as through the fossa ovalis, allowing the delivery catheter to enter the left atrium 774 of the heart.
  • such an approach can be used to deliver one or more wireless electrostimulation electrode assemblies, such as one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3.
  • a superior vena cava 792 can be used as a route into the right atrium 770 for the delivery catheter 780 in addition to or instead of the inferior vena cava 791, (e.g., as used for implant of one or more conductive pacemaker lead systems).
  • the wireless electrostimulation electrode assembly 715 can include a stent-like expandable mechanical support, and an electrostimulation circuit 740 coupled to one or more electrostimulation electrodes, or to the expandable mechanical support.
  • the wireless electrostimulation electrode assembly 715 or one or more of the stent- like wireless electrostimulation electrode assemblies 31 IA-E can include an expandable mechanical support including a portion, part or component made of a shape memory material, and the one or more electrode assemblies can self expand when the delivery catheter 780 is retracted or removed.
  • an inflation balloon can be advanced to a region inside the one more stent-like wireless electrode assemblies, and the balloon can be inflated to expand at least some of the wireless electrostimulation electrode assembly to anchor the assembly at the implant location.
  • the electrostimulation assembly 715 can include a screen, mesh or other semi-permeable or impermeable layer 741 to prevent a blood clot or other debris within the left atrial appendage 775 from escaping into the rest of the circulatory system.
  • layer 741 can include a hole or other passage to allow the inflation balloon 786 to pass through the screen when the balloon 786 is deflated, while still allowing the balloon 786 to expand the mechanical support of the electrode assembly-715.
  • the layer 741 can include a surface treatment or antithrombogenic compound to inhibit or reduce blood clot formation, or to enhance tissue growth around or on top of the layer 741.
  • an endothelial layer of tissue can grow around, throughout, or on top of the layer 741 completely occluding or blocking the opening to the left atrial appendage 775.
  • the wireless electrostimulation electrode assembly can include a screen, mesh or other semi-permeable or impermeable layer 741 to prevent a blood clot or other debris within the
  • the stent-like wireless electrostimulation electrode assemblies 31 IA-E can include one or more inductive pickups (such as one or more wire coils) separate from the expandable mechanical structure, but attached to the expandable mechanical structure.
  • the one or more inductive pickups can be collapsed, folded, or compressed to allow the electrode assembly to pass through a lumen of the delivery catheter 780, and can be expanded by, for example, a self-expanding mechanical support, or by an inflation balloon 786 passed through the lumen of the delivery catheter to the implant location.
  • the delivery catheter need not make a sharp curvature as shown in FIG.
  • the delivery catheter can be very small, such as 2Fr - 3Fr, for example, to minimize trauma associated with crossing the atrial septum to reach the left atrium.
  • the delivery system including the delivery catheter 780 and the inflation balloon 786 can be used to delivery, expand or anchor one or more other wireless electrostimulation electrode assemblies to one or more other locations within the heart, from within the heart, such as one or more right or left pulmonary veins, 779 A, 779B, the superior vena cava 792, the inferior vena cava 791, the coronary sinus 793, or one or more other locations.
  • FIG. 8 illustrates generally an example of an apparatus 800 including an external device 840.
  • the external device can include a transmitter 830 and a controller 820
  • the apparatus 800 can include one or more wireless electrostimulation electrode assemblies, such as a first wireless electrostimulation electrode assembly 810A, or a second wireless electrostimulation electrode assembly 810B.
  • the one or more wireless electrostimulation electrode assemblies can be located in one or more blood vessels near a heart 802, or endocardially in the heart 802 itself.
  • the external device 840 can include a part, portion or component similar to the controller / transmitter 220 of FIG. 2.
  • the external device 840 can include a pocket-sized assembly such as a personal digital assistant, a hand-held patient activator (e.g., to provide a patient 801 with one or more indicators or controls to assess the patient's status, or to control one or more therapy parameters), an external physician programmer for an implantable cardiac rhythm management system, a hospital bed or one or more other forms of furniture, or one or more other external devices.
  • the apparatus 800 can be used as a portion, part or component of, or in addition to a conventional cardiac rhythm management system (e.g., the conventional cardiac rhythm management system using conductive lead assemblies attached to a subcutaneous pulse-generator).
  • FIG. 9 illustrates generally an example of an apparatus 900 including an implantable device 920, such as a cardiac rhythm management pulse generator assembly, including a subcutaneous transmitter and a controller 940, and one or more wireless electrostimulation electrode assemblies, such as a first wireless electrostimulation electrode assembly 910A, or a second wireless electrostimulation electrode assembly 910B located in a patient 901 within one or more blood vessels near a heart 902, or endocardially in the heart 902 itself.
  • a lead 906 can be used to conductively couple an inductive antenna 908 to the implantable device 920.
  • the lead 906 can be constructed similarly to a conventional implantable lead, such as by using one or more coiled concentric conductors encapsulated by a flexible biocompatible insulating layer such as silicone, or one or more other materials or constructions.
  • the lead 906 can be electrically connected to the implantable device 920 using a header similar to a header used by a conventional cardiac rhythm management device, in addition to or instead of other leads, hi certain examples, the implantable device 920 can include a pacemaker, a cardiac resynchronization therapy device, an implantable cardioverter defibrillator, a neural stimulation device, or one or more other active implantable medical devices.
  • FIG. 10 illustrates generally an example of a wireless electrostimulation electrode assembly 1000 including a loop-shaped mechanical support 1001 coupled to one or more mechanical struts, such as a first strut 101OA, or a second strut 101 OB, the struts at least partially encircling and supported by a mitral valve 1078 annulus.
  • a wireless electrostimulation electrode assembly 1000 including a loop-shaped mechanical support 1001 coupled to one or more mechanical struts, such as a first strut 101OA, or a second strut 101 OB, the struts at least partially encircling and supported by a mitral valve 1078 annulus.
  • the electrostimulation assembly 1000 can be supported at least partially at the mitral valve annulus, such as at a wedge formed between a left atrial wall and a posterior region of the annulus, and the assembly 1000 can wrap around an interior of the left atrium at least partially in contact with an anterior region of endocardium opposite the posterior region of the annulus, such as, for example, below a plane formed by the bottom of the pulmonary veins, such as a first and second right pulmonary vein, 1079A, 1079B, and a first and second left pulmonary vein 1079C, 1079D.
  • a first and second right pulmonary vein, 1079A, 1079B such as a first and second right pulmonary vein, 1079A, 1079B, and a first and second left pulmonary vein 1079C, 1079D.
  • the electrostimulation assembly 1000 can include one or more electrodes around the circumference of the loop-shaped mechanical support 1001, such as a first electrode 1050, a second electrode 1060, a third electrode 1061 A, a fourth electrode 1062 A, and a fifth electrode 1063 A.
  • the mechanical support 1001 can be conductive, and can carry an electrostimulation current to one or more of the first, second, third, fourth, or fifth electrodes 1050, 1060, 106 IA, 1062 A, or 1063 A.
  • one or more electrostimulation electrodes such as one or more of the first, second, third, fourth, or fifth electrodes 1050, 1060, 1061 A, 1062 A, or 1063 A, can be formed by providing one or more openings in an insulating layer covering, coating, encapsulating, or surrounding the mechanical support 1001.
  • the electrode used for electrostimulation can be selected by a controller including an arrhythmia detector in order to deliver one or more coordinated electrostimulations using a selected group or combination of electrodes in order to regulate, terminate, or control an arrhythmia.
  • one or more cathode electrodes can be used, and a total surface area of the one or more cathode electrodes can be, for example, substantially equivalent to a surface area of an anode electrode to provide a specified current density at the one or more cathode electrodes, such as, for example, to provide reliable electrostimulation at the one or more cathode electrode locations.
  • the loop-shaped mechanical support 1001 can be folded, compressed, or collapsed, such as for delivery via a percutaneous, transluminal route through one or more blood vessels using a delivery catheter, such as shown in FIGS. 4A- D.
  • the electrostimulation assembly 1000 can include one or more components, circuits, or portions of the wireless electrostimulation electrode assembly 210 shown in FIG. 2.
  • the first or second mechanical struts 101OA, 101 OB can omitted and the loop-shaped mechanical support 1001 can be expandable, and can be directly supported at least partially by the ring formed by the mitral valve annulus 1078.
  • the loop shaped mechanical support 1001 can be in contact with cardiac tissue along its entire circumference, such as, for example, to encourage growth of a protective layer of tissue around the mechanical support 1001.
  • growth of a protective layer of tissue at least partially around, throughout, or surrounding the support 1001 can reduce a risk of forming blood clot, as compared to having one or more portions of the support 1001 exposed to a blood pool in the left atrium.
  • FIG. 11 illustrates generally an example of a method 1100 including receiving wireless energy using a first wireless electrostimulation electrode assembly at 1102, mechanically supporting the first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of a heart at 1104, and delivering at least some of the received wireless energy as an electrostimulation to a heart at 1106.
  • the first wireless electrostimulation electrode assembly can be similar to or the same as the electrostimulation assembly 110 shown in FIG. 1, the electrostimulation assembly 500 shown in FIG. 5, the electrostimulation assembly 601 shown in FIGS. 6A-B, the electrostimulation assembly 1000 shown in FIG. 10, or one or more other electrostimulation assemblies.
  • the first wireless electrostimulation electrode assembly can receive magnetically-coupled energy and deliver at least some of the received magnetically-coupled energy as an electrostimulation to the heart using one or more circuits, components or devices such as shown in the electrostimulation assembly 210 of FIG. 2.
  • FIG. 12 illustrates generally an example of a method 1200 including receiving wireless energy using a plurality of separate wireless electrostimulation electrode assemblies each configured to be intravascularly delivered to a respective implant location at 1202, mechanically supporting a first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of a heart at 1204, detecting an arrhythmia at 1206, and terminating the detected arrhythmia by delivering one or more coordinated electrostimulations to the heart at the respective implant locations at 1208.
  • the first wireless electrostimulation electrode assembly can be similar to or the same as the electrostimulation assembly 110 shown in FIG. 1, the electrostimulation assembly 500 shown in FIG. 5, the electrostimulation assembly 601 shown in FIGS.
  • one or more of the plurality of wireless electrostimulation electrode assemblies can be similar to one or more of the electrostimulation assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3.
  • one or more of the plurality of wireless electrostimulation electrode assemblies can receive magnetically-coupled energy and deliver at least some of the received magnetically-coupled energy to the respective implant locations using one or more circuits, components or devices such as shown in the electrostimulation assembly 210 of FIG. 2.
  • FIGS. 13 A-B illustrate generally examples of a stent-like wireless electrostimulation electrode assembly 1300, such as, for example, one or more of the wireless electrostimulation electrode assemblies 31 IA-E shown in FIG. 3.
  • a coiled strut 1301 can provide a mechanical support for the electrostimulation assembly 1300.
  • the coiled strut 1301 can be compressed, flattened, folded, or formed into one or more wire strands, and passed through a lumen formed by an elongate delivery catheter, similar to the examples of FIGS. 4A-D, and FIG. 7.
  • the cross section of the electrostimulation assembly 1300 when compressed, flattened, folded, or formed into one or more wire strands, the cross section of the electrostimulation assembly 1300 can be small enough for the electrostimulation assembly 1300 to be intravascularly delivered through one or more blood vessels to an implant location, and such an intravascular delivery can include a route through one or more heart chambers, such as, for example, to gain access to one or more pulmonary veins.
  • the coiled strut 1301 can self-expand, such as, for example, to decompress, open, unfold, forming a tapered coil, such as shown in FIGS. 13A-B, after the electrostimulation assembly 1300 is delivered to the implant location.
  • a portion, part or component of the coiled strut 1301 can be made of one or more conductive materials, such as, for example, an elongated tube of shape-memory material partially or completely enclosing a conductive core.
  • the elongated tube of shape-memory material can be a nickel titanium compound or alloy, such as Nitinol, and the conductive core can be silver.
  • the core can be the shape-memory material, such as the nickel titanium compound or alloy, and the elongated tube can be highly conductive, such as platinum, or platinum-iridium oxide.
  • an outer diameter of the elongated tube of shape-memory material can be less than 0.008 inches, to greater than 0.012 inches.
  • the coiled strut 1301 can be both a mechanical support and an inductive receiver coil, such as, for example, to receive wirelessly-coupled energy from a separate transmitter coil, hi the example of FIG. 13 A, one or both ends of the coiled strut can be conductively coupled to an electrostimulation circuit 1340.
  • the electrostimulation circuit 1340 can include one or more parts, components or portions of the wireless electrostimulation electrode assembly 210 shown in FIG. 2. hi the example of FIG.
  • the coiled strut, or the electrostimulation circuit 1340 can be coupled to one or more cathode electrodes 1350 located proximally to the interior of a heart chamber, such as nearby or contacting a myocardial muscle sleeve within one or more blood vessels entering or exiting a heart chamber, hi the example of FIG. 13 A, the electrostimulation circuit 1340 can be conductively coupled to one or more anode electrodes 1360 located distally to the interior of the heart chamber.
  • the one or more anode or cathode electrodes 1360, 1350 can be a part, portion, or component of the coiled strut 1301, such as, for example, one or more non-insulated portions of the strut 1301.
  • the one or more anode or cathode electrodes 1360, 1350 can include an exposed platinum portion, a platinum-indium oxide portion, or one or more other conductive biocompatible materials to be placed in contact with tissue or near tissue.
  • the electrostimulation circuit 1340 can include a rectifier electrically connected to the coiled strut 1301, and one or more of a tuning capacitor or an electrostimulation waveform shaping capacitor conductively coupled in series or parallel to the rectifier and to one or more of the electrostimulation electrodes 1360, 1350, such as, for example, to provide a specified electrostimulation waveform when the one or more anode or cathode electrodes 1360, 1350 are in contact with tissue.
  • the electrostimulation circuit can be very compact, such as about 0.020 inches by 0.030 inches, and 0.010 inches thick, hi an example, the one or more electrostimulation electrodes 1360, 1350 can provide the specified electrostimulation waveform when the electrostimulation assembly 1300 receives magnetically coupled energy containing a specified range of frequencies, hi the example of FIG. 13B, the electrostimulation circuit 1340 and the one or more anode electrodes 1360 can be included in a wall electrode 1345.
  • the wall electrode 1345 of FIG. 13B can be an anode electrode, in addition to or instead of the one or more anode electrodes 1360, such as shown in FIG. 13 A.
  • circuitry included as a portion, part, or component of the wall electrode 1345 can be similar to or the same as the electrostimulation circuit 1340, such as shown in FIG. 13 A.
  • at least a portion of the wall electrode 1345 can be platinum, platinum- iridium oxide, or one or more other conductive biocompatible materials to be placed in contact with tissue or near tissue
  • the coiled strut 1301 can be used as an inductive receiver coil separate from, and attached to, a mechanical support, such as an expandable stent body, hi such examples, the mechanical support can be selected for reliable anchoring of the electrostimulation assembly 1300 at the implant location, and the separate coiled strut 1301 can be selected to provide reliable inductive receiving or transmission of magnetic energy
  • a wireless electrostimulation electrode assembly 1300 can be located in a specified pulmonary vein, and one or more other electrostimulation assemblies can be located endocardially, or within one or more other blood vessels, and can be connected by one or more
  • the one or more small leads can be located against an endorcardial wall, such as, for example, to encourage growth of a protective endothelial layer around the one or more small leads, such as for reducing a risk of a thrombus forming.
  • an experimental prototype can be constructed to predict an efficiency of a stent-like wireless electrostimulation electrode assembly, such as the electrostimulation assembly 1300 shown in FIGS. 13A-B.
  • the electrostimulation assembly 1300 can be sized and shaped to be implanted in a pulmonary vein, such as, for example, one or more of the pulmonary veins 1079 A-D shown in FIG. 10.
  • the pulmonary vein can be conical, and the electrostimulation assembly 1300 can be tapered such as shown in FIGS. 13A-B, for example, such as to better conform to the conical anatomy of the pulmonary vein.
  • "z" can be 8 millimeters, such as to represent a separation between a nearest edge of a wireless electrostimulation electrode assembly 1300 located near the heart in the pulmonary vein and a plane formed by a transmitter coil in the right atrium, such as included as a portion, part, or component of an intravascular lead located in the right atrium.
  • an efficiency, ⁇ , and a peak load voltage,
  • the peak load voltage can represent, for example, an electrostimulation voltage across two electrostimulation electrodes connected to heart tissue, during an electrostimulation.
  • 5 Volts at 2 megaHertz can be applied to the transmitter coil.
  • 20 Volts when
  • 5 Volts
  • received power can diminish as the angle between the planes of the transmitter and receiver coils deviates from zero degrees (reducing the coupling constant, /c), resulting in orientation sensitivity.
  • multiple transmit coils in multiple planes, and even multiple coils in a single plane can help reduce such orientation sensitivity.
  • Multiple receiver coils consume little additional energy in the far field of the transmitter, compared to using a single receiver coil.
  • multiple receivers can operate near an inductive transmitter with an efficiency substantially equal to the efficiency of a single receiver, hi certain examples, the inductive transmitter can be located in one or more other locations, including an esophagus, one or more bronchi, a pericardial space, a pulmonary artery, or one or more other subcutaneous or external locations.
  • one or more types of medical imaging can be performed prior to or during an implantation of one or more electrostimulation assemblies 1300, such as, for example, to provide information that can be used to select an appropriate size and shape of electrostimulation assembly 1300 for a particular location, or a particular patient.
  • one or more pulmonary veins may range from less than 10 millimeters in diameter at a distal end, to more than 25 millimeters in diameter at a proximal end near the heart, and a corresponding range of wireless electrostimulation assembly 1300 shapes and sizes can be provided to match the one or more pulmonary veins.
  • FIG. 14 illustrates generally a section view 1400 of at least a portion of a wireless electrostimulation electrode assembly.
  • the section view of FIG. 14 can include a cross section of a portion of a wireless electrostimulation assembly 1300, such as shown in FIG. 13.
  • a conductive core 1401 can provide a low resistance path for received magnetic energy or energy to be delivered as an electrostimulation.
  • the present inventors have recognized that some conductive materials can have low resistance, but can lack shape- memory or spring-like properties.
  • a tube, a coating, a plated layer, or a jacket of shape-memory material 1403 can be included in addition to the conductive core 1401, such as, for example, to provide a combined assembly 1300 including both a highly conductive portion, and a spring-like or shape-memory portion.
  • the shape-memory material 1403 can be co-extruded along with the conductive core, or one or more other materials, such as to form a combined assembly 1300.
  • the shape-memory material 1403 can provide an expansion force, such as, for example to decompress, unfold, expand, or anchor the electrostimulation assembly 1300 at an implant location.
  • the electrostimulation assembly 1300 can at least partially self-decompress, self- unfold, or self-expand, such as, for example, using the expansion force of the shape-memory material 1403.
  • an electrode layer such as, for example, using the expansion force of the shape-memory material 1403.
  • Electrode 1405 can be attached to the shape-memory material 1403, or directly to the core 1401. hi certain examples, one or more portions of the electrode layer 1405 can be encased, surrounded, encapsulated, coated, or otherwise treated with an insulator 1407, such as, for example, a biocompatible material such as silicone, or one or more other materials.
  • an insulator 1407 such as, for example, a biocompatible material such as silicone, or one or more other materials.
  • One or more electrodes 1450 can be provided by including one or more openings, cavities, or apertures in the insulating layer 1407, such as, for example, to expose a portion of the electrode layer 1405.
  • the electrode layer can include platinum, platinum-iridium oxide, or one or more other conductive biocompatible materials, for example, to provide reliable electrostimulation when the electrode 1405 is in contact with tissue, or near one or more tissue sites to be electrostimulated.
  • the shape-memory material 1403 need not surround the core 1401, and the core itself can be a shape memory material surrounded by one or more conductive layers, such as discussed above for FIGS. 13A-B.
  • one or more wireless electrostimulation electrode assemblies can condition myocardial tissue after a myocardial infarction, such as to limit, control, or prevent adverse remodeling of myocardial tissue resulting from damage caused by the infarction
  • one or more coordinated electrostimulations delivered by one or more wireless electrostimulation electrode assemblies can limit tissue damage or death within or near one or more infracted tissue sites, hi an example, over a longer term such as from days to months, or longer, after an infarction
  • one or more coordinated electrostimulations can be delivered by one or more wireless electrostimulation electrode assemblies, for example, such as to limit an increase in infracted tissue volume, or to enhance a cardiac ejection fraction.
  • one or more stent-like wireless electrostimulation electrode assemblies can be used in other locations within a patient, such as one or more arteries, arterioles or veins, such as to enhance perfusion (e.g., such as after a stroke in a cerebral location) or to encourage diuresis (via an implant location in a renal artery), either through modulation of one or more vascular neurological pathways (such as to evoke vasodilation or vasoconstriction), or through evoking or inhibiting a contractile response in nearby muscle tissue.
  • one or more wireless electrostimulation assemblies can be placed in a renal artery or a renal vein, and dilation of the renal artery or vein can be evoked using the one or more wireless electrostimulation assemblies, hi an example, electrostimulation by one or more wireless electrostimulation electrodes to elicit diuresis can be used to enhance perfusion around one or more blood vessels or to clear debris from within or near one or more blood vessels, such as after an ischemic event, hi an example, vasodilation of pulmonary arteries can be used to control, prevent, or limit pulmonary hypertension.
  • one or more wireless electrostimulation electrode assemblies can include an antithrombogenic agent or surface treatment, such as, for example, to promote incorporation of the electrostimulation assembly into the surrounding tissue, such as a blood vessel wall, hi an example, an endothelial layer can grow around, on, or throughout the electrostimulation assembly, and can protect the electrostimulation assembly, such as to reduce a risk of thrombus formation, hi an example, one or more wireless electrostimulation electrode assemblies can include a roughened or porous surface treatment to enhance in-growth of surrounding tissue, hi an example, sub-threshold electrostimulation can be provided (e.g., delivering an electrostimulation having an energy or voltage below a threshold where muscle contraction can be elicited). In an example, such sub-threshold electrostimulation might enhance tissue ingrowth or reduce or eliminate reclosing of a blood vessel where the electrostimulation electrode is located (e.g., to prevent or reduce restenosis).
  • an antithrombogenic agent or surface treatment such as
  • Method examples described herein can be machine or computer- implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples.
  • An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, the code may be tangibly stored on one or more volatile or non- volatile computer-readable media during execution or at other times.
  • These computer- readable media may include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like.
  • RAMs random access memories
  • ROMs read only memories

Abstract

An apparatus and method can receive wireless energy using a wireless electrostimulation electrode assembly. In certain examples, at least some of the received wireless energy can be delivered as an electrostimulation to a heart. In certain examples, the wireless electrostimulation electrode can be mechanically supported at least partially using a ring formed by an annulus of a mitral valve of the heart. In certain examples, the wireless electrostimulation electrode assembly can be configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart, and can fit entirely within the heart.

Description

MULTI-SITE ATRIAL ELECTROSTIMULATION CLAIM OF PRIORITY
This patent application claims the benefit of priority, under 35 U.S. C.
Section 119(e), to Roger Hastings et al., U.S. Provisional Patent Application
Serial Number 61/063,876, entitled "WIRELESS STENT ELECTROSTIMULATION SYSTEM," filed on February 7, 2008 (Attorney
Docket No. 00279. F35PRV), incorporated herein by reference in its entirety. This patent application also claims the benefit of priority, under 35
U.S.C. Section 119(e), to Roger Hastings et al., U.S. Provisional Patent
Application Serial Number 61/059,993, entitled "WIRELESS TISSUE ELECTROSTIMULATION SYSTEM," filed on June 9, 2008 (Attorney Docket
No. 00279.F35PV2), incorporated herein by reference in its entirety.
BACKGROUND
Electrostimulation can be used to treat acute and chronic patient conditions, such as to elicit or inhibit heart muscle contractions, for example, using a cardiac rhythm management device. Cardiac rhythm management devices can include, for example, implantable pacemakers, implantable cardiac re-synchronization therapy devices, and implantable cardioverter defibrillators, among others. Cardiac rhythm management devices can be used to treat conditions such as atrial or ventricular tachycardia, atrial or ventricular fibrillation, bradycardia, and congestive heart failure, among other diseases.
An example of a cardiac rhythm management device can include a battery-operated electronics unit implanted under the skin, such as in the pectoral region, connected to one or more implantable flexible intravascular leads implanted using a catheter-based delivery system, such as to reach a location within a heart chamber or one or more coronary blood vessels.
Such leads can include one or more exposed electrodes to directly electrostimulate cardiac tissue, or to sense potentials at the tissue (e.g., for sensing intrinsic cardiac activity, or sensing an evoked response to the application of electrostimulus). Tissue growth can encapsulate the electrode. This can reduce a required electrostimulus threshold energy to achieve a desired response, but can also present a challenge if lead re-positioning or removal is needed. This may preclude using multiple leads in certain locations. Epicardial electrostimulus locations can also be used, such as when acute pacing therapy is desired and pericardial cavity access is available.
OVERVIEW
Some conditions, such as supraventricular tachyarrhythmias (SVTs), can benefit from atrial electrostimulation (e.g., pacing, or one or more other forms of electrical stimulation) at one or more sites within or near a left or right atrium of a heart, or both. In certain examples, electrostimulation can be used to depolarize tissue near one or more wireless electrostimulation electrode assemblies (e.g., including one or more electrodes that are not "tethered" by an intravascular leadwire to a CRM device electronics unit), such as to disrupt a "circus" depolarization wavefront, such as to terminate a tachyarrhythmia. In certain examples, electrostimulation can be used to spatially coordinate or resynchronize contractions within or between the left and right atria, hi certain examples, this can help improve atrial hemodynamics or reduce the risk of stroke, such as due to a blood clot (e.g., a thrombus) forming in stagnant blood in one or more heart chambers.
Example 1 describes an apparatus. In this example, the apparatus can include a first wireless electrostimulation electrode assembly including an electrostimulation circuit, a wireless receiver configured to receive wireless energy and configured to provide at least some of the received wireless energy to the electrostimulation circuit, a first expandable support mechanically coupled to the electrostimulation circuit and the wireless receiver and configured to conform to, and at least partially encircle, a ring formed by an annulus of a mitral valve of a heart. In this example, the electrostimulation circuit can be configured to deliver at least some of the received wireless energy as an electrostimulation to the heart, the first wireless electrostimulation electrode assembly can be configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart, and the first wireless electrostimulation electrode assembly can be configured to fit entirely within the heart.
In Example 2, the wireless energy of Example 1 optionally includes magnetically-coupled energy, and the wireless receiver can be optionally configured to receive the magnetically-coupled energy.
In Example 3, the apparatus of any one or more of Examples 1-2 optionally includes a transmitter configured to provide the magnetically-coupled energy, and the transmitter is optionally sized and shaped to be located subcutaneously within a patient, or outside a patient body. In Example 4, the electrostimulation circuit of any one or more of
Examples 1-3 can be optionally configured to deliver an electrostimulation including enough of the received wireless energy to depolarize cardiac tissue near the wireless electrostimulation electrode assembly. hi Example 5, the first expandable support of any one or more of Examples 1-4 optionally includes a shape memory material configured to provide an expansion force, and the first expandable support can be optionally configured to anchor the first wireless electrostimulation electrode assembly at the implant location at the annulus of the mitral valve at least in part using the expansion force when the first wireless electrostimulation electrode assembly is delivered to the implant location.
In Example 6, the first wireless electrostimulation electrode assembly of any one or more of Examples 1-5 optionally includes one or more extending tines configured to controllably extend into tissue when the first wireless electrostimulation electrode assembly is delivered to the implant location at the annulus of the mitral valve of the heart. hi Example 7, the apparatus of any one or more of Examples 1-6 optionally includes a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a blood vessel and configured to provide an electrostimulation to the heart near the blood vessel, and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
In Example 8, the blood vessel of any one or more of Examples 1-7 can be optionally selected from a list including a pulmonary vein, a coronary sinus, or a vena cava.
In Example 9, the apparatus of any one or more of Examples 1-8 optionally includes a second electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart, and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
In Example 10, the atrial appendage of the heart of any one or more of Examples 1-9 can optionally be a left atrial appendage, the second electrostimulation electrode assembly optionally includes a second expandable support configured to at least partially block the opening to the left atrial appendage of the heart, and the second expandable support can be optionally configured to anchor the second electrostimulation electrode assembly at the opening of the left atrial appendage when the second expandable support is expanded.
In Example 11, the apparatus of any one or more of Examples 1-10 optionally includes a plurality of separate wireless electrostimulation electrode assemblies, each optionally configured to be intravascularly delivered to a respective implant location and each configured to provide an electrostimulation to the heart at the respective implant location, a controller communicatively coupled to the plurality of separate wireless electrostimulation electrode assemblies, the controller optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location, and the plurality of separate wireless electrostimulation electrode assemblies optionally including the first wireless electrostimulation electrode assembly.
In Example 12, the plurality of separate wireless electrostimulation electrode assemblies of any one or more of Examples 1-11 optionally includes one or more wireless electrostimulation electrode assemblies selected from a list including a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial septum of the heart and configured to provide an electrostimulation to the heart, a third wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart, a fourth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a pulmonary vein and configured to provide an electrostimulation to the heart, a fifth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a vena cava and configured to provide an electrostimulation to the heart, a sixth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a coronary sinus and configured to provide an electrostimulation the heart. In this example, the controller can be communicatively coupled to each corresponding wireless electrostimulation electrode assembly and the controller can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location by each respective wireless electrostimulation electrode assembly. In Example 13, the controller of any one or more of Examples 1-12 optionally includes an arrhythmia detector configured to detect an arrhythmia, and the controller can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia in response to information provided by the arrhythmia detector. In Example 14, the arrhythmia of any one or more of Examples 1-13 can optionally include an atrial tachyarrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
In Example 15, the controller of any one or more of Examples 1-14 can be optionally configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia without exceeding a pain threshold of a patient. Example 16 describes a method. In this example, the method includes receiving wireless energy using a first wireless electrostimulation electrode assembly, delivering at least some of the received wireless energy as an electrostimulation to a heart, mechanically supporting the first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of the heart, wherein the first wireless electrostimulation electrode assembly can be configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart, and the first wireless electrostimulation electrode assembly can be configured to fit entirely within the heart.
In Example 17, the method of Example 16 optionally includes receiving wireless energy using a plurality of separate wireless electrostimulation electrode assemblies, the plurality optionally including the first wireless electrostimulation electrode assembly, and the plurality of separate wireless electrostimulation electrode assemblies can each be optionally configured to be intravascularly delivered to a respective implant location, delivering one or more coordinated electrostimulations to the heart at the respective implant location using at least one of the plurality of electrostimulation electrode assemblies and using at least some of the received wireless energy. In Example 18, the method of any one or more of Examples 16-17 optionally includes detecting an arrhythmia, terminating the detected arrhythmia using the delivering one or more coordinated electrostimulations and using information provided by the detecting the arrhythmia, the delivering one or more coordinated electrostimulations optionally includes delivering enough received wireless energy to depolarize cardiac tissue at each respective implant location where the one or more coordinate electrostimulations are delivered.
In Example 19, the detecting the arrhythmia of any one or more of Examples 16-18 optionally includes detecting an atrial arrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
In Example 20, the terminating the arrhythmia using the delivering the one or more coordinated electrostimulations of any one or more of Examples 16- 19 optionally includes depolarizing enough cardiac tissue to terminate the arrhythmia without exceeding a pain threshold of a patient.
This overview is intended to provide an overview of subject matter of the present patent application. It is not intended to provide an exclusive or exhaustive explanation of the invention. The detailed description is included to provide further information about the present patent application.
BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings, which are not necessarily drawn to scale, like numerals may describe similar components in different views. Like numerals having different letter suffixes may represent different instances of similar components. The drawings illustrate generally, by way of example, but not by way of limitation, various embodiments discussed in the present document.
FIG. 1 illustrates generally an example of an apparatus including a wireless electrostimulation electrode assembly at a mitral valve annulus location.
FIG. 2 illustrates generally an example of a schematic of a controller, transmitter, and a wireless electrostimulation electrode assembly.
FIG. 3 illustrates generally an example of an apparatus including a plurality of wireless electrostimulation electrode assemblies at respective implant locations within a heart and within respective blood vessels.
FIGS. 4A-D illustrate generally section views of an example of a system including a delivery catheter, actuator, and a wireless electrostimulation electrode assembly including an expandable mechanical support.
FIG. 5A-B illustrate generally examples of a wireless electrostimulation electrode assembly at a mitral valve annulus location.
FIGS. 6A-B illustrates generally section views of an example of a system including a delivery catheter, and a wireless electrostimulation electrode assembly including an expandable mechanical support and multiple extending tines. FIG. 7 illustrates generally an example of a system including a delivery catheter, actuator, inflation balloon, and wireless electrostimulation electrode assembly. FIG. 8 illustrates generally an example of an apparatus including an external device including a transmitter and a controller, and multiple wireless electrostimulation electrode assemblies.
FIG. 9 illustrates generally an example of an apparatus including an implantable device including a subcutaneous transmitter and a controller, and multiple wireless electrostimulation electrode assemblies.
FIG. 10 illustrates generally an example of a wireless electrostimulation electrode assembly including a loop-shaped mechanical support coupled to one or more mechanical struts, the mechanical struts at least partially encircling and supported by a mitral valve annulus.
FIG. 11 illustrates generally an example of a method including receiving wireless energy and delivering at least a portion of the received wireless energy as an electrostimulation to a heart.
FIG. 12 illustrates generally an example of a method including receiving wireless energy, detecting an arrhythmia, and delivering at least a portion of the received wireless energy as an electrostimulation to a heart in order to terminate the arrhythmia.
FIGS. 13 A-B illustrate generally examples of a stent- like wireless electrostimulation electrode assembly. FIG. 14 illustrates generally a section view of at least a portion of a wireless electrostimulation electrode assembly.
DETAILED DESCRIPTION Atrial tachyarrhythmias can be uni-focal, multi-focal, or unfocused. They can originate in a left or right atrium, or elsewhere, involving one or more conduction pathways through atrial heart tissue. A uni-focal atrial tachyarrhythmia can involve an ectopic focus in the atrium, and can result in a "circus" depolarization wavefront, such as within one or both atria. A multifocal atrial tachyarrhythmia can involve multiple ectopic foci in one or both atria, and can result in multiple "circus" wavefronts. In certain examples, coordinated electrostimulation can be delivered to multiple atrial wireless electrostimulation electrode implant locations, such as to depolarize cardiac tissue to disrupt the one or more "circus" wavefronts to terminate the arrhythmia, whether uni-focal or multi-focal. Similarly, in certain examples, atrioventricular tachyarrhythmias such as AV nodal reentrant tachycardia (AVNRT), atrioventricular reentrant tachycardia (AVRT), or atrial flutter, may be terminated or regulated (e.g., controlled by high-rate pacing, or one or more other electrostimulations). This can involve disrupting one or more primary or accessory conduction pathways followed by one or more arrhythmic depolarization waves, such as by using one or more wireless electrostimulation electrode assemblies to provide coordinated electrostimulations nearby. The likelihood of disrupting a pathway used by a reentrant depolarization (and thus terminating the arrhythmia) can increase as the energy used for electrostimulation increases or as the number of electrostimulation sites increases. Thus, the present inventors have recognized, among other things, that providing at least one electrostimulation electrode assembly in the left atrium (e.g., such as anchored to a mitral valve annulus) can increase the likelihood of converting a tachyarrhythmia as compared to using only a single unipolar or bipolar electrode assembly in the right atrium (such as provided by a pacemaker using a "tethered" intravascular lead system). More electrostimulation sites can more readily disrupt the one or more conduction pathways followed by a reentrant depolarization waveform, since such pathways are more likely to be near one of the multiple electrostimulation sites. Also, the present inventors have recognized, among other things, that using a plurality of electrostimulation electrodes dispersed at various locations about the left or right atria, or both, can help increase the likelihood of inhibiting, preventing, regulating, or terminating an SVT, and may enable pain-free cardioversion of SVTs. Such cardioversion might be pain free by keeping the energy delivered to each electrostimulation location below a pain threshold of a patient while still achieving a sufficient electric field intensity across a region of cardiac tissue to cause a depolarization throughout the region, in bulk.
In certain patients, ablation or other surgical procedures (e.g., a Cox maze procedure) can be performed, such as to reduce an occurrence of or eliminate one or more atrial arrhythmias. However, such surgeries can permanently impair conduction through regions that have been incised or ablated. Also, certain patients can have damaged conduction paths within one or both atria, such as due to scarring around or within tissue that has experienced a previous myocardial infarction. The present inventors have recognized, among other things, that the one or more electrostimulation electrode assemblies can be used to provide one or more atrial pacing therapies such as bradyarrhythmia therapy or atrial resynchronization therapy. Such resynchronization therapy can include delivering one or more electrostimulations to multiple sites in the left or right atrium, or both, simultaneously or nearly simultaneously to spatially coordinate the depolarization such as to provide a more uniform depolarization wavefront. Such a uniform depolarization can disrupt, inhibit, or prevent one or more "circus" or reentrant wavefronts, thereby reducing a likelihood of atrial tachyarrhythmia (e.g., inhibiting or preventing an arrhythmia from developing). Such pacing therapies can be called "atrial resynchronization therapy," and can improve or restore more normal atrial conduction and contractile behavior for patients with one or more damaged conduction pathways. This can help improve atrial hemodynamics (e.g., improving atrial fill, reducing a risk of clotting due to stagnant blood in the left atrium, etc.).
Generally, intravascular leads are not chronically implanted in the left heart chambers, which risks clotting and mechanical dislodgement due to the more significant motions, acceleration and impingement of cardiac tissue on the lead and electrode assembly, when implanted endocardially in a left ventricle or a left atrium. Wireless electrostimulation assemblies can eliminate the need for the wired connection between the pulse generator assembly and an electrode assembly at a pacing site. Generally, pacing energy can be wirelessly supplied to the site from a tiny rechargeable battery located in the body of the wireless pacing electrode. This can enable an autonomous pacing assembly, but size considerations can result in frequent (e.g., daily) battery recharge, such as via wireless magnetic induction. Further, constructing various wireless pacing devices using a high magnetic permeability material, such as in ferrite-core inductors, can present a compatibility problem with magnetic resonance imaging (MRI) equipment. In an example, the present apparatus can provide electrostimulation at patient implant locations where using intravascular lead-wires is problematic, or to electrostimulate at multiple sites that are separate and distinct from the location of a controller that transmits wireless energy to wireless electrostimulation apparatuses at the sites.
The present wireless electrostimulation apparatus can, in certain examples, also improve the range of wireless coupling, such as for wireless power transmission, or for wireless communication of information. For example, such range can be several centimeters for electrostimulation applications. This can involve using one or more inductor core materials having lower relative magnetic permeability than ferrite or using a tuned receiver design, or both. In an example, multiple wireless electrostimulation electrode assemblies can wirelessly receive energy used for electrostimulations from a common transmitter of magnetically-coupled energy (e.g., an inductive transmitter) with limited loss in efficiency as compared to using a single wireless electrostimulation assembly.
In certain examples, the wireless electrostimulation power transmitter can be located either subcutaneously within the patient, or included as part of an external device, such as a hospital bed, operating table, hand-held device, physician programmer, hat or clothing, or in one or more other locations. For a subcutaneously-implanted controller/transmitter (such as an implantable cardiac rhythm management device), explanting the controller/transmitter unit can permit replacing a battery in the controller/transmitter, without explanting the separate wireless electrostimulation electrode assemblies. Enhanced efficiency of wireless coupling of electrostimulation energy, such as from resonant coupling between the controller/transmitter and the one or more receiving wireless electrostimulation assemblies can increase the time between rechargings or battery replacements. For an external inductive transmitter, distance between the controller/transmitter and the one or more receiving wireless electrostimulation electrode assemblies can be increased, such as using resonant coupling to transmit electrostimulation energy therebetween.
The wireless electrostimulation electrode assemblies can be implanted at or near a cardiac location (e.g., such as within one or more blood vessels, or entirely within a heart chamber), and can include an expandable inductive loop antenna. In certain examples, during implantation, the expandable loop can be initially collapsed, folded, or compressed, such as to allow easier implant (such as via a delivery catheter through an intravascular route), and then unfolded, expanded, opened, or uncompressed to achieve a larger loop area, and hence greater coupling to the inductive transmit antenna. In a cardiac pacing example, an inductive transmit antenna can be incorporated into a cardiac lead system, and can be configured to expand, unfold, or open when implanted at a desired location, such as in the right side of the heart (e.g., in the right atrium or the right ventricle at or near a location accessible by a pacemaker or defibrillator intravascular lead).
In an example, a wireless electrostimulation electrode assembly can be configured to be implanted in a heart at a mitral valve annulus. In certain examples, the wireless electrostimulation electrode assemblies can include one or more electrode assemblies including an expandable mechanical support and an electrostimulation circuit. In certain examples, the expandable mechanical support can be sized and shaped to anchor an associated wireless electrostimulation electrode assembly in a blood vessel, such as a pulmonary vein, a vena cava (inferior or superior), a coronary sinus, or one or more other blood vessels.
FIG. 1 illustrates generally an example of a sectional view of a heart 102, showing an example of a wireless electrostimulation apparatus 100 including a wireless electrostimulation electrode assembly 110 implanted within the heart 102 at a mitral valve annulus, where an anterior leaflet 178 A and a posterior leaflet 178B terminate in the left atrium 174. In certain examples, the wireless electrostimulation electrode assembly 110 can include an electrostimulation circuit 140 electrically connected to one or more electrically conductive electrodes, such as a first electrode 150 and a second electrode 160 located at or near cardiac tissue of the heart 102 to electrostimulate the tissue. In an example, the first electrode 150 can be an anode and the second electrode 160 can be a cathode, such as to form a closed electrostimulation circuit conductively coupled to cardiac tissue, hi certain examples, one or more forms of wireless energy can be provided, such as wireless energy from a location within the heart 114 A, or wireless energy from a location outside the heart 114B, and at least some of the wireless energy 114A-B can be received by the electrostimulation assembly 1 10. In an example, at least some of the wireless energy 114A-B can be provided as an electrostimulation to the heart 102, such as using the first electrode 150 and the second electrode 160, and the electrostimulation circuit 140. In certain examples, the wireless energy from a location within the heart 114A can be provided by one or more other implantable assemblies contained entirely within the heart, such as a battery-operated controller and transmitter. In certain examples, the wireless energy from a location within the heart 114A can be provided by a transmitter located on a cardiac rhythm management device lead system, such as located within a right atrium 170, a right ventricle 172, a location within a left ventricle 176, a coronary sinus near the left ventricle 176, or from one or more other locations. In certain examples, the wireless energy from a location outside the heart 114B can be provided from a subcutaneous location, such as from a subcutaneous lead system or transmitter attached to or part of a cardiac rhythm management device, or provided by a transmitter located outside the patient body, or from one or more other locations. In certain examples, the wireless energy from a location within the heart 114A or from a location outside the heart 114B can include acoustic energy (e.g., ultrasonic energy), optical energy, electromagnetic energy (e.g., electric field energy, magnetic field energy, or an electromagnetic wave), or one or more other forms of energy. In an example, a body of the wireless electrostimulation electrode assembly 110 can include an expandable mechanical support that is sized, shaped, or otherwise configured to anchor the assembly 110 at the mitral valve annulus.
FIG. 2 illustrates generally an example of a schematic of a wireless electrostimulation apparatus 200 including a controller / transmitter 220, and a wireless electrostimulation electrode assembly 210. The example in FIG. 2 shows a controller / transmitter 220 that can include a battery 226, a voltage regulator 225, and a microprocessor 224. In certain examples, the microprocessor 224 comprises an input-output (I/O). A switch 228 can be coupled to the microprocessor 224 using the input-output, such as to control current flow from the battery 226 or an optional energy storage device such as a capacitor 227 to an inductive antenna 206. In an example, the inductive antenna can include a wire loop inductor 208. In another example, the inductive antenna 206 can include multiple wire loops, at least some of which can be configured to be offset from each other or otherwise configured or arranged to generate two or more magnetic fields that can be spatially orthogonal to one another, such as to reduce orientation sensitivity of wireless energy transmission or wireless information communication using the inductive antenna 206. A tuning element 229 can be included, such as to allow a range of frequencies to be selected at which magnetically-coupled energy 214 will be generated by the inductive antenna 206. The resulting inductance-capacitance (LC) circuit can form a resonant "tank" circuit, which can have an operable range of resonant frequencies selected from a range of 300 KHz to 10 MHz, but selected below the self-resonant frequency of the inductor 208 comprising the inductive antenna 206.
Certain examples of the tuning element 229 can include, but are not restricted to, a capacitor, a variable-capacitance diode (e.g., "varicap" diode), an active circuit modeling a capacitor of a selected value, or the like. In some examples, the switch 228 and the tuning element 229 can be replaced, such as by a combination of a voltage-controlled oscillator and power amplifier coupled to directly drive the inductive antenna 206, such as to generate the magnetically- coupled energy 214 at a specified range of frequencies. The switch 228 can be implemented either mechanically, such as using a microminiature relay, or as solid-state device (e.g., FET, BJT, IGBT, SCR, thyristor, or the like). In certain examples, the regulator 225, the microprocessor 224, the sensing circuit 223, and the switch 228 can be co-integrated in a single integrated circuit or multi-chip module package. The "microprocessor" can include, among other things, a microcontroller including one or more of a volatile or non- volatile memory, multiple input/output channels, an analog-to-digital converter, a power supply, a digital-to-analog converter, or one or more other circuits, modules, or components that, in an example, can be co-integrated in a single integrated circuit, a single circuit package, a multi-chip module package, a hybrid, a polyimide flex-circuit assembly, or the like. In certain examples, the initiation, timing, duration, or frequency range of the magnetically-coupled energy 214 can be controlled by the microprocessor 224, which can be provided with input from a sensing circuit 223. hi an example, the sensing circuit 223 can be coupled to one or more electrodes 204A, 204B in contact with tissue, or implanted subcutaneously, such as within or near cardiac tissue 202A. In an example, the wireless energy transmission source can be external to the body, and the electrodes 204A, 204B can be coupled to the skin of the patient (e.g., to measure an electrocardiogram). In an example, the controller / transmitter 220 can be included in an implantable cardiac rhythm management device that can include one or more sense electrodes 222A, 222B coupled to the sensing circuit. In an example, the one or more of the sense electrodes 222 A, 222B can be disposed on the housing of the controller / transmitter 220. In an example, the controller / transmitter 220 can include an arrhythmia detector (such as using the microprocessor 224) configured to use information provided by the one or more sense electrodes 222A, 222B or other sensing information, such as to detect an arrhythmia. In an example, such information can be used to control one or more wireless electrostimulation electrode assemblies 210, such as to provide coordinated electrostimulation to inhibit, terminate, or regulate the detected arrhythmia.
The magnetically-coupled energy 214 can be generated for either (or both) transferring the operating or electrostimulation energy 214A to the wireless electrostimulation electrode assembly 210, or information communication 214B with the wireless electrostimulation electrode assembly 210. In an example, a first range of frequencies can be established for wireless energy transfer, and a second range of frequencies can be established for commanding the wireless electrostimulation electrode assembly 210 to deliver an electrostimulus).
In the example shown in FIG. 2, a filter 209 can be configured to discriminate between the operating energy 214A and the information communication 214B. For example, the filter 209 can be configured to detect a particular range of frequencies included in the communication 214B captured by the wireless electrostimulation electrode assembly 210, such as by using an inductive pickup 212. The filter 209 can be coupled to stimulus control logic 216. In certain examples, the logic 216 can be configured to inhibit or to initiate tissue electrostimulation, such as in response to the filter 209 detecting one or more specified signals. The filter 209 can include, in certain examples, a bandpass filter, which can be coupled to a threshold comparator. In certain examples, the filter 209 can include a digital demodulator. In certain examples, communication 214B can be encoded digitally and can include (or be transmitted concurrently to) operating energy 214A being wirelessly communicated to the wireless electrostimulation electrode assembly 210. Examples of digital encoding of communication 214B can include, but are not restricted to, on-off keying, amplitude-shift keying, phase-shift keying, frequency-shift keying, or the like.
In certain examples, the combined capacitance of the tuning element 229 and actual or parasitic capacitances of the inductive antenna 206 can vary when the wireless energy transmission source is implanted in or near tissue 202E. The effect of tissue interaction with the system can be reduced by at least partially surrounding the inductive antenna 206 or the inductive pickup 212 with a protective material or encapsulant (e.g., silicone or one or more other encapsulating compounds). Such encapsulation can inhibit or prevent tissue 202E or liquid (e.g., blood or one or more other bodily fluids) from penetrating into the cavities between individual turns of the windings of the inductive pickup 212 or the inductive antenna 206, which would otherwise increase the effective relative dielectric constant seen by the pickup 212, or the antenna 206.
In certain examples, the microprocessor 224 can be configured to adjust the capacitance of the tuning element 229, or to adjust the frequency of a corresponding voltage-controlled oscillator, such as to achieve a desired level of efficiency in coupling to the wireless electrostimulation electrode assembly 210. In an example, a cardiac pacing electrostimulus can be applied, such as using electrodes 250 and 260, and the evoked response can be observed, such as using the sensing electrodes 205 A, 205B, the leads 222A, 222B, an external electrocardiogram sensing apparatus, or one or more other sources of physiologic information. The tuning element 229, or a corresponding frequency synthesizer, can be adjusted by the microprocessor 224, such as to vary the generated range of frequencies of magnetically-coupled energy 214, for example, until a desired or reliable "capture," (e.g., activation of cardiac tissue resulting from electrostimulation) is observed.
In an example, the wireless electrostimulation electrode assembly 210 can include an inductive pickup 212 and an optional discrete tuning element 211. In an example, the value of the capacitance of the tuning element 211 can be selected before implanting the wireless electrostimulation electrode assembly, such as to achieve a desired resonant frequency when implanted, such as when surrounded by blood or muscle tissue, hi certain examples, to reduce the size of the wireless electrostimulation electrode assembly 210, a discrete capacitor, such as used for tuning element 211, can be omitted, and the capacitance used to achieve resonance of the inductive pickup 212 can be provided by the parasitic capacitance of the physical coil structure of the inductive pickup 212 (for example, the inter-winding capacitance), or one or more other sources of distributed capacitance.
In an example, the magnetically-coupled energy 214A can be rectified, such as by a full-wave rectifier 213, as shown in the example in FIG. 2, or by a half- wave rectifier, which can save space by reducing the number of diode components used in the wireless electrostimulation electrode assembly 210. Rectified energy can be stored in an optional capacitor 215, such as shown in the example in FIG. 2. hi an example, the capacitor 215 can act like a filter capacitor, such as to help suppress ripple voltage. Stimulus control logic 216 can be coupled to a switch 217. The switch 217 can include a solid-state device (e.g., FET, BJT, IGBT, SCR, thyristor, etc.). In an example, such as to reduce the size of the wireless electrostimulation electrode assembly 210, one or more of the filter 209, the logic 216, the switch 217, or the rectifier 213, or one or more other circuits, components, or modules can be co-integrated into a single integrated circuit package, or for example, into a multi-chip module or the like similar to that described above for the controller / transmitter 220. hi certain examples, multiple storage devices 215 and switches 217 can be used, such as to arrange stored voltages in a desired series, parallel, or series- parallel combination, for example, such as to achieve an electrostimulus peak voltage in excess of the maximum voltage stored on a single capacitor 215 using operating energy 214A. hi an example, a direct-current (DC) blocking device 218 can be used to inhibit a DC-stimulus component from being coupled to the electrostimulus electrodes 250, 260. The electrostimulus electrodes 250, 260 can be conductively coupled to the muscle tissue 202E to be electrostimulated (e.g., myocardial tissue). In an electrostimulation example, the electrode 250 can be used as the cathode and the electrode 260 can be used as the anode.
The blocking device 218 and the shunt device 219 can form a high-pass network configured such that the upper cutoff frequency (or resulting time- domain pulse shape) can be selected or even programmably adjusted, such as to form or shape a desired electrostimulus waveform. In an illustrative example, the blocking device 218 can be selected as a capacitor having a capacitance of about 1 microFarad, and the shunt device 219 can be selected as an approximately 5 kiloOhm resistor, such as to achieve a desired cardiac tissue electrostimulation pacing pulse.
The present inventors have recognized that, among other things, tissue and body fluid can absorb and disperse inductive energy, and that such absorption and dispersive effects can rapidly increase at frequencies greater than 100 KHz. These effects can severely limit the range and maximum achievable efficiency of typical magnetic coupling schemes. One technique for decreasing such losses can be to substantially or completely surround the inductive antenna 206 or inductive pickup 212 with a high relative permeability magnetic material, such as an iron-powder core, a ferrite material, or the like. Such materials can effectively magnify the magnetically-coupled energy density experienced by a nearby winding structure, at a given incident magnetic field intensity.
The high relative magnetic permeability of such materials can render the resultant implantable device assemblies incompatible with magnetic resonance imaging (MRI) equipment. Locally-induced forces or torques (e.g., induced in single components) associated with the strong bias field present near operating MRI equipment could result in mechanical damage to the inductive antenna 206 or the inductive pickup 212 assemblies if they incorporate a high relative magnetic permeability material.
MRI equipment can also induce large voltages, across the terminals of the inductive antenna 206 or the inductive pickup 212, and large currents. This can induce an internal temperature rise. This can damage (e.g., by electrical short-circuiting or dielectric failure) inductors or other components electrically coupled thereto, or can thermally damage surrounding tissue 202E. In an example, one or more protection devices (e.g., discharge tubes, gaps, solid-state transient-suppression devices) can be additionally or alternatively included to inhibit or prevent MRI-related electrical damage. A small wireless electrostimulation electrode assembly 210 is generally desired (e.g., to allow intravascular introduction and placement) and such additional protection devices can use additional space and may not mitigate the MRI- induced forces and torques.
The present inventors have also recognized, among other things, that ferrite core materials can also have other limitations. For example, internal loss mechanisms can preclude using ferrite as core material for highly-tuned inductors at frequencies above a few MHz. This can prevent the resonant "tank circuit" in the inductive transmit network or inductive receiver network from achieving high power coupling efficiencies, since the quality factors ("Q") of both networks are limited by the resistive damping effects of increasing losses within the ferrite core material.
By contrast, the present inventors have recognized that, in a different approach, the core materials or mechanical supports surrounding the inductive antenna 206 or the inductive pickup 212 can include one or more materials other than ferrites, such as one or more materials having a relative magnetic permeability less than 1.1. hi certain examples, the inductive antenna 206 or the inductive pickup 212 can be surrounded by, encompassed by, or located near a material or a mechanical support having a relative magnetic permeability substantially equal to 1, such as air, one or more bodily tissues (e.g., muscle, fat, bone, etc.), or one or more bodily fluids such as blood. In these examples, an effective relative magnetic permeability seen by the inductive antenna 206 or the inductive pickup 212 can be substantially equal to 1, such as such as representing an inhomogeneous medium around the inductive antenna 206 or the inductive pickup 212.
Materials, such as shape-memory Nickel-Titanium (NiTi or Nitinol) compounds, are effectively non-ferromagnetic and can have other beneficial mechanical properties. For example, the shape-memory property can be used to provide self-expansion (e.g., after implant) of the loop antenna 206 or the inductive pickup 212. Increasing or maximizing the area of a loop forming an inductive antenna 206, or inductive pickup 212, can enhance the mutual coupling of two nearby such inductive devices. In some examples, such a shape-memory material can be used as a mechanical support, such as to provide an expansion force to expand a wound coil that is configured to be used as either an inductive transmit antenna (e.g., inductive antenna 206) or as an inductive receiver (e.g. inductive pickup 212). Such materials can also help mitigate ferrite efficiency loss and allow more efficient coupling of time-varying magnetic flux through tissue, such as at frequencies up to several MHz. The term "air core" can be used to describe inductive transmitter 208 and inductive pickup 212 structures that do not have a ferrite core within a wound loop of such structures, even though the actual construction of such devices might include non- ferromagnetic metallic support structures and, when implanted, tissue or bodily fluid may be present within the core of the inductive transmitter 208 or inductive pickup 212. hi an illustrative example, a mathematical analysis of a simplified combination of the controller / transmitter 220 and wireless electrostimulation electrode assembly 210 can be used to estimate power coupling efficiency, r\, and electrostimulus output voltage magnitude, |VL|. The combination of the switch 228, and the battery 226 can be represented as an AC voltage source operating at angular frequency ω, and peak output voltage V0. The inductive antenna 206 can be modeled as a combination of an ideal inductor, L, 208 in series with a transmit circuit resistance R. The tuning element 229 can be modeled as a capacitor, C. The transmit circuit impedance can be represented as Z = R + i ( ωL - 1/ωC ), in which i =
Figure imgf000022_0001
. At resonance, C = l/ω2L, and Z = R. The imaginary components, due to the reactances of the capacitor and inductor, can cancel each other (unity power factor).
Similarly, for the electrostimulation circuit that can be included in the wireless electrostimulation electrode assembly 210, the inductor 212 can be modeled as Li , and its corresponding loss as resistance "r" in series with Li . The tuning element 211 can be modeled as a parallel capacitor Ci, and the tissue load 202E appearing across electrostimulus electrodes 250, 260 can be modeled as RL. Neglecting the rectifier 213, the switch 217, the shunt capacitor 215, the blocking device 218, and the shunt resistor 219, the receiver inductive pickup impedance can be represented as Zi = r + ϊ'ωLi and the impedance associated with the tissue load and tuning element can be represented as ZL = RL / ( 1 + /ωRLC, ).
For the wireless electrostimulation electrode assembly 210, this can be represented as a lossy inductive pickup Z1 = r + /G)L1 in parallel with a load represented by ZL = RL / ( 1 + JU)RLCI ). The total parallel impedance Z2 = r + RL / ( 1 + (G)RLC1)2 ) + i [ωLi - ωRL 2 Ci / / ( 1 + (ωRLCi)2 ]. At resonance, 1 + (G)RLC,)2 = RL 2C, / L1, and Z2 = r + RL / ( 1 + (ωRLC,)2 ) = r[ 1 + Li/(rRLCi) ].
The magnitude of ZL= -V(LI/CI) .
The mutual inductance, M, of the transmit antenna 206 and the inductive pickup 212 can be represented as the product of the self inductances of the two inductors 208, 212 and a coupling constant, K: M2 = /c L L1. Power coupling efficiency and peak output voltage at the tissue load 202E can be represented as: ij = κQQ,x / [( 1 + x )( l + x + KQQ1 )] (1) |VL| =
Figure imgf000023_0001
V0 / ( 1 + x + /CQQ1 ) (2) where Q = ωL/R = quality factor of transmitter, Qi = ωh\/τ - quality factor of receiver, and x = Li/(rRLCi). The following relation can be obtained:
KQQ1 » 1 + x, η → x / ( 1 + x ) (3) and when x»l, the power coupling efficiency, η, approaches 1 (corresponding to 100%). Thus, for small values of the coupling constant, K, if the quality factors are sufficiently large, the power coupling efficiency can approach unity.
Generally, the wireless electrostimulation electrode assembly 210 receiver resonant frequency and quality factor Qi can vary depending on the specific implant configuration of the inductive pickup 212, and the resulting tissue and blood proximity effects on the electrical response of the inductive pickup 212. However, by actively varying the value of tuning element 229 in the controller / transmitter 220, as described previously, the controller / transmitter 220 transmitter resonant frequency can be varied, such as to compensate for changes in the wireless electrostimulation electrode assembly 210 receiver resonant frequency or to control electrostimulus amplitude or energy achieved at electrodes 250, 260.
In certain examples, if the transmitter 220 quality factor, Q, is selected to be much greater than the receiver quality factor, Qi, the receiver can have a broader "tuning envelope" than the transmitter. With a broader wireless electrostimulation electrode assembly 210 receiver response characteristic, the transmitter tuning element 229 can be adjusted more easily (e.g., less precisely) to provide an operating frequency at resonance corresponding the resonant frequency of the receiver in the wireless electrostimulation electrode assembly 210 (e.g., the transmitter can be tuned to be more sharply "peaked" at resonance than the receiver, and transmitter resonant frequency can then be swept until centered on receiver resonant frequency).
In certain examples, varying the resonant frequency of the transmitter by changing the capacitance of the tuning element 229 can also control the magnitude of the electrostimulus voltage coupled to the tissue load 202E.
Selecting a value for the tuning element 229 that shifts the resonant frequency of the controller / transmitter 220 away from the resonant frequency of the wireless electrostimulation electrode assembly 210 can result in decreasing maximum voltage, I VL|, coupled to the tissue load 202E. This can reduce the size of the wireless electrostimulation electrode assembly 210 by eliminating or reducing the complexity of logic 216 and the switch 217 such as by allowing electrostimulation amplitude control to be accomplished by the controller / transmitter 220.
In certain examples, the operating energy 214A can be limited in duration or maximum amplitude such as to avoid tissue heating or regulatory limits for average or instantaneous power transmitted through tissue. The resulting rectified energy can be integrated or otherwise accumulated by, for example, the capacitor 215. |VJ can, for instance, be established by a series- or shunt-regulation component such as a Zener diode 230. hi certain examples, the Zener diode 230 can be used to simplify or eliminate the stimulus control logic 216 and the switch 217 when a pulse-width modulation (PWM) scheme is used at the controller / transmitter 220. A microprocessor, state machine, timing logic, and the like can be omitted from the wireless electrostimulation electrode assembly 210 to reduce complexity, physical volume, etc.
In one example, the stimulus control logic 216 can still be used to inhibit electrostimulation delivery to the tissue load 202E (e.g., by opening the switch 217 when an intrinsic event is sensed), but is not required to control the level of electrostimulation energy content delivered to the tissue load 202E.
In certain examples, the operating energy 214A can be established at a specific burst duration (e.g., a burst can be a square pulse envelope commencing a sequence of multiple resonant oscillations). The duration or pulse width of the burst of operating energy 214A can be related to the energy content delivered to the tissue load 202E when the diode 230 is clamping the voltage across the capacitor 215.
If the tissue 202E is modeled as a cardiac tissue load having a resistance RL= 1 kiloOhm in parallel with a series-combination of a 1 kiloOhm resistor (rθ and a 1 microFarad capacitor (CL), a cardiac tissue electrostimulation pacing pulse of greater than 4V peak amplitude, |VL|, can be achieved using a resonant frequency of 1 MHz.
In an illustrative example, at a leading edge of a cardiac tissue electrostimulation pulse, the load capacitor can be represented effectively as a short circuit, and the AC resistance of the model cardiac tissue load 202E is equal to around 500 ohms (1 kiloOhm in parallel with 1 kiloOhm).
In certain examples, the burst duration of the operating energy 214A can be controlled by the microprocessor 224 and the switch 228 at the controller / transmitter 220 to achieve a desired energy content coupled to the tissue load 202E.
A theoretical voltage delivered across a cardiac tissue capacitance, VCAP, can be represented as:
VcAP = VcLAMp [ l - e-w/ rLC L ] (4) where VCLAMP represents the voltage clamping threshold of the diode
230, and w represents the burst pulse duration (in seconds). For small burst pulse durations, VCAP can be approximated as:
VCAP = VCLAMP [W/ΓLCL] for w « rLCL (5)
In an example, VCLAMP can be 5.6V (e.g., established by the Zener diode 230), w can be 775 microseconds, ΓL = R = 1 kiloOhm, and C = I microFarad. Using EQUATION 4, VCAP can be computed as approximately 3 Volts. In another example, w can be 1250 microseconds, and VCAP can be computed as approximately 4 Volts. In certain examples, the volume occupied by wireless electrostimulation electrode assembly 210 can be decreased by limiting the total energy stored, for example, the capacitor 215. An estimate of the desired stored energy for various electrostimulation pulses can be made. For example, if RL= 500 Ohms, and |VL| = 2.5 V, a square-wave pulse of duration T = 0.4 milliseconds can correspond to a stored electrostimulation energy of T|VL|2 / RL = 5 microJoules.
The capacitor 215 can be specified as a capacitor = Cs, in microFarads. The energy stored in the capacitor 215 can be represented as λA CS|VL|2. The number of electrostimulation delivery cycles that the energy stored in the capacitor 215 can deliver can be represented as: the energy stored on the capacitor = 1A CS|VL|2, divided by the electrostimulation energy consumed by a single electrostimulation cycle delivered to the tissue impedance = T|VL|2 / RL- Thus, the number of cycles that capacitor 215 can supply can be represented as = RLCS/2T. Tradeoffs can be made between the capacitor 215 value Cs, load resistance RL and, for example, pulse width, to achieve a desired wireless electrostimulation electrode assembly 210 volume and a desired electrostimulation duration, for instance, during an interval when the inductive operating energy 214A is absent or insufficient. For example, the number of desired electrostimulation cycles can be = N, and value for capacitor 215 to provide N electrostimulation cycles can be represented as Cs = 2TN/RL- In an example, an electrostimulation pulse duration can be specified as T = 0.4 msec, the load resistance can be RL = 500 Ohms, and the capacitance Cs can be represented for N=I as Cs = 1.6 μF. A low voltage 1.6 μF capacitor 215 can be small (e.g., sub-millimeter dimensions on each axis).
In certain examples, back-up storage can be desired for patient protection (e.g., to provide continued electrostimulation for a limited duration in the temporary absence of the operating energy 214A). A heart rate can be specified = HR in Hertz, a number of cardiac cycle to be paced in a total time = TstOred, in seconds, can be represented = HRTstored, and the size of the capacitor to store a corresponding amount of energy can be represented, Cs = 2THRTstOred/RL- For example, one hour = 3600 sec of stored electrostimulation energy and a heart rate of 72 beats per minute or 1.2 Hz can be specified, resulting in, for example, a number of pacing electrostimulation cycles HRTstored = 4320, and a total stored energy = 21.6 milliJoules. The tissue impedance RL can be specified as 500 Ohms and pulse width can be specified as T = 0.4 msec, and the capacitance 215 can be represented Cs = 6912 μF. Such a capacitor can occupy several cubic millimeters of volume in the receiver circuit.
In certain examples, a compromise between the capacitor 215 value Cs and the physical size of the capacitor 215 can be made. In an illustrative example, the capacitor 215 can be specified, Cs = 320 μF, and electrostimulation pulses can be specified, |VL| = 2.5 volts.
In another illustrative example, the total energy stored on capacitor 215 is 1 milliJoule, and can be enough energy to deliver 200 electrostimulation cycles of pulse width T = 0.4 msec to into a tissue load RL =500 Ohms. In another illustrative example, capacitor 215 can be specified Cs = 320 μF and the electrostimulation cycle rate of 72 electrostimulation cycles per minute can result in continued electrostimulation delivery, for approximately 2.8 minutes, by wireless electrostimulation electrode assembly 210, after the operating energy 214A to Cs is inhibited or interrupted.
The capacitor 215 can also be specified to accommodate the quiescent power consumed by, for example, the stimulus control logic 216 comprising a microprocessor, which can be very small depending upon the device used, but in some cases can be comparable to, or larger than, the average pacing power. In certain examples, the power consumed by the wireless electrostimulation electrode assembly 210 can be reduced if the stimulus control logic 216 and the filter 209 are omitted and the switch 217 is permanently closed or omitted. For certain examples, the capacitor Cs can be a filter capacitor, and the operating energy 214A received by the wireless electrostimulation electrode assembly 210 can be rectified and delivered directly to the tissue load (e.g., the delivered electrostimulation pulse width can correspond to the width of a transmitted energy 214A burst pulse, provided that the time constant T = CsR1Js less than about one half of the pulse width). In certain examples, such direct conversion of energy 214A into an electrostimulation delivery can be achieved when Cs < 0.4 μF (e.g., corresponding to an electrostimulation pulse width of T = 0.4 msec and load RL = 500 Ohms).
In certain examples, the sensing circuitry 232 can be coupled to the cardiac tissue 202E to provide physiologic information to stimulus control logic 216 in response to sensed potentials detected by the sensing circuitry 232. Signaling to the stimulus control logic 216 by the sensing circuitry 232 can occur in response to intrinsic tissue activity (e.g., the sensing circuitry 232 establishes a threshold level or window and intrinsic activity can cause a voltage fluctuation exceeding a threshold level or window resulting in a threshold crossing signal to the stimulus control logic). The stimulus control logic 216 can inhibit electrostimulation using the switch 217 in response to, for example, detection of sensed events provided by the sensing circuitry 232.
In certain examples, a shunt device 219 can also provide charge neutralization. Charge neutralization can include providing a path between the electrostimulus electrodes 250, 260 to slowly discharge an afterpotential occurring during or after an electrostimulation, resulting in a net neutral charge delivered by the electrostimulation electrodes 250, 260. For the example of a pacing waveform described above, charge neutralization can be observed as a smaller amplitude negative-phase pulse of longer duration following the positive-phase cardiac tissue electrostimulation pulse. In certain examples, the wireless electrostimulation electrode assembly 210 can include multiple electrostimulation output blocks electrically connected to multiple electrostimulation electrodes 250, 260.In certain examples, one or more capacitors 215, can be coupled to one or more respective cathode electrodes 250, such as through one or more respective switches 217. In an example, the one or more cathode electrodes 250 can use a commonly-shared anode electrode 260.
FIG. 3 illustrates generally an example of an apparatus 300 including a plurality of wireless electrostimulation electrode assemblies at respective implant locations within a heart 302 and within respective blood vessels. hi the example of FIG. 3, a first wireless electrostimulation electrode assembly 310 can be located within a heart 302 at a mitral valve 378 annulus, as shown and discussed above in FIG. 1. A controller / transmitter 320 can include one or more wireless couplings to one or more wireless electrostimulation electrode assemblies, such as a wireless coupling 314E to the first assembly 310. In an example, the first assembly 310 can receive operating energy or communicate (e.g., control information, sensing information, a signal to initiate an electrostimulation, or one or more other forms of information) using the wireless coupling 314E.
In certain examples, one or more additional wireless electrostimulation electrode assemblies can be implanted at other locations within the heart, or within one or more blood vessels, resulting in a plurality of wireless electrostimulation electrode assemblies available to deliver one or more coordinated electrostimulations, such as to locations within a right atrium 379, a left atrium 374, or a left ventricle 376. In an example, an apparatus including the plurality of wireless electrostimulation electrode assemblies can also include one or more intravascularly-introduced endocardial leads, such as to provide electrostimulation to the right ventricle 372, the right atrium 379, or one or more other locations.
In an example, a second wireless electrostimulation electrode assembly 315 can be located at or near an ostium of left atrial appendage 375. Such a second assembly 315 can also be used, for example, to partially or completely occlude or block the opening to the left atrial appendage 375. In this example, the second assembly 315 can include an expandable mesh, or screen, or other semi-permeable or impermeable structure to prevent a blood clot or other debris within the left atrial appendage 375 from being released elsewhere into the heart 302, or vasculature (e.g., see FIG. 7). In an example, a third wireless electrostimulation electrode assembly can be located at a right atrial appendage. In an example, the third wireless electrostimulation electrode assembly can be configured to occlude or block the opening to the right atrial appendage. In certain examples, one or more wireless electrostimulation electrode assemblies can be located in one or more pulmonary veins, such as a fourth wireless electrostimulation electrode assembly 31 IA located within a right pulmonary vein 379A, or a fifth wireless electrostimulation electrode assembly 31 IB located within a left pulmonary vein 379B. In certain examples, the fourth or fifth assemblies 311 A, 311B can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314A, 314C. In certain examples, one or more wireless electrostimulation electrode assemblies can be located in the vena cava, such as a sixth wireless electrostimulation electrode assembly 311C located in a superior vena cava 392, or a seventh wireless electrostimulation electrode assembly 31 ID located in an inferior vena cava 391. In certain examples, the sixth or seventh assemblies 311 C, 311D can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314H, 3141. In certain examples, a body of one or more intravascularly-introduced endocardial leads can occupy a vena cava after a sixth or seventh assembly 311 C, or 311 D is implanted, since the sixth or seventh assembly 311 C, or 31 ID can be stent-like and need not occupy a large portion of a cross section of the vena cava. hi certain examples, an eighth wireless electrostimulation electrode assembly 31 IE can be located in a coronary sinus, hi an example, the eighth assembly 31 IE can receive operating energy or communicate with the controller / transmitter 320 using a wireless coupling 314J. hi an example, the eighth assembly 31 IE is located within the coronary sinus as closely as possible to the ostium of the coronary sinus, such as to place one or more electrostimulation electrodes in electrical contact with a muscle sleeve portion of the coronary sinus, hi certain examples, if an ablation procedure has been performed near or around the ostium of the coronary sinus, the eighth assembly 31 IE can be used to terminate or control a reentrant arrhythmia having a focus or conduction pathway near the ostium of the coronary sinus, hi certain examples, one or more wireless electrostimulation electrode "seed" assemblies can be implanted partially or completely within the myocardium of the heart 302, such as in left atrium 374, or in the left ventricle 376 where intravascularly-introduced endocardial leads are contra- indicated, hi an example, the eighth assembly 313 can receive operating energy or communicate with the controller / transmitter 320 using a wireless coupling 314B. hi an example, a ninth wireless electrostimulation electrode assembly 313 can be located in the atrial septal region of the heart 302. In certain examples, a tenth or an eleventh wireless electrostimulation electrode assembly 317A, 317B can be located partially or completely within myocardial tissue in the left ventricle 376. hi certain examples, the tenth or eleventh assemblies 317A, 317B can receive operating energy or communicate with the controller / transmitter 320 using respective wireless couplings 314F, 314G. hi an example, one or more of the wireless couplings 314A- J can use magnetically-coupled energy, such as inductive coupling, between the controller / transmitter 320 and one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B to provide operating energy to, or to communicate with, the one or more wireless electrostimulation electrode assemblies 310, 311 A-E, 313, 315, 317A-B. In certain examples, one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include circuitry or components similar to the wireless electrostimulation electrode assembly 210 shown in FIG. 2. hi an example, the transmitter / controller 320 can be a subcutaneous implantable medical device such as a cardiac rhythm management device. In an example, the transmitter / controller 320 can include circuitry or components similar to the controller / transmitter 220 shown in FIG. 2. hi certain examples, one or more of the wireless electrostimulation electrode assemblies 310, 31 IA- E, 313, 315, 317A-B can be delivered into the heart or into the one or more blood vessels using an intravascular, transluminal route, such as through one or more delivery catheters. In certain examples, one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include one or more expandable mechanical supports configured to fold, collapse, or contract during delivery to an implant location, allowing the one or more wireless electrostimulation electrode assemblies to pass through the lumen of a delivery catheter when the delivery catheter is passed through one or more blood vessels. In certain examples, the wireless electrostimulation electrode assemblies 31 IA-E can be stent-like, as shown in FIG. 3, and can be located in one or more blood vessels so that one or more electrostimulation electrodes included with the wireless electrostimulation electrode assemblies 31 IA-E can be in contact with a muscle sleeve near the opening or ostium of the one or more blood vessels, hi certain examples, one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can include multiple electrodes coupled to an electrostimulation circuit included as a portion, part or component of each of the respective assemblies 310, 31 IA-E, 313, 315, 317A-B. In an example, the multiple electrodes can be multiple cathode electrodes included on a portion of the one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B. In an example, the multiple cathode electrodes can be located closer to the heart 302, such as contacting the muscle sleeve near the opening or ostium of the one or more blood vessels. In an example, the multiple cathode electrodes can share a common anode electrode.
In certain examples, the controller / transmitter 320 can include an arrhythmia detector 324. In certain examples, the arrhythmia detector can detect, identify, or categorize one or more arrhythmias and can provide communication or operating energy to one or more wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B, such as to provide one or more coordinated electrostimulations to regulate, control or terminate the arrhythmia. In certain examples, the arrhythmia detector 324 can detect one or more arrhythmias using physiologic information, such as provided by one or more electrocardiogram sensing electrodes. In certain examples, the arrhythmia detector 324 can include one or more timers or comparators, such as to detect a shortened QRS duration, a shortened P-wave to QRS duration, multiple P-waves or one or more other arrhythmic indications derived from information from the one or more electrocardiogram sensing electrodes, or from other physiologic sensors. In certain examples, the arrhythmia detector can be a portion, part or component of a microprocessor, microcontroller, multi-chip module, or one or more other circuits or modules, such as shown in the controller / transmitter 220 in FIG. 2. In some patients, one or more conduction pathways of the heart 302 can be damaged, such as due to previous myocardial infarct, disease, or one or more other acute or chronic causes or conditions. Intravascularly-introduced endocardial pacemaker or defibrillator lead systems can be incapable of use at locations near such damaged pathways. For example, such intravascular leads can be contra-indicated for use at many locations where such conduction pathway damage can occur (e.g., the left heart, or within one or more blood vessels near or within the heart.) The present inventors have recognized that a likelihood that an arrhythmia can be detected, prevented, or terminated can be increased when endocardially-implanted or vascularly-implanted wireless electrostimulation electrode assemblies are used since a greater variety of implant locations can be available compared to intravascularly "tethered" conductive electrostimulation lead systems, and such wireless assemblies can be compact and can fit entirely within a chamber of the heart or within one or more blood vessels. Studies might show that multi-site atrial pacing, including left atrial sites, at locations that can be known as "atrial fibrillation triggers," can prevent or reduce an incidence of atrial fibrillation or other atrial arrhythmias. In an example, one or more locations in each of the left and right atria can be paced simultaneously to provide "atrial resynchronization therapy." In this example, tissue can be depolarized before the arrival of an arrhythmic depolarization wavefront, and such tissue can be in a refractory period, thus breaking the propagation of the arrhythmic depolarization wavefront (e.g., preventing the depolarization wavefront from activating tissue that has been previously electrostimulated, since such tissue is in a refractory period).
In certain examples, the one or more electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B can be used to defibrillate the heart 302. In these examples, multi-site or distributed defibrillation, as distinct from pacing therapies, can require less total energy as compared to two pole defibrillation (e.g., defibrillation using only two electrodes). In an illustrative example, a threshold electric field intensity can be determined when two electrodes are placed across the heart (or atria in the case of AFIB). In this example, the two electrodes can reliably defibrillate the heart 302 when the threshold electric field intensity can be exceeded. The electric field in tissue can be reduced in proportion to the inverse square of the distance from a defibrillation electrode. The threshold electric field can be represented as the electric field needed to fully depolarize tissue that is farthest from an electrode. Tissue of the heart 302 can be modeled a as spherical shell of radius R, and two defibrillation electrodes can be separated by a distance 7iR. hi an illustrative example, if an array of N electrodes can be distributed uniformly over the tissue shell, the separation between electrodes in the array can be represented by 7τR-v(2/N). In this example, a minimum electric field needed to depolarize tissue midway between the array of electrodes can be proportional to the inverse square of their separation, and thus the ratio of minimum electric field needed for N electrodes compared to the minimum electric field needed two electrodes can be represented as 2/N. Defibrillation energy can be proportional to the square of the electric field, so a ratio of defibrillation energy to be delivered between any pair of electrodes in the array as compared to two electrodes alone can be represented as 4/N2. hi this illustrative example, since there are N/2 pairs of electrodes in the array, the total energy delivered to the array to provide defibrillation, divided by the total energy needed if only two electrodes are used, can be represented as 2/N. In an illustrative example, a clinical requirement for painless atrial defibrillation can be that no more than one Joule total energy can be delivered to the tissue to avoid pain. In this example, if a typical defibrillation between only two implanted electrodes is 4 Joules, then a painless, one Joule, shock can be delivered using 8 distributed electrodes, with 0.25 Joules delivered between respective electrode pairs.
FIGS. 4A-D illustrate generally section views of an example of a system including an elongate delivery catheter 480, actuator 482, a pull wire 483, and a wireless electrostimulation electrode assembly 401 including an expandable mechanical support, and including an electrostimulation circuit 440. In FIG. 4A, the delivery catheter 480 can be steered, introduced, advanced, or otherwise navigated to a location within the heart or within a blood vessel, near a desired implant location 402, such as a blood vessel location, or some other constraining location within the heart (e.g. an atrial appendage, an aorta, a mitral valve annulus, or one or more other locations). In some examples, the delivery catheter may be introduced into the interior of a heart via a subclavian or transfemoral approach as is used for various minimally-invasive procedures such as pacemaker or defibrillator lead implantation, or such as used for percutaneous coronary interventional procedures, hi the example of FIG. 4, the actuator can be attached to the electrostimulation assembly 401, such as by forcing, displacing or constraining a portion of the electrostimulation assembly 401 into a channel within the actuator 482, and holding the electrostimulation assembly 401 captive in the channel using the pull wire 483. The actuator 482, electrostimulation assembly 401, and pull wire 483 can together be translated, rotated, or pushed through the lumen 481 formed by the elongate delivery catheter 480. In FIG. 4B, the delivery catheter 480 can be further steered or advanced into the implant location 402. In an example, the actuator 482, electrostimulation assembly 401, and pull wire 483 can together be translated, rotated, or pushed out of the lumen 481 formed by the elongate delivery catheter 480, exiting the delivery catheter 480. hi the example shown in FIG. 4C, the delivery catheter 480 can be retracted, leaving the actuator 482, pull wire 483, and electrostimulation assembly 401 in place at the implant location 402. hi an example, one or more additional actuators or manipulators (e.g., one or more pusher tubes, push rods, push or pull wires, or one or more other actuators) can be included within the lumen 481 of the delivery catheter 480, such as to expand, rotate, move, or assemble the electrostimulation assembly 440. hi the example shown in FIG. 4C, the wireless electrostimulation assembly 440 can include a portion, part or component, such as a mechanical support or body, made of a shape-memory material such as stainless steel, NiTi (nickel titanium), a polymer material, or one or more other biocompatible materials, hi an example, when the electrostimulation assembly 440 is constrained by the delivery catheter 480, the electrostimulation assembly 440 can be in a folded, compressed, or collapsed configuration, and can occupy less area, length, width, or height. In an example, when the electrostimulation assembly 440 is no longer constrained by the delivery catheter 480, the electrostimulation assembly 440 can expand, unfold, open, or decompress to possess a larger area, length, width, or height, such as constrained by an implant location 402. hi an example, an expansion force can be provided by the electrostimulation assembly 440, such as imparted by a shape memory material, and the expansion force can anchor the electrostimulation assembly 440 to the implant location, such as to prevent the electrostimulation assembly 440 from dislodging or moving away from the implant location 402. hi certain examples, one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3 can be delivered, manipulated, assembled or moved using, for example, a portion, part, or component of the system of FIGS. 4A-D.
FIGS. 5A-5B illustrate generally examples of a wireless electrostimulation electrode assembly 500 at a mitral valve annulus location within the left atrium of a heart 502. An expandable mechanical support 501 can conform to and at least partially encircle a ring formed by the mitral valve annulus, such as just above the anterior and posterior leaflets 578A, 578B. A portion, part, or component of the mechanical support 501 can be made from a shape memory material to provide an expansion force to anchor the electrostimulation assembly 500 at the mitral valve location. In an example, the electrode assembly 500 of FIGS. 5A-B can be delivered, assembled, manipulated, or moved using a transluminal, intravascular, catheter-based approach such as shown in FIGS 4A-D. In certain examples, the cross-section or shape of the expandable mechanical support 501 can include a circular cross section (e.g., including a wire shape or tubular shape, etc.), an elliptical cross section, a rectangular cross section, or one or more other shapes, such as to provide a flexible mechanical support including at least a portion configured to conform to the ring of the mitral valve annulus. In certain examples, the expandable mechanical support 501 can be fabricated using extrusion, laser cutting, stamping, molding, lithographic etching, or using one or more other techniques, methods, or processes.
In FIGS. 5A-B, the electrode assembly 500 can include one or more electrostimulation electrodes 550, 560, 561 coupled to cardiac tissue of the heart 502. hi some examples, a fibrous tissue layer at the annulus can inhibit electrostimulation or raise a threshold needed to evoke a depolarization, reducing the efficiency of the electrostimulation, hi such examples, the electrostimulation electrode assembly 500 can include electrodes having a spine, a tine, a helix, a barb or one or more other features to penetrate into the fibrous layer and through to a myocardial tissue layer in order to provide electrostimulation to the myocardial tissue directly, such as shown in FIGS. 6A-B. In an example, the electrode 550 can be an anode electrode, and the electrode 560 can be a cathode electrode, hi certain examples, the electrostimulation assembly 500 can include multiple cathode electrodes, such as, for example, electrodes 560-561, and a commonly shared anode, such as electrode 550. In FIGS. 5A-B, an electrostimulation circuit 540 can be coupled to electrodes 550, 560, and 561 using conductive connections 503A, 503C, and 503B, respectively, hi an example, the electrostimulation assembly 540 can include one or more parts, components, or circuits such as shown in the wireless electrostimulation electrode assembly 210 of FIG. 2. hi an example, the electrostimulation assembly 540 can be similar to or the same as the wireless electrostimulation electrode assembly 110 shown in FIG. 1. hi the example of FIG. 5 A, the electrostimulation assembly 500 can include one or more inductive pickups 512A, 512B to receive magnetically-coupled energy from a location within or outside the heart 502, such as from a controller / transmitter 220, 320 as shown in FIGS. 2-3. hi an example, the one or more inductive pickups 512A, 512B can be one or more inductive coils wrapped around or on one or more sides of the mechanical support 501. hi an example, the one or more inductive pickups 512A, 512B can be configured to receive or transmit magnetic fields in a spatially orthogonal manner to minimize sensitivity to a particular orientation of the electrostimulation assembly 500, such as when the electrostimulation assembly transmits or receives magnetically-coupled energy. In certain examples, such as the examples of FIGS. 5A-B, the expandable mechanical support 501 need not completely encircle the ring formed by the annulus of the mitral valve. For example, patients can have annulus shapes and sizes that can vary, such as for an individual patient over time, or between different patients. In certain examples, such as shown in FIGS. 5A-B, a gap 507 along the circumference of the expandable mechanical support 501 can allow the expandable mechanical support 501 to flex or bend to occupy a larger or smaller ring size, and to conform to the shape of the ring formed by the mitral valve annulus. In certain examples, diagnostic imaging such CT, PET, fluoroscopic imaging, ultrasonic imaging, or one or more other forms of imaging can be used to non-invasively assess a size of the ring formed by the mitral valve annulus, and a corresponding expandable mechanical support 501 can be selected for a particular patient at a particular time (such as shortly after imaging, the support 501 sized and shaped to fit the particular patient), hi certain examples, a wireless electrostimulation electrode assembly 500 such as shown in FIGS. 5A- B can be a portion, part or component of a prosthetic implant for mitral valve reconstruction, or such an electrostimulation assembly can be implanted during mitral valve annuloplasty procedure. In the example of FIG. 5B, one or more inductive pickups 512 can include one or more turns of wire, for example, included on one or more faces of the electrostimulation assembly 500, such as, for example, to receive or transmit magnetic energy over a cross sectional area including a substantial portion of a cross section of the mitral valve annulus. In certain examples, the gap 507 can be crossed by a flexible portion of the inductive pickup 512, such as, for example, to better allow the inductive pickup and the mechanical support 501 to adjust or conform to the anatomy of the mitral valve annulus of the particular patient. FIGS. 6 A-B illustrates generally section views of an example of a system 600 including a delivery catheter 680, and a wireless electrostimulation electrode assembly 601 including an expandable mechanical support and one or more extending tines 655A-D. In an example, a delivery system similar to FIG. 5 can be used to move, manipulate, assemble, or rotate the electrostimulation assembly 601 at or near the mitral valve annulus 678 above the anterior and posterior leaflets 678A, 678B in the left atrium of a heart 602. hi FIG. 6A, the one or more extending tines 655A-D can be in a collapsed, folded, or retracted position such that the electrostimulation assembly 601 can be freely moved, translated, or rotated within the delivery catheter 680. In FIG. 6B, when the delivery catheter 680 is retracted, the one or more extending tines 655A-D can be extended into tissue at or near the mitral valve annulus 678 to anchor the electrostimulation assembly 601 to the annulus 678 within the heart. In an example, the extending tines can include a portion, part, or component made of a shape memory material, such that when the delivery catheter 680 is retracted, the extending tines can automatically extend, unfold, pop out of a cavity, or otherwise deploy into cardiac tissue such as to anchor the electrostimulation assembly 601. hi an example, the one or more extending tines 655A-D can provide one or more electrostimulation sites penetrating through a fibrous layer at the mitral valve annulus 678. In an example, one or more of the extending tines 655A-D can be an electrode coupled to an electrostimulation circuit included as a portion, part or component of the wireless electrostimulation electrode assembly 601. hi certain examples, one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3 can include a spine, a tine, a helix, a barb or one or more other features to penetrate into cardiac tissue, such as the extending tines of FIGS. 6A-6B, such as to anchor the one or more wireless electrostimulation electrode assemblies, or to penetrate into the myocardium from within a heart or within a blood vessel. FIG. 7 illustrates generally an example of a system 700 including a delivery catheter 780, an inflation balloon 786, and wireless electrostimulation electrode assembly 715 located at a left atrial appendage 775. In an example, a transfemoral approach can be used to guide the delivery catheter through the vasculature to the inferior vena cava 791, into a right atrium of a heart 702, and then through the atrial septal region, such as through the fossa ovalis, allowing the delivery catheter to enter the left atrium 774 of the heart. In certain examples, such an approach can be used to deliver one or more wireless electrostimulation electrode assemblies, such as one or more of the wireless electrostimulation electrode assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3. A superior vena cava 792 can be used as a route into the right atrium 770 for the delivery catheter 780 in addition to or instead of the inferior vena cava 791, (e.g., as used for implant of one or more conductive pacemaker lead systems). In the example of FIG. 7, the wireless electrostimulation electrode assembly 715 can include a stent-like expandable mechanical support, and an electrostimulation circuit 740 coupled to one or more electrostimulation electrodes, or to the expandable mechanical support. In certain examples, the wireless electrostimulation electrode assembly 715 or one or more of the stent- like wireless electrostimulation electrode assemblies 31 IA-E can include an expandable mechanical support including a portion, part or component made of a shape memory material, and the one or more electrode assemblies can self expand when the delivery catheter 780 is retracted or removed. In the example of FIG. 7, an inflation balloon can be advanced to a region inside the one more stent-like wireless electrode assemblies, and the balloon can be inflated to expand at least some of the wireless electrostimulation electrode assembly to anchor the assembly at the implant location. In FIG. 7, the electrostimulation assembly 715 can include a screen, mesh or other semi-permeable or impermeable layer 741 to prevent a blood clot or other debris within the left atrial appendage 775 from escaping into the rest of the circulatory system. In this example, layer 741 can include a hole or other passage to allow the inflation balloon 786 to pass through the screen when the balloon 786 is deflated, while still allowing the balloon 786 to expand the mechanical support of the electrode assembly-715. In an example, the layer 741 can include a surface treatment or antithrombogenic compound to inhibit or reduce blood clot formation, or to enhance tissue growth around or on top of the layer 741. In an example, an endothelial layer of tissue can grow around, throughout, or on top of the layer 741 completely occluding or blocking the opening to the left atrial appendage 775. In certain examples, the wireless electrostimulation electrode assembly
715 or one or more of the stent-like wireless electrostimulation electrode assemblies 31 IA-E can include one or more inductive pickups (such as one or more wire coils) separate from the expandable mechanical structure, but attached to the expandable mechanical structure. The one or more inductive pickups can be collapsed, folded, or compressed to allow the electrode assembly to pass through a lumen of the delivery catheter 780, and can be expanded by, for example, a self-expanding mechanical support, or by an inflation balloon 786 passed through the lumen of the delivery catheter to the implant location. The delivery catheter need not make a sharp curvature as shown in FIG. 7, such as when a suitable trans-septal path from the right atrium 770 into the left atrium 774 can be found near or above the inferior vena cava 791, such as near or through the fossa ovalis. In certain examples, the delivery catheter can be very small, such as 2Fr - 3Fr, for example, to minimize trauma associated with crossing the atrial septum to reach the left atrium. In certain examples, the delivery system including the delivery catheter 780 and the inflation balloon 786 can be used to delivery, expand or anchor one or more other wireless electrostimulation electrode assemblies to one or more other locations within the heart, from within the heart, such as one or more right or left pulmonary veins, 779 A, 779B, the superior vena cava 792, the inferior vena cava 791, the coronary sinus 793, or one or more other locations.
FIG. 8 illustrates generally an example of an apparatus 800 including an external device 840. In certain examples, the external device can include a transmitter 830 and a controller 820, and the apparatus 800 can include one or more wireless electrostimulation electrode assemblies, such as a first wireless electrostimulation electrode assembly 810A, or a second wireless electrostimulation electrode assembly 810B. In certain examples, the one or more wireless electrostimulation electrode assemblies can be located in one or more blood vessels near a heart 802, or endocardially in the heart 802 itself. In certain examples, the external device 840 can include a part, portion or component similar to the controller / transmitter 220 of FIG. 2. In certain examples, the external device 840 can include a pocket-sized assembly such as a personal digital assistant, a hand-held patient activator (e.g., to provide a patient 801 with one or more indicators or controls to assess the patient's status, or to control one or more therapy parameters), an external physician programmer for an implantable cardiac rhythm management system, a hospital bed or one or more other forms of furniture, or one or more other external devices. In certain examples, the apparatus 800 can be used as a portion, part or component of, or in addition to a conventional cardiac rhythm management system (e.g., the conventional cardiac rhythm management system using conductive lead assemblies attached to a subcutaneous pulse-generator).
FIG. 9 illustrates generally an example of an apparatus 900 including an implantable device 920, such as a cardiac rhythm management pulse generator assembly, including a subcutaneous transmitter and a controller 940, and one or more wireless electrostimulation electrode assemblies, such as a first wireless electrostimulation electrode assembly 910A, or a second wireless electrostimulation electrode assembly 910B located in a patient 901 within one or more blood vessels near a heart 902, or endocardially in the heart 902 itself. In the example of FIG. 8, a lead 906 can be used to conductively couple an inductive antenna 908 to the implantable device 920. In an example, the lead 906 can be constructed similarly to a conventional implantable lead, such as by using one or more coiled concentric conductors encapsulated by a flexible biocompatible insulating layer such as silicone, or one or more other materials or constructions. In an example, the lead 906 can be electrically connected to the implantable device 920 using a header similar to a header used by a conventional cardiac rhythm management device, in addition to or instead of other leads, hi certain examples, the implantable device 920 can include a pacemaker, a cardiac resynchronization therapy device, an implantable cardioverter defibrillator, a neural stimulation device, or one or more other active implantable medical devices.
FIG. 10 illustrates generally an example of a wireless electrostimulation electrode assembly 1000 including a loop-shaped mechanical support 1001 coupled to one or more mechanical struts, such as a first strut 101OA, or a second strut 101 OB, the struts at least partially encircling and supported by a mitral valve 1078 annulus. In the example of FIG. 10, the electrostimulation assembly 1000 can be supported at least partially at the mitral valve annulus, such as at a wedge formed between a left atrial wall and a posterior region of the annulus, and the assembly 1000 can wrap around an interior of the left atrium at least partially in contact with an anterior region of endocardium opposite the posterior region of the annulus, such as, for example, below a plane formed by the bottom of the pulmonary veins, such as a first and second right pulmonary vein, 1079A, 1079B, and a first and second left pulmonary vein 1079C, 1079D. In the example of FIG. 10, the electrostimulation assembly 1000 can include one or more electrodes around the circumference of the loop-shaped mechanical support 1001, such as a first electrode 1050, a second electrode 1060, a third electrode 1061 A, a fourth electrode 1062 A, and a fifth electrode 1063 A. In some examples, the mechanical support 1001 can be conductive, and can carry an electrostimulation current to one or more of the first, second, third, fourth, or fifth electrodes 1050, 1060, 106 IA, 1062 A, or 1063 A. In certain examples, one or more electrostimulation electrodes, such as one or more of the first, second, third, fourth, or fifth electrodes 1050, 1060, 1061 A, 1062 A, or 1063 A, can be formed by providing one or more openings in an insulating layer covering, coating, encapsulating, or surrounding the mechanical support 1001. In certain examples, the electrode used for electrostimulation can be selected by a controller including an arrhythmia detector in order to deliver one or more coordinated electrostimulations using a selected group or combination of electrodes in order to regulate, terminate, or control an arrhythmia. In certain examples, one or more cathode electrodes can be used, and a total surface area of the one or more cathode electrodes can be, for example, substantially equivalent to a surface area of an anode electrode to provide a specified current density at the one or more cathode electrodes, such as, for example, to provide reliable electrostimulation at the one or more cathode electrode locations. In an example, the loop-shaped mechanical support 1001 can be folded, compressed, or collapsed, such as for delivery via a percutaneous, transluminal route through one or more blood vessels using a delivery catheter, such as shown in FIGS. 4A- D. In an example, the electrostimulation assembly 1000 can include one or more components, circuits, or portions of the wireless electrostimulation electrode assembly 210 shown in FIG. 2. In an example, the first or second mechanical struts 101OA, 101 OB can omitted and the loop-shaped mechanical support 1001 can be expandable, and can be directly supported at least partially by the ring formed by the mitral valve annulus 1078. In certain examples, the loop shaped mechanical support 1001 can be in contact with cardiac tissue along its entire circumference, such as, for example, to encourage growth of a protective layer of tissue around the mechanical support 1001. In an example, growth of a protective layer of tissue at least partially around, throughout, or surrounding the support 1001 can reduce a risk of forming blood clot, as compared to having one or more portions of the support 1001 exposed to a blood pool in the left atrium.
FIG. 11 illustrates generally an example of a method 1100 including receiving wireless energy using a first wireless electrostimulation electrode assembly at 1102, mechanically supporting the first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of a heart at 1104, and delivering at least some of the received wireless energy as an electrostimulation to a heart at 1106. In certain examples, the first wireless electrostimulation electrode assembly can be similar to or the same as the electrostimulation assembly 110 shown in FIG. 1, the electrostimulation assembly 500 shown in FIG. 5, the electrostimulation assembly 601 shown in FIGS. 6A-B, the electrostimulation assembly 1000 shown in FIG. 10, or one or more other electrostimulation assemblies. In certain examples, the first wireless electrostimulation electrode assembly can receive magnetically-coupled energy and deliver at least some of the received magnetically-coupled energy as an electrostimulation to the heart using one or more circuits, components or devices such as shown in the electrostimulation assembly 210 of FIG. 2. FIG. 12 illustrates generally an example of a method 1200 including receiving wireless energy using a plurality of separate wireless electrostimulation electrode assemblies each configured to be intravascularly delivered to a respective implant location at 1202, mechanically supporting a first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of a heart at 1204, detecting an arrhythmia at 1206, and terminating the detected arrhythmia by delivering one or more coordinated electrostimulations to the heart at the respective implant locations at 1208. In certain examples, the first wireless electrostimulation electrode assembly can be similar to or the same as the electrostimulation assembly 110 shown in FIG. 1, the electrostimulation assembly 500 shown in FIG. 5, the electrostimulation assembly 601 shown in FIGS. 6A-B, the electrostimulation assembly 1000 shown in FIG. 10, or one or more other electrostimulation assemblies, hi certain examples, one or more of the plurality of wireless electrostimulation electrode assemblies can be similar to one or more of the electrostimulation assemblies 310, 31 IA-E, 313, 315, 317A-B shown in FIG. 3. hi certain examples, one or more of the plurality of wireless electrostimulation electrode assemblies can receive magnetically-coupled energy and deliver at least some of the received magnetically-coupled energy to the respective implant locations using one or more circuits, components or devices such as shown in the electrostimulation assembly 210 of FIG. 2.
FIGS. 13 A-B illustrate generally examples of a stent-like wireless electrostimulation electrode assembly 1300, such as, for example, one or more of the wireless electrostimulation electrode assemblies 31 IA-E shown in FIG. 3. hi FIGS. 13A-B, a coiled strut 1301 can provide a mechanical support for the electrostimulation assembly 1300. hi certain examples, the coiled strut 1301 can be compressed, flattened, folded, or formed into one or more wire strands, and passed through a lumen formed by an elongate delivery catheter, similar to the examples of FIGS. 4A-D, and FIG. 7. In these examples, when compressed, flattened, folded, or formed into one or more wire strands, the cross section of the electrostimulation assembly 1300 can be small enough for the electrostimulation assembly 1300 to be intravascularly delivered through one or more blood vessels to an implant location, and such an intravascular delivery can include a route through one or more heart chambers, such as, for example, to gain access to one or more pulmonary veins. In certain examples, the coiled strut 1301 can self-expand, such as, for example, to decompress, open, unfold, forming a tapered coil, such as shown in FIGS. 13A-B, after the electrostimulation assembly 1300 is delivered to the implant location. In certain examples, a portion, part or component of the coiled strut 1301 can be made of one or more conductive materials, such as, for example, an elongated tube of shape-memory material partially or completely enclosing a conductive core. In an example, the elongated tube of shape-memory material can be a nickel titanium compound or alloy, such as Nitinol, and the conductive core can be silver. In an example, the core can be the shape-memory material, such as the nickel titanium compound or alloy, and the elongated tube can be highly conductive, such as platinum, or platinum-iridium oxide. In an illustrative example, an outer diameter of the elongated tube of shape-memory material can be less than 0.008 inches, to greater than 0.012 inches. In certain examples, the coiled strut 1301 can be both a mechanical support and an inductive receiver coil, such as, for example, to receive wirelessly-coupled energy from a separate transmitter coil, hi the example of FIG. 13 A, one or both ends of the coiled strut can be conductively coupled to an electrostimulation circuit 1340. In certain examples, the electrostimulation circuit 1340 can include one or more parts, components or portions of the wireless electrostimulation electrode assembly 210 shown in FIG. 2. hi the example of FIG. 13 A, the coiled strut, or the electrostimulation circuit 1340, can be coupled to one or more cathode electrodes 1350 located proximally to the interior of a heart chamber, such as nearby or contacting a myocardial muscle sleeve within one or more blood vessels entering or exiting a heart chamber, hi the example of FIG. 13 A, the electrostimulation circuit 1340 can be conductively coupled to one or more anode electrodes 1360 located distally to the interior of the heart chamber. In certain examples, the one or more anode or cathode electrodes 1360, 1350 can be a part, portion, or component of the coiled strut 1301, such as, for example, one or more non-insulated portions of the strut 1301. hi certain examples, the one or more anode or cathode electrodes 1360, 1350 can include an exposed platinum portion, a platinum-indium oxide portion, or one or more other conductive biocompatible materials to be placed in contact with tissue or near tissue. In an example, the electrostimulation circuit 1340 can include a rectifier electrically connected to the coiled strut 1301, and one or more of a tuning capacitor or an electrostimulation waveform shaping capacitor conductively coupled in series or parallel to the rectifier and to one or more of the electrostimulation electrodes 1360, 1350, such as, for example, to provide a specified electrostimulation waveform when the one or more anode or cathode electrodes 1360, 1350 are in contact with tissue. In this example, the electrostimulation circuit can be very compact, such as about 0.020 inches by 0.030 inches, and 0.010 inches thick, hi an example, the one or more electrostimulation electrodes 1360, 1350 can provide the specified electrostimulation waveform when the electrostimulation assembly 1300 receives magnetically coupled energy containing a specified range of frequencies, hi the example of FIG. 13B, the electrostimulation circuit 1340 and the one or more anode electrodes 1360 can be included in a wall electrode 1345. In certain examples, the wall electrode 1345 of FIG. 13B can be an anode electrode, in addition to or instead of the one or more anode electrodes 1360, such as shown in FIG. 13 A. hi an example, circuitry included as a portion, part, or component of the wall electrode 1345 can be similar to or the same as the electrostimulation circuit 1340, such as shown in FIG. 13 A. hi an example, at least a portion of the wall electrode 1345 can be platinum, platinum- iridium oxide, or one or more other conductive biocompatible materials to be placed in contact with tissue or near tissue, hi certain examples, the coiled strut 1301 can be used as an inductive receiver coil separate from, and attached to, a mechanical support, such as an expandable stent body, hi such examples, the mechanical support can be selected for reliable anchoring of the electrostimulation assembly 1300 at the implant location, and the separate coiled strut 1301 can be selected to provide reliable inductive receiving or transmission of magnetic energy, hi certain examples, a wireless electrostimulation electrode assembly 1300 can be located in a specified pulmonary vein, and one or more other electrostimulation assemblies can be located endocardially, or within one or more other blood vessels, and can be connected by one or more small leads to the wireless electrostimulation electrode assembly 1300 located in the specified pulmonary vein, without requiring the one or more small leads to exit the left atrium or the left ventricle. In these examples, the one or more small leads can be located against an endorcardial wall, such as, for example, to encourage growth of a protective endothelial layer around the one or more small leads, such as for reducing a risk of a thrombus forming.
In an illustrative example, an experimental prototype can be constructed to predict an efficiency of a stent-like wireless electrostimulation electrode assembly, such as the electrostimulation assembly 1300 shown in FIGS. 13A-B. In this illustrative example, the electrostimulation assembly 1300 can be sized and shaped to be implanted in a pulmonary vein, such as, for example, one or more of the pulmonary veins 1079 A-D shown in FIG. 10. In this example, the pulmonary vein can be conical, and the electrostimulation assembly 1300 can be tapered such as shown in FIGS. 13A-B, for example, such as to better conform to the conical anatomy of the pulmonary vein. A transmitter, for example, similar to the controller / transmitter 220 shown in FIG. 2 can have a transmitter coil represented by the following electrical parameters: Diameter = D = 40 millimeters Number of Turns = N = 7 Coil Resistance R = 5.5 Ohms Relative Magnetic Permeability = Air = μ = 1
Coil Self Inductance = L = 6.3 microHenry
Coil Tuning Capacitance = C = 0.001 microFarad @ 2.0 megaHertz resonance.
In this illustrative example, a receiver coil, such as coil 1301, included as a portion, part or component of the wireless electrostimulation electrode assembly 1300, can be represented by the following electrical parameters: Avg. Stent Diameter = Di = 17.5 millimeters Stent Length = Ls = 20 millimeters Number of Turns = Ni = 16 Coil Resistance Ri = 1.6 Ohms
Relative Magnetic Permeability = Air = μ = 1 Coil Self Inductance = Li = 3.5 microHenry Coil Tuning Capacitance = C1 = 0.0017 microFarad @ 2.0 megaHertz resonance.
In this illustrative example, the stent diameter, Dj, can be selected to approximate a taper in a diameter of the pulmonary vein (or one or more other veins), such as from the first diameter, Da = 15 millimeters, to the second diameter, Db = 20 millimeters, over the first 20 millimeters of the vein, corresponding to the stent length, Ls = 20mm. In this illustrative example, "z" can represent the separation (e.g., an elevation) between the plane of the transmitter coil located elsewhere, such as in the right atrium, and the nearest edge of the receiver coil, and a coupling constant, K, can be represented by the following equations: κ = [τrDi2 f(z) 2] / [32DLs] (6) where f(z) = (z + Ls) / ^(D, / 2) 2 + (z + Ls) 2 - z / ^f(D1 / 2y + z z . (7) In this illustrative example, "z" can be 8 millimeters, such as to represent a separation between a nearest edge of a wireless electrostimulation electrode assembly 1300 located near the heart in the pulmonary vein and a plane formed by a transmitter coil in the right atrium, such as included as a portion, part, or component of an intravascular lead located in the right atrium. Using EQUATIONS (1) and (2) as discussed above for FIG. 2, an efficiency, η, and a peak load voltage, |VL| can be determined. The peak load voltage can represent, for example, an electrostimulation voltage across two electrostimulation electrodes connected to heart tissue, during an electrostimulation. In this illustrative example, a resistive load, RL = 500 Ohms, can be placed across the receiver coil contacts, such as shown in discussed in FIG. 2, and a transmit coil excitation voltage of |V0| = 5 Volts at 2 megaHertz can be applied to the transmitter coil. Using EQUATIONS (1) and (2), and the coupling constant, K, of EQUATIONS (6) and (7), |VL| = 20 Volts when |V0| = 5 Volts, and η = 32 % when z = 8 millimeters. In an illustrative example, if a cardiac rhythm management device using a tethered intravascular lead has a battery that can last 15 years providing a similar electrostimulation load voltage, then at η = 10%, the wireless electrostimulation electrode assembly could be powered for 1.5 years using a subcutaneous transmitter and a similar battery to that of the tethered cardiac rhythm management device.
In certain examples, received power can diminish as the angle between the planes of the transmitter and receiver coils deviates from zero degrees (reducing the coupling constant, /c), resulting in orientation sensitivity. In certain examples, multiple transmit coils in multiple planes, and even multiple coils in a single plane, can help reduce such orientation sensitivity. Multiple receiver coils consume little additional energy in the far field of the transmitter, compared to using a single receiver coil. Thus, multiple receivers can operate near an inductive transmitter with an efficiency substantially equal to the efficiency of a single receiver, hi certain examples, the inductive transmitter can be located in one or more other locations, including an esophagus, one or more bronchi, a pericardial space, a pulmonary artery, or one or more other subcutaneous or external locations. Similar to the discussion for FIG. 10, in certain examples, one or more types of medical imaging can be performed prior to or during an implantation of one or more electrostimulation assemblies 1300, such as, for example, to provide information that can be used to select an appropriate size and shape of electrostimulation assembly 1300 for a particular location, or a particular patient. In an illustrative example, one or more pulmonary veins may range from less than 10 millimeters in diameter at a distal end, to more than 25 millimeters in diameter at a proximal end near the heart, and a corresponding range of wireless electrostimulation assembly 1300 shapes and sizes can be provided to match the one or more pulmonary veins.
FIG. 14 illustrates generally a section view 1400 of at least a portion of a wireless electrostimulation electrode assembly. In an illustrative example, the section view of FIG. 14 can include a cross section of a portion of a wireless electrostimulation assembly 1300, such as shown in FIG. 13. A conductive core 1401 can provide a low resistance path for received magnetic energy or energy to be delivered as an electrostimulation. The present inventors have recognized that some conductive materials can have low resistance, but can lack shape- memory or spring-like properties. The present inventors have also recognized that a tube, a coating, a plated layer, or a jacket of shape-memory material 1403 can be included in addition to the conductive core 1401, such as, for example, to provide a combined assembly 1300 including both a highly conductive portion, and a spring-like or shape-memory portion. In an example, the shape-memory material 1403 can be co-extruded along with the conductive core, or one or more other materials, such as to form a combined assembly 1300. hi certain examples, the shape-memory material 1403 can provide an expansion force, such as, for example to decompress, unfold, expand, or anchor the electrostimulation assembly 1300 at an implant location. In certain examples, the electrostimulation assembly 1300 can at least partially self-decompress, self- unfold, or self-expand, such as, for example, using the expansion force of the shape-memory material 1403. In the example of FIG. 14, an electrode layer
1405 can be attached to the shape-memory material 1403, or directly to the core 1401. hi certain examples, one or more portions of the electrode layer 1405 can be encased, surrounded, encapsulated, coated, or otherwise treated with an insulator 1407, such as, for example, a biocompatible material such as silicone, or one or more other materials. One or more electrodes 1450 can be provided by including one or more openings, cavities, or apertures in the insulating layer 1407, such as, for example, to expose a portion of the electrode layer 1405. hi certain examples, at least a portion of the electrode layer can include platinum, platinum-iridium oxide, or one or more other conductive biocompatible materials, for example, to provide reliable electrostimulation when the electrode 1405 is in contact with tissue, or near one or more tissue sites to be electrostimulated. In certain examples, the shape-memory material 1403 need not surround the core 1401, and the core itself can be a shape memory material surrounded by one or more conductive layers, such as discussed above for FIGS. 13A-B.
Additional Examples hi an example, one or more wireless electrostimulation electrode assemblies can condition myocardial tissue after a myocardial infarction, such as to limit, control, or prevent adverse remodeling of myocardial tissue resulting from damage caused by the infarction, hi such an example, one or more coordinated electrostimulations delivered by one or more wireless electrostimulation electrode assemblies can limit tissue damage or death within or near one or more infracted tissue sites, hi an example, over a longer term such as from days to months, or longer, after an infarction, one or more coordinated electrostimulations can be delivered by one or more wireless electrostimulation electrode assemblies, for example, such as to limit an increase in infracted tissue volume, or to enhance a cardiac ejection fraction. Such examples called "myocardial salvage," or "remodeling control therapy."
In certain examples, one or more stent-like wireless electrostimulation electrode assemblies, such as shown in FIGS. 3, 7, can be used in other locations within a patient, such as one or more arteries, arterioles or veins, such as to enhance perfusion (e.g., such as after a stroke in a cerebral location) or to encourage diuresis (via an implant location in a renal artery), either through modulation of one or more vascular neurological pathways (such as to evoke vasodilation or vasoconstriction), or through evoking or inhibiting a contractile response in nearby muscle tissue. In an example, one or more wireless electrostimulation assemblies can be placed in a renal artery or a renal vein, and dilation of the renal artery or vein can be evoked using the one or more wireless electrostimulation assemblies, hi an example, electrostimulation by one or more wireless electrostimulation electrodes to elicit diuresis can be used to enhance perfusion around one or more blood vessels or to clear debris from within or near one or more blood vessels, such as after an ischemic event, hi an example, vasodilation of pulmonary arteries can be used to control, prevent, or limit pulmonary hypertension.
In certain examples, one or more wireless electrostimulation electrode assemblies can include an antithrombogenic agent or surface treatment, such as, for example, to promote incorporation of the electrostimulation assembly into the surrounding tissue, such as a blood vessel wall, hi an example, an endothelial layer can grow around, on, or throughout the electrostimulation assembly, and can protect the electrostimulation assembly, such as to reduce a risk of thrombus formation, hi an example, one or more wireless electrostimulation electrode assemblies can include a roughened or porous surface treatment to enhance in-growth of surrounding tissue, hi an example, sub-threshold electrostimulation can be provided (e.g., delivering an electrostimulation having an energy or voltage below a threshold where muscle contraction can be elicited). In an example, such sub-threshold electrostimulation might enhance tissue ingrowth or reduce or eliminate reclosing of a blood vessel where the electrostimulation electrode is located (e.g., to prevent or reduce restenosis).
Additional Notes
The above detailed description includes references to the accompanying drawings, which form a part of the detailed description. The drawings show, by way of illustration, specific embodiments in which the invention can be practiced. These embodiments are also referred to herein as "examples." Such examples can include elements in addition to those shown and described.
However, the present inventors also contemplate examples in which only those elements shown and described are provided.
All publications, patents, and patent documents referred to in this document are incorporated by reference herein in their entirety, as though individually incorporated by reference. In the event of inconsistent usages between this document and those documents so incorporated by reference, the usage in the incorporated reference(s) should be considered supplementary to that of this document; for irreconcilable inconsistencies, the usage in this document controls. In this document, the terms "a" or "an" are used, as is common in patent documents, to include one or more than one, independent of any other instances or usages of "at least one" or "one or more." In this document, the term "or" is used to refer to a nonexclusive or, such that "A or B" includes "A but not B," "B but not A," and "A and B," unless otherwise indicated. In the appended claims, the terms "including" and "in which" are used as the plain-English equivalents of the respective terms "comprising" and "wherein." Also, in the following claims, the terms "including" and "comprising" are open-ended, that is, a system, device, article, or process that includes elements in addition to those listed after such a term in a claim are still deemed to fall within the scope of that claim. Moreover, in the following claims, the terms "first," "second," and
"third," etc. are used merely as labels, and are not intended to impose numerical requirements on their objects. Method examples described herein can be machine or computer- implemented at least in part. Some examples can include a computer-readable medium or machine-readable medium encoded with instructions operable to configure an electronic device to perform methods as described in the above examples. An implementation of such methods can include code, such as microcode, assembly language code, a higher-level language code, or the like. Such code can include computer readable instructions for performing various methods. The code may form portions of computer program products. Further, the code may be tangibly stored on one or more volatile or non- volatile computer-readable media during execution or at other times. These computer- readable media may include, but are not limited to, hard disks, removable magnetic disks, removable optical disks (e.g., compact disks and digital video disks), magnetic cassettes, memory cards or sticks, random access memories (RAMs), read only memories (ROMs), and the like. The above description is intended to be illustrative, and not restrictive.
For example, the above-described examples (or one or more aspects thereof) may be used in combination with each other. Other embodiments can be used, such as by one of ordinary skill in the art upon reviewing the above description. The Abstract is provided to comply with 37 C.F.R. §1.72(b), to allow the reader to quickly ascertain the nature of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. Also, in the above Detailed Description, various features may be grouped together to streamline the disclosure. This should not be interpreted as intending that an unclaimed disclosed feature is essential to any claim. Rather, inventive subject matter may lie in less than all features of a particular disclosed embodiment. Thus, the following claims are hereby incorporated into the Detailed Description, with each claim standing on its own as a separate embodiment. The scope of the invention should be determined with reference to the appended claims, along with the full scope of equivalents to which such claims are entitled.

Claims

WHAT IS CLAIMED IS:
1. An apparatus, comprising: a first wireless electrostimulation electrode assembly comprising: an electrostimulation circuit; a wireless receiver configured to receive wireless energy and configured to provide at least some of the received wireless energy to the electrostimulation circuit; a first expandable support mechanically coupled to the electrostimulation circuit and the wireless receiver and configured to conform to, and at least partially encircle, a ring formed by an annulus of a mitral valve of a heart; and wherein the electrostimulation circuit is configured to deliver at least some of the received wireless energy as an electrostimulation to the heart; wherein the first wireless electrostimulation electrode assembly is configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart; and wherein the first wireless electrostimulation electrode assembly is configured to fit entirely within the heart.
2. The apparatus of claim 1, wherein the wireless energy includes magnetically-coupled energy, and wherein the wireless receiver is configured to receive the magnetically-coupled energy.
3. The apparatus of claim 2, comprising a transmitter configured to provide the magnetically-coupled energy, and wherein the transmitter is sized and1 shaped to be located subcutaneously within a patient, or outside a patient body.
4. The apparatus of any of claims 1 through 3, wherein the electrostimulation circuit is configured to deliver an electrostimulation including enough of the received wireless energy to depolarize cardiac tissue near the wireless electrostimulation electrode assembly.
5. The apparatus of any of claims 1 through 4, wherein the first expandable support includes a shape memory material configured to provide an expansion force, and the first expandable support is configured to anchor the first wireless electrostimulation electrode assembly at the implant location at the annulus of the mitral valve at least in part using the expansion force when the first wireless electrostimulation electrode assembly is delivered to the implant location.
6. The apparatus of any of claims 1 through 5, wherein the first wireless electrostimulation electrode assembly includes one or more extending tines configured to controllably extend into tissue when the first wireless electrostimulation electrode assembly is delivered to the implant location at the annulus of the mitral valve of the heart.
7. The apparatus of any of claims 1 through 6, comprising: a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a blood vessel and configured to provide an electrostimulation to the heart near the blood vessel; and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies and configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
8. The apparatus of claim 7, wherein the blood vessel is selected from a list including a pulmonary vein, a coronary sinus, or a vena cava.
9. The apparatus of any of claims 1 through 8, comprising a second electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart; and a controller communicatively coupled to the first and second wireless electrostimulation electrode assemblies and configured to coordinate delivery of the electrostimulation by the first and second wireless electrostimulation electrode assemblies.
10. The apparatus of claim 9, wherein the atrial appendage of the heart is a left atrial appendage, and wherein the second electrostimulation electrode assembly includes a second expandable support configured to at least partially block the opening to the left atrial appendage of the heart and configured to anchor the second electrostimulation electrode assembly at the opening of the left atrial appendage when the second expandable support is expanded.
11. The apparatus of any of claims 1 through 10, comprising: a plurality of separate wireless electrostimulation electrode assemblies, each configured to be intravascularly delivered to a respective implant location and each configured to provide an electrostimulation to the heart at the respective implant location; a controller communicatively coupled to the plurality of separate wireless electrostimulation electrode assemblies and configured to coordinate delivery of the electrostimulation to the heart at each respective implant location; and wherein the plurality of separate wireless electrostimulation electrode assemblies includes the first wireless electrostimulation electrode assembly.
12. The apparatus of claim 11, wherein the plurality of separate wireless electrostimulation electrode assemblies includes one or more wireless electrostimulation electrode assemblies selected from a list including: a second wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial septum of the heart and configured to provide an electrostimulation to the heart; a third wireless electrostimulation electrode assembly configured to be intravascularly delivered to an endocardial location at an atrial appendage of the heart and configured to provide an electrostimulation to the heart; and a fourth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a pulmonary vein and configured to provide an electrostimulation to the heart; a fifth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a vena cava and configured to provide an electrostimulation to the heart; a sixth wireless electrostimulation electrode assembly configured to be intravascularly delivered to an implant location within a coronary sinus and configured to provide an electrostimulation the heart; wherein the controller is communicatively coupled to each corresponding wireless electrostimulation electrode assembly and the controller is configured to coordinate delivery of the electrostimulation to the heart at each respective implant location by each respective wireless electrostimulation electrode assembly.
13. The apparatus of any of claims 11 through 12, wherein the controller includes an arrhythmia detector configured to detect an arrhythmia, and wherein the controller is configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia in response to information provided by the arrhythmia detector.
14. The apparatus of claim 13, wherein the arrhythmia includes an atrial tachyarrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
15. The apparatus of any of claims 13 through 14, wherein the controller is configured to coordinate delivery of the electrostimulation to the heart at each respective implant location to terminate the arrhythmia without exceeding a pain threshold of a patient.
16. A method, comprising: receiving wireless energy using a first wireless electrostimulation electrode assembly; delivering at least some of the received wireless energy as an electrostimulation to a heart; mechanically supporting the first wireless electrostimulation electrode assembly at least partially using a ring formed by an annulus of a mitral valve of the heart; wherein the first wireless electrostimulation electrode assembly is configured to be intravascularly delivered to an implant location within a chamber of the heart at the annulus of the mitral valve of the heart; and wherein the first wireless electrostimulation electrode assembly is configured to fit entirely within the heart.
17. The method of claim 16, comprising: receiving wireless energy using a plurality of separate wireless electrostimulation electrode assemblies, the plurality including the first wireless electrostimulation electrode assembly, and wherein the plurality of separate wireless electrostimulation electrode assemblies are each configured to be intravascularly delivered to a respective implant location; delivering one or more coordinated electrostimulations to the heart at the respective implant location using at least one of the plurality of electrostimulation electrode assemblies and using at least some of the received wireless energy.
18. The method of claim 17, including: detecting an arrhythmia; terminating the detected arrhythmia using the delivering one or more coordinated electrostimulations and using information provided by the detecting the arrhythmia; and wherein the delivering one or more coordinated electrostimulations includes delivering enough received wireless energy to depolarize cardiac tissue at each respective implant location where the one or more coordinated electrostimulations are delivered.
19. The method of claim 18, wherein the detecting the arrhythmia includes detecting an atrial arrhythmia selected from a list including an atrial fibrillation, an atrial tachycardia, an atrial flutter, an atrioventricular nodal reentrant tachycardia, or an atrioventricular reentrant tachycardia.
20. The method of any claims 18 through 19, wherein the terminating the arrhythmia using the delivering one or more coordinated electrostimulations includes depolarizing enough cardiac tissue to terminate the arrhythmia without exceeding a pain threshold of a patient.
PCT/US2009/000693 2008-02-07 2009-02-04 Multi-site atrial electrostimulation WO2009099597A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6387608P 2008-02-07 2008-02-07
US61/063,876 2008-02-07
US5999308P 2008-06-09 2008-06-09
US61/059,993 2008-06-09

Publications (1)

Publication Number Publication Date
WO2009099597A1 true WO2009099597A1 (en) 2009-08-13

Family

ID=40513737

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2009/000587 WO2009099550A1 (en) 2008-02-07 2009-01-29 Wireless tissue electrostimulation
PCT/US2009/000693 WO2009099597A1 (en) 2008-02-07 2009-02-04 Multi-site atrial electrostimulation

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2009/000587 WO2009099550A1 (en) 2008-02-07 2009-01-29 Wireless tissue electrostimulation

Country Status (4)

Country Link
US (6) US8738147B2 (en)
EP (1) EP2254663B1 (en)
JP (1) JP5153892B2 (en)
WO (2) WO2009099550A1 (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7840281B2 (en) 2006-07-21 2010-11-23 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US7937161B2 (en) 2006-03-31 2011-05-03 Boston Scientific Scimed, Inc. Cardiac stimulation electrodes, delivery devices, and implantation configurations
US8050774B2 (en) 2005-12-22 2011-11-01 Boston Scientific Scimed, Inc. Electrode apparatus, systems and methods
US8204605B2 (en) 2008-02-07 2012-06-19 Cardiac Pacemakers, Inc. Multi-site atrial electrostimulation
US8478408B2 (en) 2004-10-20 2013-07-02 Boston Scientific Scimed Inc. Leadless cardiac stimulation systems
US8644934B2 (en) 2006-09-13 2014-02-04 Boston Scientific Scimed Inc. Cardiac stimulation using leadless electrode assemblies
WO2014043039A1 (en) * 2012-09-11 2014-03-20 Native Cardiocascular Llc Device and methods for targeted tissue drug delivery
EP2862594A1 (en) * 2013-10-17 2015-04-22 BIOTRONIK SE & Co. KG Active, reversible fixing of CRT electrodes
US10022538B2 (en) 2005-12-09 2018-07-17 Boston Scientific Scimed, Inc. Cardiac stimulation system
US10583301B2 (en) 2016-11-08 2020-03-10 Cardiac Pacemakers, Inc. Implantable medical device for atrial deployment

Families Citing this family (336)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8150519B2 (en) 2002-04-08 2012-04-03 Ardian, Inc. Methods and apparatus for bilateral renal neuromodulation
US8145316B2 (en) 2002-04-08 2012-03-27 Ardian, Inc. Methods and apparatus for renal neuromodulation
AU2002952691A0 (en) 2002-11-15 2002-11-28 Sunshine Heart Company Pty Ltd Heart assist device utilising aortic deformation
JP2007504910A (en) 2003-09-12 2007-03-08 ミノウ・メディカル・エルエルシイ Selectable biased reshaping and / or excision of atherosclerotic material
AU2004284842B2 (en) 2003-10-31 2010-03-04 Nuwellis, Inc. Synchronisation control system
US9713730B2 (en) 2004-09-10 2017-07-25 Boston Scientific Scimed, Inc. Apparatus and method for treatment of in-stent restenosis
US8396548B2 (en) 2008-11-14 2013-03-12 Vessix Vascular, Inc. Selective drug delivery in a lumen
CA2583404A1 (en) * 2004-10-20 2006-04-27 Boston Scientific Limited Leadless cardiac stimulation systems
US8175702B2 (en) 2004-11-04 2012-05-08 The Washington University Method for low-voltage termination of cardiac arrhythmias by effectively unpinning anatomical reentries
DE102005003632A1 (en) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Catheter for the transvascular implantation of heart valve prostheses
WO2007013065A2 (en) 2005-07-25 2007-02-01 Rainbow Medical Ltd. Electrical stimulation of blood vessels
WO2007087875A1 (en) * 2006-01-13 2007-08-09 Universität Duisburg-Essen Stimulation system, in particular a cardiac pacemaker
US9130602B2 (en) 2006-01-18 2015-09-08 Qualcomm Incorporated Method and apparatus for delivering energy to an electrical or electronic device via a wireless link
US8447234B2 (en) * 2006-01-18 2013-05-21 Qualcomm Incorporated Method and system for powering an electronic device via a wireless link
US8019435B2 (en) 2006-05-02 2011-09-13 Boston Scientific Scimed, Inc. Control of arterial smooth muscle tone
US8290600B2 (en) 2006-07-21 2012-10-16 Boston Scientific Scimed, Inc. Electrical stimulation of body tissue using interconnected electrode assemblies
WO2008049082A2 (en) 2006-10-18 2008-04-24 Minnow Medical, Inc. Inducing desirable temperature effects on body tissue
AU2007310991B2 (en) 2006-10-18 2013-06-20 Boston Scientific Scimed, Inc. System for inducing desirable temperature effects on body tissue
EP2954868A1 (en) 2006-10-18 2015-12-16 Vessix Vascular, Inc. Tuned rf energy and electrical tissue characterization for selective treatment of target tissues
US9774086B2 (en) 2007-03-02 2017-09-26 Qualcomm Incorporated Wireless power apparatus and methods
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
US9124120B2 (en) 2007-06-11 2015-09-01 Qualcomm Incorporated Wireless power system and proximity effects
WO2009023155A2 (en) 2007-08-09 2009-02-19 Nigelpower, Llc Increasing the q factor of a resonator
EP2188863A1 (en) 2007-09-13 2010-05-26 QUALCOMM Incorporated Maximizing power yield from wireless power magnetic resonators
KR20100067676A (en) 2007-09-17 2010-06-21 퀄컴 인코포레이티드 Transmitters and receivers for wireless energy transfer
CN103904787B (en) 2007-10-11 2017-06-06 高通股份有限公司 Shifted using the wireless power of magneto mechanical systems
US8560066B2 (en) 2007-12-11 2013-10-15 Washington University Method and device for three-stage atrial cardioversion therapy
US8874208B2 (en) 2007-12-11 2014-10-28 The Washington University Methods and devices for three-stage ventricular therapy
WO2009076557A2 (en) * 2007-12-11 2009-06-18 Washington University Of St. Louis Method and device for low-energy termination of atrial tachyarrhythmias
EP2695587A1 (en) * 2008-01-25 2014-02-12 JenaValve Technology Inc. Medical apparatus for the therapeutic treatment of an insufficient cardiac valve
US8626290B2 (en) 2008-01-31 2014-01-07 Enopace Biomedical Ltd. Acute myocardial infarction treatment by electrical stimulation of the thoracic aorta
US8538535B2 (en) 2010-08-05 2013-09-17 Rainbow Medical Ltd. Enhancing perfusion by contraction
US9005106B2 (en) 2008-01-31 2015-04-14 Enopace Biomedical Ltd Intra-aortic electrical counterpulsation
US8626299B2 (en) 2008-01-31 2014-01-07 Enopace Biomedical Ltd. Thoracic aorta and vagus nerve stimulation
BR112012021347A2 (en) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent for positioning and anchoring a valve prosthesis at an implantation site in a patient's heart
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US8629576B2 (en) 2008-03-28 2014-01-14 Qualcomm Incorporated Tuning and gain control in electro-magnetic power systems
US20090241972A1 (en) * 2008-04-01 2009-10-01 Cardiometrix, Inc. Enhanced implantable loop antenna system and method
US20100010565A1 (en) * 2008-07-09 2010-01-14 Samuel Victor Lichtenstein Extended range wireless muscular and neural stimulation
CN102271603A (en) 2008-11-17 2011-12-07 明诺医学股份有限公司 Selective accumulation of energy with or without knowledge of tissue topography
US9700712B2 (en) * 2009-01-26 2017-07-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Dipolar antenna system and related methods
US8527068B2 (en) * 2009-02-02 2013-09-03 Nanostim, Inc. Leadless cardiac pacemaker with secondary fixation capability
US20110077708A1 (en) * 2009-09-28 2011-03-31 Alan Ostroff MRI Compatible Leadless Cardiac Pacemaker
US8417340B2 (en) 2009-10-13 2013-04-09 Empire Technology Development Llc Implant with antenna array
WO2011049716A1 (en) * 2009-10-19 2011-04-28 Cardiac Pacemakers, Inc. Cardiorenal electrical stimulation system
CA2795251A1 (en) 2010-04-02 2011-10-06 William S. Peters Combination heart assist systems, methods, and devices
EP2555699B1 (en) 2010-04-09 2019-04-03 Vessix Vascular, Inc. Power generating and control apparatus for the treatment of tissue
US9192790B2 (en) 2010-04-14 2015-11-24 Boston Scientific Scimed, Inc. Focused ultrasonic renal denervation
US8594806B2 (en) 2010-04-30 2013-11-26 Cyberonics, Inc. Recharging and communication lead for an implantable device
WO2011143443A2 (en) * 2010-05-12 2011-11-17 Medical Device Innovations Llc Method and device for treatment of arrhythmias and other maladies
US20130109987A1 (en) * 2011-05-12 2013-05-02 Medical Device Innovations Inc. Method and device for treatment of arrhythmias and other maladies
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
US8473067B2 (en) 2010-06-11 2013-06-25 Boston Scientific Scimed, Inc. Renal denervation and stimulation employing wireless vascular energy transfer arrangement
EP2394695B1 (en) * 2010-06-14 2012-09-26 Sorin CRM SAS Standalone intracardiac capsule and implantation accessory
US9044616B2 (en) * 2010-07-01 2015-06-02 Boston Scientific Neuromodulation Corporation Charging system for an implantable medical device employing magnetic and electric fields
CN103249374B (en) 2010-07-02 2015-08-05 Pfm医疗股份公司 Left atrial appendage occlusion device
US9155589B2 (en) 2010-07-30 2015-10-13 Boston Scientific Scimed, Inc. Sequential activation RF electrode set for renal nerve ablation
US9084609B2 (en) 2010-07-30 2015-07-21 Boston Scientific Scime, Inc. Spiral balloon catheter for renal nerve ablation
US9408661B2 (en) 2010-07-30 2016-08-09 Patrick A. Haverkost RF electrodes on multiple flexible wires for renal nerve ablation
US9463062B2 (en) 2010-07-30 2016-10-11 Boston Scientific Scimed, Inc. Cooled conductive balloon RF catheter for renal nerve ablation
US9358365B2 (en) 2010-07-30 2016-06-07 Boston Scientific Scimed, Inc. Precision electrode movement control for renal nerve ablation
WO2012013360A1 (en) * 2010-07-30 2012-02-02 Md Start Sa Implantable electrode device, in particular for sensing an intracardiac electrogram
AU2011292039B2 (en) * 2010-08-17 2013-11-28 Boston Scientific Neuromodulation Corporation Telemetry-based wake up of an implantable medical device in a therapeutic network
JP2013540022A (en) 2010-10-13 2013-10-31 ナノスティム・インコーポレイテッド Leadless cardiac pacemaker with screw anti-rotation element
US8974451B2 (en) 2010-10-25 2015-03-10 Boston Scientific Scimed, Inc. Renal nerve ablation using conductive fluid jet and RF energy
US9220558B2 (en) 2010-10-27 2015-12-29 Boston Scientific Scimed, Inc. RF renal denervation catheter with multiple independent electrodes
US9457186B2 (en) 2010-11-15 2016-10-04 Bluewind Medical Ltd. Bilateral feedback
US9028485B2 (en) 2010-11-15 2015-05-12 Boston Scientific Scimed, Inc. Self-expanding cooling electrode for renal nerve ablation
US9668811B2 (en) 2010-11-16 2017-06-06 Boston Scientific Scimed, Inc. Minimally invasive access for renal nerve ablation
US9089350B2 (en) 2010-11-16 2015-07-28 Boston Scientific Scimed, Inc. Renal denervation catheter with RF electrode and integral contrast dye injection arrangement
US9326751B2 (en) 2010-11-17 2016-05-03 Boston Scientific Scimed, Inc. Catheter guidance of external energy for renal denervation
US9060761B2 (en) 2010-11-18 2015-06-23 Boston Scientific Scime, Inc. Catheter-focused magnetic field induced renal nerve ablation
US9023034B2 (en) 2010-11-22 2015-05-05 Boston Scientific Scimed, Inc. Renal ablation electrode with force-activatable conduction apparatus
US9192435B2 (en) 2010-11-22 2015-11-24 Boston Scientific Scimed, Inc. Renal denervation catheter with cooled RF electrode
JP2014501136A (en) 2010-12-13 2014-01-20 ナノスティム・インコーポレイテッド Delivery catheter system and method
US20120157993A1 (en) 2010-12-15 2012-06-21 Jenson Mark L Bipolar Off-Wall Electrode Device for Renal Nerve Ablation
EP2654889B1 (en) 2010-12-20 2017-03-01 Pacesetter, Inc. Leadless pacemaker with radial fixation mechanism
US8649863B2 (en) 2010-12-20 2014-02-11 Rainbow Medical Ltd. Pacemaker with no production
US9220561B2 (en) 2011-01-19 2015-12-29 Boston Scientific Scimed, Inc. Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury
US8888843B2 (en) 2011-01-28 2014-11-18 Middle Peak Medical, Inc. Device, system, and method for transcatheter treatment of valve regurgitation
US8845717B2 (en) 2011-01-28 2014-09-30 Middle Park Medical, Inc. Coaptation enhancement implant, system, and method
CN106902457B (en) 2011-01-28 2022-10-21 斯蒂维科技公司 Neurostimulator system
US9220897B2 (en) 2011-04-04 2015-12-29 Micron Devices Llc Implantable lead
CN103492022A (en) 2011-04-04 2014-01-01 斯蒂维科技公司 Implantable lead
EP2520332A1 (en) * 2011-05-05 2012-11-07 Magnetic Pacing Technologies GmbH Implantable stimulation device for defribillation and pacing
WO2012154599A2 (en) * 2011-05-06 2012-11-15 Ndsu Research Foundation Intelligent self-organizing electrode stimulation delivery system
AU2012283908B2 (en) 2011-07-20 2017-02-16 Boston Scientific Scimed, Inc. Percutaneous devices and methods to visualize, target and ablate nerves
AU2012287189B2 (en) 2011-07-22 2016-10-06 Boston Scientific Scimed, Inc. Nerve modulation system with a nerve modulation element positionable in a helical guide
EP2736592B1 (en) 2011-07-29 2018-01-10 Micron Devices LLC Remote control of power or polarity selection for a neural stimulator
EP2741810B1 (en) 2011-08-12 2021-03-31 Stimwave Technologies Incorporated Microwave field stimulator
US9793579B2 (en) 2013-11-08 2017-10-17 Leviticus Cardio Ltd. Batteries for use in implantable medical devices
US9343224B2 (en) * 2011-08-19 2016-05-17 Leviticus Cardio Ltd. Coplanar energy transfer
US10543303B2 (en) 2013-11-08 2020-01-28 Leviticus Cardio Ltd. Batteries for use in implantable medical devices
US9642958B2 (en) 2011-08-19 2017-05-09 Leviticus Cardio Ltd. Coplanar wireless energy transfer
US8702619B2 (en) 2011-08-26 2014-04-22 Symap Holding Limited Mapping sympathetic nerve distribution for renal ablation and catheters for same
US9014821B2 (en) 2011-08-26 2015-04-21 Symap Holding Limited System and method for locating and identifying the functional nerves innervating the wall of arteries and catheters for same
US9526637B2 (en) 2011-09-09 2016-12-27 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US8855783B2 (en) 2011-09-09 2014-10-07 Enopace Biomedical Ltd. Detector-based arterial stimulation
US9242103B2 (en) 2011-09-15 2016-01-26 Micron Devices Llc Relay module for implant
US9186210B2 (en) 2011-10-10 2015-11-17 Boston Scientific Scimed, Inc. Medical devices including ablation electrodes
WO2013055815A1 (en) 2011-10-11 2013-04-18 Boston Scientific Scimed, Inc. Off -wall electrode device for nerve modulation
US9420955B2 (en) 2011-10-11 2016-08-23 Boston Scientific Scimed, Inc. Intravascular temperature monitoring system and method
US9364284B2 (en) 2011-10-12 2016-06-14 Boston Scientific Scimed, Inc. Method of making an off-wall spacer cage
EP2768568B1 (en) 2011-10-18 2020-05-06 Boston Scientific Scimed, Inc. Integrated crossing balloon catheter
EP2768563B1 (en) 2011-10-18 2016-11-09 Boston Scientific Scimed, Inc. Deflectable medical devices
US9421362B2 (en) 2011-10-28 2016-08-23 Medtronic, Inc. Modular lead end
WO2013062863A1 (en) 2011-10-28 2013-05-02 Medtronic, Inc. Lead end having slotted member
US9138576B2 (en) 2011-10-28 2015-09-22 Medtronic, Inc. Lead end having inner support
US9265436B2 (en) * 2011-11-04 2016-02-23 Pacesetter, Inc. Leadless intra-cardiac medical device with built-in telemetry system
CN104023662B (en) 2011-11-08 2018-02-09 波士顿科学西美德公司 Hole portion renal nerve melts
US9119600B2 (en) 2011-11-15 2015-09-01 Boston Scientific Scimed, Inc. Device and methods for renal nerve modulation monitoring
US9119632B2 (en) 2011-11-21 2015-09-01 Boston Scientific Scimed, Inc. Deflectable renal nerve ablation catheter
US9079043B2 (en) * 2011-11-21 2015-07-14 Thoratec Corporation Transcutaneous power transmission utilizing non-planar resonators
WO2013076380A1 (en) 2011-11-24 2013-05-30 Berneman Laurent Medical device having electrodes for muscle stimulation and an electromagnetic probe
WO2013082283A1 (en) * 2011-11-30 2013-06-06 Medtronic, Inc. Medical electrical stimulation lead including expandable coiled fixation element
US9265969B2 (en) 2011-12-21 2016-02-23 Cardiac Pacemakers, Inc. Methods for modulating cell function
EP3138521B1 (en) 2011-12-23 2019-05-29 Vessix Vascular, Inc. Apparatuses for remodeling tissue of or adjacent to a body passage
US9433760B2 (en) 2011-12-28 2016-09-06 Boston Scientific Scimed, Inc. Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements
US9050106B2 (en) 2011-12-29 2015-06-09 Boston Scientific Scimed, Inc. Off-wall electrode device and methods for nerve modulation
US20150018728A1 (en) 2012-01-26 2015-01-15 Bluewind Medical Ltd. Wireless neurostimulators
US9386991B2 (en) 2012-02-02 2016-07-12 Rainbow Medical Ltd. Pressure-enhanced blood flow treatment
EP2825251A4 (en) * 2012-03-13 2015-02-25 Sunshine Heart Co Pty Ltd Methods, systems, and devices relating to wireless power transfer
US20130296965A1 (en) * 2012-05-07 2013-11-07 Cardiac Pacemakers, Inc. Method for blood pressure modulation using electrical stimulation of the coronary baroreceptors
WO2013169927A1 (en) 2012-05-08 2013-11-14 Boston Scientific Scimed, Inc. Renal nerve modulation devices
WO2013177006A2 (en) 2012-05-21 2013-11-28 Stimwave Technologies, Incorporated Methods and devices for modulating excitable tissue of the exiting spinal nerves
US10245436B2 (en) * 2012-07-17 2019-04-02 Stimwave Technologies Incorporated Miniature implantable device and methods
EP2885050A1 (en) * 2012-08-16 2015-06-24 Cardiac Pacemakers, Inc. Therapy delivery architecture for implantable medical device
WO2014032016A1 (en) 2012-08-24 2014-02-27 Boston Scientific Scimed, Inc. Intravascular catheter with a balloon comprising separate microporous regions
US8888709B2 (en) 2012-09-12 2014-11-18 Boston Scientific Scimed, Inc. Method and apparatus for sensing and avoiding cardiac conduction system during valve deployment
CN104780859B (en) 2012-09-17 2017-07-25 波士顿科学西美德公司 Self-positioning electrode system and method for renal regulation
WO2014047411A1 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. System for nerve modulation and innocuous thermal gradient nerve block
WO2014047454A2 (en) 2012-09-21 2014-03-27 Boston Scientific Scimed, Inc. Self-cooling ultrasound ablation catheter
US10835305B2 (en) 2012-10-10 2020-11-17 Boston Scientific Scimed, Inc. Renal nerve modulation devices and methods
CN104902836B (en) 2012-11-05 2017-08-08 毕达哥拉斯医疗有限公司 Controlled tissue melts
US9770593B2 (en) * 2012-11-05 2017-09-26 Pythagoras Medical Ltd. Patient selection using a transluminally-applied electric current
WO2014087337A1 (en) 2012-12-06 2014-06-12 Bluewind Medical Ltd. Delivery of implantable neurostimulators
US8868178B2 (en) 2012-12-11 2014-10-21 Galvani, Ltd. Arrhythmia electrotherapy device and method with provisions for mitigating patient discomfort
US9254393B2 (en) 2012-12-26 2016-02-09 Micron Devices Llc Wearable antenna assembly
US9370663B2 (en) * 2013-02-07 2016-06-21 Biotronik SE & Co., KG Implantable medical device, medical system and method for data communication
US9381365B2 (en) 2013-02-07 2016-07-05 Biotronik Se & Co. Kg Implantable medical device, medical system and method for data communication
JP6183448B2 (en) * 2013-02-22 2017-08-23 株式会社村田製作所 Sensor tag and sensor tag manufacturing method
WO2014163987A1 (en) 2013-03-11 2014-10-09 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9693821B2 (en) 2013-03-11 2017-07-04 Boston Scientific Scimed, Inc. Medical devices for modulating nerves
US9694172B2 (en) 2013-03-12 2017-07-04 Cardiac Pacemakers, Inc. Implantable medical devices with separate fixation mechanism
US9998180B2 (en) * 2013-03-13 2018-06-12 Integrated Device Technology, Inc. Apparatuses and related methods for modulating power of a wireless power receiver
US9808311B2 (en) 2013-03-13 2017-11-07 Boston Scientific Scimed, Inc. Deflectable medical devices
US10265122B2 (en) 2013-03-15 2019-04-23 Boston Scientific Scimed, Inc. Nerve ablation devices and related methods of use
JP6220044B2 (en) 2013-03-15 2017-10-25 ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. Medical device for renal nerve ablation
AU2014237950B2 (en) 2013-03-15 2017-04-13 Boston Scientific Scimed, Inc. Control unit for use with electrode pads and a method for estimating an electrical leakage
AU2014241205B2 (en) * 2013-03-27 2019-01-17 Autonomix Medical, Inc. Neurological traffic and receptor evaluation and modification: systems and methods
US8948883B2 (en) 2013-04-24 2015-02-03 Medtronic, Inc. Electrode assemblies and associated fixation members for implantable medical devices
AU2014268445B2 (en) * 2013-05-22 2019-03-07 Deep Brain Innovations LLC Deep brain stimulator and method of use
US20140363326A1 (en) 2013-06-10 2014-12-11 Grid Logic Incorporated System and method for additive manufacturing
WO2014205129A1 (en) 2013-06-18 2014-12-24 Enterowave, Inc. Method and apparatus for minimally invasive implantable modulators
US9592399B2 (en) 2013-06-20 2017-03-14 Cardiac Pacemakers, Inc. Deployable multi-electrode leadless electrostimulator
WO2014205399A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation having rotatable shafts
WO2014205388A1 (en) 2013-06-21 2014-12-24 Boston Scientific Scimed, Inc. Renal denervation balloon catheter with ride along electrode support
EP2818202B1 (en) 2013-06-24 2016-04-13 Sorin CRM SAS Coupling system between a medical device and an accessory for in situ implantation thereof
EP2818201B1 (en) * 2013-06-24 2016-07-20 Sorin CRM SAS Intracardiac capsule and accessory for in situ implantation by the femoral route
US9707036B2 (en) 2013-06-25 2017-07-18 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation using localized indifferent electrodes
EP3016605B1 (en) 2013-07-01 2019-06-05 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
US9601267B2 (en) 2013-07-03 2017-03-21 Qualcomm Incorporated Wireless power transmitter with a plurality of magnetic oscillators
US10660698B2 (en) 2013-07-11 2020-05-26 Boston Scientific Scimed, Inc. Devices and methods for nerve modulation
CN105377170A (en) 2013-07-11 2016-03-02 波士顿科学国际有限公司 Medical device with stretchable electrode assemblies
CN105682594B (en) 2013-07-19 2018-06-22 波士顿科学国际有限公司 Helical bipolar electrodes renal denervation dominates air bag
WO2015013205A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Medical devices for renal nerve ablation
WO2015013301A1 (en) 2013-07-22 2015-01-29 Boston Scientific Scimed, Inc. Renal nerve ablation catheter having twist balloon
US9504842B2 (en) * 2013-07-23 2016-11-29 Ado Holding Sa Electronic medical system with implantable medical device, having wireless power supply transfer
US10071243B2 (en) 2013-07-31 2018-09-11 Medtronic, Inc. Fixation for implantable medical devices
US9867540B2 (en) * 2013-08-09 2018-01-16 Senseonics, Incorporated Co-planar, near field communication telemetry link for an analyte sensor
WO2015023488A1 (en) * 2013-08-16 2015-02-19 Cardiac Pacemakers, Inc. Leadless cardiac pacing devices
EP4049605A1 (en) 2013-08-22 2022-08-31 Boston Scientific Scimed Inc. Flexible circuit having improved adhesion to a renal nerve modulation balloon
US9867694B2 (en) 2013-08-30 2018-01-16 Jenavalve Technology Inc. Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
CN105555218B (en) 2013-09-04 2019-01-15 波士顿科学国际有限公司 With radio frequency (RF) foley's tube rinsed with cooling capacity
CN105530885B (en) 2013-09-13 2020-09-22 波士顿科学国际有限公司 Ablation balloon with vapor deposited covering
US10241850B2 (en) 2013-10-02 2019-03-26 Grid Logic Incorporated Non-magnetodielectric flux concentrator
US10350683B2 (en) 2013-10-02 2019-07-16 Grid Logic Incorporated Multiple flux concentrator heating
US9687166B2 (en) 2013-10-14 2017-06-27 Boston Scientific Scimed, Inc. High resolution cardiac mapping electrode array catheter
US11246654B2 (en) 2013-10-14 2022-02-15 Boston Scientific Scimed, Inc. Flexible renal nerve ablation devices and related methods of use and manufacture
CN105636537B (en) 2013-10-15 2018-08-17 波士顿科学国际有限公司 Medical instrument sacculus
US9770606B2 (en) 2013-10-15 2017-09-26 Boston Scientific Scimed, Inc. Ultrasound ablation catheter with cooling infusion and centering basket
EP3057521B1 (en) 2013-10-18 2020-03-25 Boston Scientific Scimed, Inc. Balloon catheters with flexible conducting wires
US10166098B2 (en) 2013-10-25 2019-01-01 Middle Peak Medical, Inc. Systems and methods for transcatheter treatment of valve regurgitation
US10271898B2 (en) 2013-10-25 2019-04-30 Boston Scientific Scimed, Inc. Embedded thermocouple in denervation flex circuit
EP3065673A4 (en) 2013-11-06 2017-07-12 Enopace Biomedical Ltd. Wireless endovascular stent-based electrodes
US8831747B1 (en) 2013-11-19 2014-09-09 Pacesetter, Inc. Leadless neurostimulation device and method including the same
US9789319B2 (en) * 2013-11-21 2017-10-17 Medtronic, Inc. Systems and methods for leadless cardiac resynchronization therapy
DE102013224283A1 (en) * 2013-11-27 2015-06-11 Deutsches Herzzentrum Berlin Device for transcutaneous implantation of epicardial pacemaker electrodes
US9721085B1 (en) * 2013-12-18 2017-08-01 Maxim Integrated Products, Inc. Method and battery pack device with antenna and diode
US9592393B2 (en) 2013-12-20 2017-03-14 Cardiac Pacemakers, Inc. Leadless pacemaker with end-of-life protection
CN105899157B (en) 2014-01-06 2019-08-09 波士顿科学国际有限公司 Tear-proof flexible circuit assembly
EP3092038B1 (en) 2014-01-10 2017-12-27 Cardiac Pacemakers, Inc. Methods and systems for improved communication between medical devices
US9592391B2 (en) 2014-01-10 2017-03-14 Cardiac Pacemakers, Inc. Systems and methods for detecting cardiac arrhythmias
US11000679B2 (en) 2014-02-04 2021-05-11 Boston Scientific Scimed, Inc. Balloon protection and rewrapping devices and related methods of use
CN106572881B (en) 2014-02-04 2019-07-26 波士顿科学国际有限公司 Substitution of the heat sensor on bipolar electrode is placed
US10004907B2 (en) * 2014-02-21 2018-06-26 Pacesetter, Inc. Automatic capture verification within leadless implantable medical devices
US10004913B2 (en) 2014-03-03 2018-06-26 The Board Of Trustees Of The Leland Stanford Junior University Methods and apparatus for power conversion and data transmission in implantable sensors, stimulators, and actuators
GB2527075A (en) 2014-03-17 2015-12-16 Daassist As Percutaneous system, devices and methods
US20170027460A1 (en) 2015-07-29 2017-02-02 NeuroMedic, Inc. Intraluminal microneurography probe
US9999463B2 (en) 2014-04-14 2018-06-19 NeuroMedic, Inc. Monitoring nerve activity
US10478249B2 (en) 2014-05-07 2019-11-19 Pythagoras Medical Ltd. Controlled tissue ablation techniques
US10434329B2 (en) 2014-05-09 2019-10-08 The Board Of Trustees Of The Leland Stanford Junior University Autofocus wireless power transfer to implantable devices in freely moving animals
WO2015175572A1 (en) 2014-05-12 2015-11-19 Micron Devices Llc Remote rf power system with low profile transmitting antenna
CA2958061A1 (en) 2014-06-18 2015-12-23 Middle Peak Medical, Inc. Mitral valve implants for the treatment of valvular regurgitation
JP6740140B2 (en) 2014-06-24 2020-08-12 ポラレス・メディカル・インコーポレイテッド System and method for securing an implant
EP2987526A1 (en) 2014-08-21 2016-02-24 BIOTRONIK SE & Co. KG Medical implant comprising a fixing device
WO2016033197A2 (en) 2014-08-28 2016-03-03 Cardiac Pacemakers, Inc. Medical device with triggered blanking period
US10716931B2 (en) * 2014-09-09 2020-07-21 Pacesetter, Inc. Systems and methods for implanting a medical device
CN104571507B (en) * 2014-12-27 2019-07-23 北京智谷睿拓技术服务有限公司 Exchange method and user equipment
US9764146B2 (en) 2015-01-21 2017-09-19 Bluewind Medical Ltd. Extracorporeal implant controllers
US9597521B2 (en) 2015-01-21 2017-03-21 Bluewind Medical Ltd. Transmitting coils for neurostimulation
US10004896B2 (en) 2015-01-21 2018-06-26 Bluewind Medical Ltd. Anchors and implant devices
WO2016126613A1 (en) 2015-02-06 2016-08-11 Cardiac Pacemakers, Inc. Systems and methods for treating cardiac arrhythmias
US10220213B2 (en) 2015-02-06 2019-03-05 Cardiac Pacemakers, Inc. Systems and methods for safe delivery of electrical stimulation therapy
US10046167B2 (en) 2015-02-09 2018-08-14 Cardiac Pacemakers, Inc. Implantable medical device with radiopaque ID tag
CN107530002B (en) 2015-03-04 2021-04-30 心脏起搏器股份公司 System and method for treating cardiac arrhythmias
EP3069754B1 (en) 2015-03-16 2017-10-25 Sorin CRM SAS In situ implantation accessory for self-contained intracardiac capsule
US10050700B2 (en) 2015-03-18 2018-08-14 Cardiac Pacemakers, Inc. Communications in a medical device system with temporal optimization
US10213610B2 (en) 2015-03-18 2019-02-26 Cardiac Pacemakers, Inc. Communications in a medical device system with link quality assessment
EP3288495B1 (en) 2015-05-01 2019-09-25 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
US10383685B2 (en) 2015-05-07 2019-08-20 Pythagoras Medical Ltd. Techniques for use with nerve tissue
US9468773B1 (en) * 2015-05-07 2016-10-18 Medtronic, Inc. Interventional medical systems and implantable medical devices including tethering features, and associated methods
US9782589B2 (en) 2015-06-10 2017-10-10 Bluewind Medical Ltd. Implantable electrostimulator for improving blood flow
US20170117739A1 (en) * 2015-10-26 2017-04-27 Nuheart As System, apparatus and method for improved contactless power transfer in implantable devices
CN108136187B (en) 2015-08-20 2021-06-29 心脏起搏器股份公司 System and method for communication between medical devices
EP3337560B1 (en) * 2015-08-20 2019-12-18 Cardiac Pacemakers, Inc. Implantable medical device with modified surface texture
WO2017031221A1 (en) 2015-08-20 2017-02-23 Cardiac Pacemakers, Inc. Systems and methods for communication between medical devices
US9956414B2 (en) 2015-08-27 2018-05-01 Cardiac Pacemakers, Inc. Temporal configuration of a motion sensor in an implantable medical device
US9968787B2 (en) 2015-08-27 2018-05-15 Cardiac Pacemakers, Inc. Spatial configuration of a motion sensor in an implantable medical device
US10159842B2 (en) 2015-08-28 2018-12-25 Cardiac Pacemakers, Inc. System and method for detecting tamponade
US10226631B2 (en) 2015-08-28 2019-03-12 Cardiac Pacemakers, Inc. Systems and methods for infarct detection
US10137305B2 (en) 2015-08-28 2018-11-27 Cardiac Pacemakers, Inc. Systems and methods for behaviorally responsive signal detection and therapy delivery
WO2017044389A1 (en) 2015-09-11 2017-03-16 Cardiac Pacemakers, Inc. Arrhythmia detection and confirmation
EP3359251B1 (en) 2015-10-08 2019-08-07 Cardiac Pacemakers, Inc. Adjusting pacing rates in an implantable medical device
US10434283B2 (en) * 2015-10-29 2019-10-08 Medtronic, Inc. Interventional medical systems, associated assemblies and methods
US9592121B1 (en) 2015-11-06 2017-03-14 Middle Peak Medical, Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
US10105540B2 (en) 2015-11-09 2018-10-23 Bluewind Medical Ltd. Optimization of application of current
US9713707B2 (en) 2015-11-12 2017-07-25 Bluewind Medical Ltd. Inhibition of implant migration
WO2017106693A1 (en) 2015-12-17 2017-06-22 Cardiac Pacemakers, Inc. Conducted communication in a medical device system
US10905886B2 (en) 2015-12-28 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device for deployment across the atrioventricular septum
US10893847B2 (en) 2015-12-30 2021-01-19 Nuheart As Transcatheter insertion system
WO2017127548A1 (en) 2016-01-19 2017-07-27 Cardiac Pacemakers, Inc. Devices for wirelessly recharging a rechargeable battery of an implantable medical device
US10099050B2 (en) 2016-01-21 2018-10-16 Medtronic, Inc. Interventional medical devices, device systems, and fixation components thereof
US10463853B2 (en) 2016-01-21 2019-11-05 Medtronic, Inc. Interventional medical systems
CN108697886B (en) 2016-01-29 2022-11-08 艾克索尼克斯股份有限公司 Method and system for frequency adjustment to optimize charging of an implantable neurostimulator
WO2017136768A1 (en) 2016-02-03 2017-08-10 Grid Logic Incorporated System and method for manufacturing a part
CN109069840B (en) 2016-02-04 2022-03-15 心脏起搏器股份公司 Delivery system with force sensor for leadless cardiac devices
EP3436142A1 (en) 2016-03-31 2019-02-06 Cardiac Pacemakers, Inc. Implantable medical device with rechargeable battery
US10780280B2 (en) 2016-04-26 2020-09-22 Mayo Foundation For Medical Education And Research Devices and methods for cardiac pacing and resynchronization
US10668294B2 (en) 2016-05-10 2020-06-02 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker configured for over the wire delivery
US10328272B2 (en) 2016-05-10 2019-06-25 Cardiac Pacemakers, Inc. Retrievability for implantable medical devices
EP4183371A1 (en) 2016-05-13 2023-05-24 JenaValve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
US11678932B2 (en) 2016-05-18 2023-06-20 Symap Medical (Suzhou) Limited Electrode catheter with incremental advancement
US10881868B2 (en) 2016-05-24 2021-01-05 Sorin Crm Sas Torque limiting mechanism between a medical device and its implantation accessory
EP3474945B1 (en) 2016-06-27 2022-12-28 Cardiac Pacemakers, Inc. Cardiac therapy system using subcutaneously sensed p-waves for resynchronization pacing management
WO2018009569A1 (en) 2016-07-06 2018-01-11 Cardiac Pacemakers, Inc. Method and system for determining an atrial contraction timing fiducial in a leadless cardiac pacemaker system
WO2018009392A1 (en) 2016-07-07 2018-01-11 Cardiac Pacemakers, Inc. Leadless pacemaker using pressure measurements for pacing capture verification
EP3484577A4 (en) 2016-07-18 2020-03-25 Nalu Medical, Inc. Methods and systems for treating pelvic disorders and pain conditions
WO2018017226A1 (en) 2016-07-20 2018-01-25 Cardiac Pacemakers, Inc. System for utilizing an atrial contraction timing fiducial in a leadless cardiac pacemaker system
US10238864B2 (en) * 2016-07-29 2019-03-26 Medtronic, Inc. Interventional medical systems and associated tethering assemblies and methods
EP3500342B1 (en) 2016-08-19 2020-05-13 Cardiac Pacemakers, Inc. Trans-septal implantable medical device
WO2018039322A1 (en) 2016-08-24 2018-03-01 Cardiac Pacemakers, Inc. Cardiac resynchronization using fusion promotion for timing management
CN109640809B (en) 2016-08-24 2021-08-17 心脏起搏器股份公司 Integrated multi-device cardiac resynchronization therapy using P-wave to pacing timing
US10758737B2 (en) 2016-09-21 2020-09-01 Cardiac Pacemakers, Inc. Using sensor data from an intracardially implanted medical device to influence operation of an extracardially implantable cardioverter
US10994145B2 (en) 2016-09-21 2021-05-04 Cardiac Pacemakers, Inc. Implantable cardiac monitor
WO2018057318A1 (en) 2016-09-21 2018-03-29 Cardiac Pacemakers, Inc. Leadless stimulation device with a housing that houses internal components of the leadless stimulation device and functions as the battery case and a terminal of an internal battery
US10537672B2 (en) 2016-10-07 2020-01-21 Nuheart As Transcatheter device and system for the delivery of intracorporeal devices
US10335528B2 (en) 2016-10-07 2019-07-02 Nuheart As Transcatheter method and system for the delivery of intracorporeal devices
US10463305B2 (en) 2016-10-27 2019-11-05 Cardiac Pacemakers, Inc. Multi-device cardiac resynchronization therapy with timing enhancements
WO2018081133A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Implantable medical device having a sense channel with performance adjustment
US10413733B2 (en) 2016-10-27 2019-09-17 Cardiac Pacemakers, Inc. Implantable medical device with gyroscope
WO2018081017A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
WO2018081225A1 (en) 2016-10-27 2018-05-03 Cardiac Pacemakers, Inc. Implantable medical device delivery system with integrated sensor
EP3532160B1 (en) 2016-10-27 2023-01-25 Cardiac Pacemakers, Inc. Separate device in managing the pace pulse energy of a cardiac pacemaker
US10434317B2 (en) 2016-10-31 2019-10-08 Cardiac Pacemakers, Inc. Systems and methods for activity level pacing
WO2018081713A1 (en) 2016-10-31 2018-05-03 Cardiac Pacemakers, Inc Systems for activity level pacing
EP3538213B1 (en) 2016-11-09 2023-04-12 Cardiac Pacemakers, Inc. Systems and devices for setting cardiac pacing pulse parameters for a cardiac pacing device
WO2018094344A2 (en) 2016-11-21 2018-05-24 Cardiac Pacemakers, Inc Leadless cardiac pacemaker with multimode communication
US10881869B2 (en) 2016-11-21 2021-01-05 Cardiac Pacemakers, Inc. Wireless re-charge of an implantable medical device
US10639486B2 (en) 2016-11-21 2020-05-05 Cardiac Pacemakers, Inc. Implantable medical device with recharge coil
US10894163B2 (en) 2016-11-21 2021-01-19 Cardiac Pacemakers, Inc. LCP based predictive timing for cardiac resynchronization
WO2018094342A1 (en) 2016-11-21 2018-05-24 Cardiac Pacemakers, Inc Implantable medical device with a magnetically permeable housing and an inductive coil disposed about the housing
US10124178B2 (en) 2016-11-23 2018-11-13 Bluewind Medical Ltd. Implant and delivery tool therefor
US11207532B2 (en) 2017-01-04 2021-12-28 Cardiac Pacemakers, Inc. Dynamic sensing updates using postural input in a multiple device cardiac rhythm management system
EP3573709A1 (en) 2017-01-26 2019-12-04 Cardiac Pacemakers, Inc. Leadless device with overmolded components
US10737102B2 (en) 2017-01-26 2020-08-11 Cardiac Pacemakers, Inc. Leadless implantable device with detachable fixation
EP3573706A1 (en) 2017-01-26 2019-12-04 Cardiac Pacemakers, Inc. Intra-body device communication with redundant message transmission
WO2018138658A1 (en) 2017-01-27 2018-08-02 Jenavalve Technology, Inc. Heart valve mimicry
EP3585475A4 (en) 2017-02-24 2021-01-06 Nalu Medical, Inc. Apparatus with sequentially implanted stimulators
US10653524B2 (en) 2017-03-13 2020-05-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
JP7159230B2 (en) 2017-03-13 2022-10-24 ポラレス・メディカル・インコーポレイテッド Devices, systems and methods for transcatheter treatment of valvular regurgitation
US10478303B2 (en) 2017-03-13 2019-11-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
AU2018248361B2 (en) 2017-04-03 2020-08-27 Cardiac Pacemakers, Inc. Cardiac pacemaker with pacing pulse energy adjustment based on sensed heart rate
US10905872B2 (en) 2017-04-03 2021-02-02 Cardiac Pacemakers, Inc. Implantable medical device with a movable electrode biased toward an extended position
US10537670B2 (en) 2017-04-28 2020-01-21 Nuheart As Ventricular assist device and method
US10888646B2 (en) 2017-04-28 2021-01-12 Nuheart As Ventricular assist device and method
US20180353764A1 (en) 2017-06-13 2018-12-13 Bluewind Medical Ltd. Antenna configuration
US11065459B2 (en) 2017-08-18 2021-07-20 Cardiac Pacemakers, Inc. Implantable medical device with pressure sensor
US10918875B2 (en) 2017-08-18 2021-02-16 Cardiac Pacemakers, Inc. Implantable medical device with a flux concentrator and a receiving coil disposed about the flux concentrator
EP3684465B1 (en) 2017-09-20 2021-07-14 Cardiac Pacemakers, Inc. Implantable medical device with multiple modes of operation
EP3459469A1 (en) 2017-09-23 2019-03-27 Universität Zürich Medical occluder device
US11185703B2 (en) * 2017-11-07 2021-11-30 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker for bundle of his pacing
WO2019108440A1 (en) * 2017-11-30 2019-06-06 Tendyne Holdings, Inc. Prosthetic heart valve and methods for cardiac hemodynamic optimization and monitoring
WO2019108830A1 (en) 2017-12-01 2019-06-06 Cardiac Pacemakers, Inc. Leadless cardiac pacemaker with reversionary behavior
EP3717064B1 (en) 2017-12-01 2023-06-07 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials during ventricular filling from a ventricularly implanted leadless cardiac pacemaker
EP3717059A1 (en) 2017-12-01 2020-10-07 Cardiac Pacemakers, Inc. Methods and systems for detecting atrial contraction timing fiducials within a search window from a ventricularly implanted leadless cardiac pacemaker
CN111432875A (en) 2017-12-01 2020-07-17 心脏起搏器股份公司 Method and system for detecting atrial contraction timing references and determining cardiac intervals from a ventricular-implantable leadless cardiac pacemaker
US11529523B2 (en) 2018-01-04 2022-12-20 Cardiac Pacemakers, Inc. Handheld bridge device for providing a communication bridge between an implanted medical device and a smartphone
WO2019136148A1 (en) 2018-01-04 2019-07-11 Cardiac Pacemakers, Inc. Dual chamber pacing without beat-to-beat communication
CN108434600B (en) * 2018-02-26 2021-11-02 郭成军 Intracardiac implant, cardiac pacemaker, implant device
US10668291B2 (en) * 2018-03-06 2020-06-02 Medtronic, Inc. Impingement detection for implantable medical devices
JP2021518192A (en) 2018-03-23 2021-08-02 メドトロニック,インコーポレイテッド VfA cardiac resynchronization therapy
EP3768160B1 (en) 2018-03-23 2023-06-07 Medtronic, Inc. Vfa cardiac therapy for tachycardia
US11400296B2 (en) 2018-03-23 2022-08-02 Medtronic, Inc. AV synchronous VfA cardiac therapy
CN110314282B (en) * 2018-03-31 2023-08-04 长庚医疗财团法人林口长庚纪念医院 Cardiac rhythm regulating device and cardiac rhythm regulating system
BR112020024640A2 (en) * 2018-06-03 2021-03-02 Olga Bokeriya systems, methods and devices for the treatment of bradyarrhythmias, tachyarrhythmias and heart failure
EP3586913A1 (en) * 2018-06-25 2020-01-01 BIOTRONIK SE & Co. KG Device for activating cell structures by means of electromagnetic energy
US11266840B2 (en) * 2018-06-27 2022-03-08 Arizona Board Of Regents On Behalf Of Arizona State University Wireless cardiac pace making
WO2020065582A1 (en) 2018-09-26 2020-04-02 Medtronic, Inc. Capture in ventricle-from-atrium cardiac therapy
FR3087344B1 (en) * 2018-10-17 2021-04-23 Cairdac COUPLING SYSTEM BETWEEN AN AUTONOMOUS HEART CAPSULE AND ITS IMPLEMENTATION TOOL
US11679265B2 (en) 2019-02-14 2023-06-20 Medtronic, Inc. Lead-in-lead systems and methods for cardiac therapy
US11696713B2 (en) 2019-03-15 2023-07-11 Arizona Board Of Regents On Behalf Of Arizona State University Contour electrocorticography (ECoG) array
US11428588B2 (en) 2019-03-28 2022-08-30 Arizona Board Of Regents On Behalf Of Arizona State University Fully-passive pressure sensors and methods for their use
US11759632B2 (en) 2019-03-28 2023-09-19 Medtronic, Inc. Fixation components for implantable medical devices
US11697025B2 (en) 2019-03-29 2023-07-11 Medtronic, Inc. Cardiac conduction system capture
US11213676B2 (en) 2019-04-01 2022-01-04 Medtronic, Inc. Delivery systems for VfA cardiac therapy
US11712188B2 (en) 2019-05-07 2023-08-01 Medtronic, Inc. Posterior left bundle branch engagement
US11305127B2 (en) 2019-08-26 2022-04-19 Medtronic Inc. VfA delivery and implant region detection
US11813466B2 (en) 2020-01-27 2023-11-14 Medtronic, Inc. Atrioventricular nodal stimulation
US11911168B2 (en) 2020-04-03 2024-02-27 Medtronic, Inc. Cardiac conduction system therapy benefit determination
US11813672B2 (en) 2020-05-08 2023-11-14 Grid Logic Incorporated System and method for manufacturing a part
US11813464B2 (en) 2020-07-31 2023-11-14 Medtronic, Inc. Cardiac conduction system evaluation
US11794002B2 (en) 2020-12-15 2023-10-24 Industrial Technology Research Institute Neuromodulation probe
US11464634B2 (en) 2020-12-16 2022-10-11 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation with secondary anchors
US11759321B2 (en) 2021-06-25 2023-09-19 Polares Medical Inc. Device, system, and method for transcatheter treatment of valvular regurgitation
US11400299B1 (en) * 2021-09-14 2022-08-02 Rainbow Medical Ltd. Flexible antenna for stimulator

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010226A1 (en) * 1993-10-14 1995-04-20 Ep Technologies, Inc. Locating and ablating pathways in the heart
EP0758542A1 (en) * 1995-08-16 1997-02-19 Ats Medical, Inc. Heart valve prosthesis incorporating electronic monitoring and/or pacing circuitry
WO1999064104A1 (en) * 1998-06-12 1999-12-16 St. Jude Medical Ab Inflatable electrode for temporary pacing
WO2001000114A1 (en) * 1999-06-25 2001-01-04 Vahid Saadat Apparatus and methods for treating tissue
US20060085041A1 (en) * 2004-10-20 2006-04-20 Hastings Roger N Leadless cardiac stimulation systems
US20070106357A1 (en) * 2005-11-04 2007-05-10 Stephen Denker Intravascular Electronics Carrier Electrode for a Transvascular Tissue Stimulation System

Family Cites Families (261)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3057356A (en) 1960-07-22 1962-10-09 Wilson Greatbatch Inc Medical cardiac pacemaker
US3357434A (en) 1964-04-06 1967-12-12 Avco Corp Inductively linked receiver
US3667477A (en) 1966-11-25 1972-06-06 Canadian Patents Dev Implantable vesical stimulator
US3596662A (en) 1968-09-04 1971-08-03 Medtronic Inc Electrode for cardiac stimulator
US3713449A (en) * 1970-08-31 1973-01-30 P Mulier Cardiac pacer with externally controllable variable width output pulse
US3835864A (en) 1970-09-21 1974-09-17 Rasor Ass Inc Intra-cardiac stimulator
US3943936A (en) * 1970-09-21 1976-03-16 Rasor Associates, Inc. Self powered pacers and stimulators
US3727616A (en) * 1971-06-15 1973-04-17 Gen Dynamics Corp Electronic system for the stimulation of biological systems
US3902501A (en) 1973-06-21 1975-09-02 Medtronic Inc Endocardial electrode
US3942535A (en) * 1973-09-27 1976-03-09 G. D. Searle & Co. Rechargeable tissue stimulating system
FR2300580A1 (en) 1975-02-14 1976-09-10 Ethicon Inc NEEDLE SURGICAL ELECTRODES IMPROVEMENT
SE7610696L (en) 1976-09-28 1978-03-29 Reenstierna Bertil KIT AND DEVICE FOR INSERTING AND FIXING "PACEMAKER - ELECTROD" IN (HUMAN) HEART
US4256115A (en) * 1976-12-20 1981-03-17 American Technology, Inc. Leadless cardiac pacer
US4157720A (en) 1977-09-16 1979-06-12 Greatbatch W Cardiac pacemaker
US4198991A (en) * 1978-05-17 1980-04-22 Cordis Corporation Cardiac pacer lead
US4721118A (en) * 1981-04-20 1988-01-26 Cordis Leads, Inc. Pervenous electrical pacing lead with foldable fins
US4441210A (en) * 1981-09-18 1984-04-03 Hochmair Erwin S Transcutaneous signal transmission system and methods
US4543955A (en) 1983-08-01 1985-10-01 Cordis Corporation System for controlling body implantable action device
FR2559391B3 (en) 1984-02-09 1986-12-19 Martin Jacques IMPLANTABLE HEART STIMULATOR
DE3414072A1 (en) * 1984-04-13 1985-10-17 Siemens AG, 1000 Berlin und 8000 München ENDOCARDIAL ELECTRODE ARRANGEMENT
JPS61203730A (en) 1985-03-07 1986-09-09 Yanase & Assoc:Kk Radio receiver
US4681111A (en) 1985-04-05 1987-07-21 Siemens-Pacesetter, Inc. Analog and digital telemetry system for an implantable device
US4644957A (en) 1985-04-08 1987-02-24 Ricciardelli Robert H Applicator structure for biological needle probes employing spiral-shaped retaining coils
US4860750A (en) 1986-04-17 1989-08-29 Intermedics Inc. Sidelock pacer lead connector
US4830006B1 (en) * 1986-06-17 1997-10-28 Intermedics Inc Implantable cardiac stimulator for detection and treatment of ventricular arrhythmias
IT1214738B (en) * 1986-11-11 1990-01-18 Sbm Soc Brevetti Medicina IMPROVEMENT IN CARDIAC STIMULATION SYSTEMS VIA PACEMAKER
US4858623A (en) 1987-07-13 1989-08-22 Intermedics, Inc. Active fixation mechanism for lead assembly of an implantable cardiac stimulator
JPH02307481A (en) 1989-05-08 1990-12-20 Intermedics Inc Positive fixing mechanism for lead assembly of buried cardiotonic device
US4953564A (en) 1989-08-23 1990-09-04 Medtronic, Inc. Screw-in drug eluting lead
US4987897A (en) * 1989-09-18 1991-01-29 Medtronic, Inc. Body bus medical device communication system
US5255693A (en) 1989-11-02 1993-10-26 Possis Medical, Inc. Cardiac lead
US5143090A (en) 1989-11-02 1992-09-01 Possis Medical, Inc. Cardiac lead
US5178149A (en) * 1989-11-06 1993-01-12 Michael Imburgia Transesophageal probe having simultaneous pacing and echocardiographic capability, and method of diagnosing heart disease using same
US5314458A (en) 1990-06-01 1994-05-24 University Of Michigan Single channel microstimulator
US5113869A (en) * 1990-08-21 1992-05-19 Telectronics Pacing Systems, Inc. Implantable ambulatory electrocardiogram monitor
US5170802A (en) 1991-01-07 1992-12-15 Medtronic, Inc. Implantable electrode for location within a blood vessel
US5139033A (en) 1991-03-04 1992-08-18 Cardiac Pacemakers, Inc. Sutureless myocardial lead implantation device
US5383915A (en) * 1991-04-10 1995-01-24 Angeion Corporation Wireless programmer/repeater system for an implanted medical device
US5954757A (en) 1991-05-17 1999-09-21 Gray; Noel Desmond Heart pacemaker
US6044300A (en) * 1991-05-17 2000-03-28 Gray; Noel Desmond Heart pacemaker
US6144879A (en) 1991-05-17 2000-11-07 Gray; Noel Desmond Heart pacemaker
WO1994008657A1 (en) 1992-10-20 1994-04-28 Noel Desmond Gray A heart pacemaker
US5243977A (en) 1991-06-26 1993-09-14 Trabucco Hector O Pacemaker
US5324325A (en) 1991-06-27 1994-06-28 Siemens Pacesetter, Inc. Myocardial steroid releasing lead
US5335664A (en) 1991-09-17 1994-08-09 Casio Computer Co., Ltd. Monitor system and biological signal transmitter therefor
US5246014A (en) 1991-11-08 1993-09-21 Medtronic, Inc. Implantable lead system
US5261916A (en) 1991-12-12 1993-11-16 Target Therapeutics Detachable pusher-vasoocclusive coil assembly with interlocking ball and keyway coupling
US5312439A (en) 1991-12-12 1994-05-17 Loeb Gerald E Implantable device having an electrolytic storage electrode
US5234437A (en) 1991-12-12 1993-08-10 Target Therapeutics, Inc. Detachable pusher-vasoocclusion coil assembly with threaded coupling
DK0791333T3 (en) * 1991-12-12 2000-05-01 Target Therapeutics Inc Several extruder-carocclusion coil construction with interlocking coupling
US5193539A (en) 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Implantable microstimulator
US5193540A (en) * 1991-12-18 1993-03-16 Alfred E. Mann Foundation For Scientific Research Structure and method of manufacture of an implantable microstimulator
JPH05245215A (en) 1992-03-03 1993-09-24 Terumo Corp Heart pace maker
FR2691905B1 (en) * 1992-06-03 1998-10-16 Jacques Brehier EXTRACTIBLE CARDIAC PROBE AND METHOD FOR IMPLEMENTING SAME.
US5336252A (en) 1992-06-22 1994-08-09 Cohen Donald M System and method for implanting cardiac electrical leads
US5447533A (en) 1992-09-03 1995-09-05 Pacesetter, Inc. Implantable stimulation lead having an advanceable therapeutic drug delivery system
US5250071A (en) 1992-09-22 1993-10-05 Target Therapeutics, Inc. Detachable embolic coil assembly using interlocking clasps and method of use
US5312415A (en) * 1992-09-22 1994-05-17 Target Therapeutics, Inc. Assembly for placement of embolic coils using frictional placement
US5350397A (en) 1992-11-13 1994-09-27 Target Therapeutics, Inc. Axially detachable embolic coil assembly
US5300107A (en) 1992-10-22 1994-04-05 Medtronic, Inc. Universal tined myocardial pacing lead
US5622168A (en) * 1992-11-18 1997-04-22 John L. Essmyer Conductive hydrogels and physiological electrodes and electrode assemblies therefrom
US5342408A (en) 1993-01-07 1994-08-30 Incontrol, Inc. Telemetry system for an implantable cardiac device
US5411537A (en) 1993-10-29 1995-05-02 Intermedics, Inc. Rechargeable biomedical battery powered devices with recharging and control system therefor
US5800535A (en) 1994-02-09 1998-09-01 The University Of Iowa Research Foundation Wireless prosthetic electrode for the brain
US5487760A (en) * 1994-03-08 1996-01-30 Ats Medical, Inc. Heart valve prosthesis incorporating electronic sensing, monitoring and/or pacing circuitry
US5571148A (en) 1994-08-10 1996-11-05 Loeb; Gerald E. Implantable multichannel stimulator
US5628778A (en) 1994-11-21 1997-05-13 Medtronic Inc. Single pass medical electrical lead
IL116561A0 (en) 1994-12-30 1996-03-31 Target Therapeutics Inc Severable joint for detachable devices placed within the body
US5591217A (en) 1995-01-04 1997-01-07 Plexus, Inc. Implantable stimulator with replenishable, high value capacitive power source and method therefor
US5876429A (en) * 1995-06-07 1999-03-02 Intermedics, Inc. Methods and devices for in vivo repair of cardiac stimulator leads
US5775331A (en) 1995-06-07 1998-07-07 Uromed Corporation Apparatus and method for locating a nerve
CN1168511C (en) 1996-01-08 2004-09-29 伊帕斯动力公司 Electrical muscle controller
US7167748B2 (en) 1996-01-08 2007-01-23 Impulse Dynamics Nv Electrical muscle controller
US8321013B2 (en) 1996-01-08 2012-11-27 Impulse Dynamics, N.V. Electrical muscle controller and pacing with hemodynamic enhancement
JP4175662B2 (en) 1996-01-08 2008-11-05 インパルス ダイナミクス エヌ.ヴイ. Electric muscle control device
US6363279B1 (en) * 1996-01-08 2002-03-26 Impulse Dynamics N.V. Electrical muscle controller
US9713723B2 (en) 1996-01-11 2017-07-25 Impulse Dynamics Nv Signal delivery through the right ventricular septum
US5772693A (en) 1996-02-09 1998-06-30 Cardiac Control Systems, Inc. Single preformed catheter configuration for a dual-chamber pacemaker system
WO1997032629A1 (en) 1996-03-06 1997-09-12 Advanced Bionics Corporation Magnetless implantable stimulator and external transmitter and implant tools for aligning same
US5755764A (en) 1996-09-10 1998-05-26 Sulzer Intermedics Inc. Implantable cardiac stimulation catheter
US5735887A (en) 1996-12-10 1998-04-07 Exonix Corporation Closed-loop, RF-coupled implanted medical device
US5814089A (en) 1996-12-18 1998-09-29 Medtronic, Inc. Leadless multisite implantable stimulus and diagnostic system
US6695885B2 (en) 1997-02-26 2004-02-24 Alfred E. Mann Foundation For Scientific Research Method and apparatus for coupling an implantable stimulator/sensor to a prosthetic device
US6208894B1 (en) * 1997-02-26 2001-03-27 Alfred E. Mann Foundation For Scientific Research And Advanced Bionics System of implantable devices for monitoring and/or affecting body parameters
US6164284A (en) 1997-02-26 2000-12-26 Schulman; Joseph H. System of implantable devices for monitoring and/or affecting body parameters
US7114502B2 (en) 1997-02-26 2006-10-03 Alfred E. Mann Foundation For Scientific Research Battery-powered patient implantable device
US6200303B1 (en) * 1997-04-30 2001-03-13 Beth Israel Deaconess Medical Center, Inc. Method and kit for transvenously accessing the pericardial space via the right atrium
US5871532A (en) * 1997-05-22 1999-02-16 Sulzer Intermedics Inc. Epicardial lead for minimally invasive implantation
IT1292016B1 (en) * 1997-05-28 1999-01-25 Valerio Cigaina IMPLANT DEVICE PARTICULARLY FOR ELECTROSTIMULATION AND / OR ELECTRO-REGISTRATION OF ENDOABDOMINAL VISCERS
US6381495B1 (en) * 1997-05-28 2002-04-30 Transneuronix, Inc. Medical device for use in laparoscopic surgery
US5861019A (en) * 1997-07-25 1999-01-19 Medtronic Inc. Implantable medical device microstrip telemetry antenna
US5779715A (en) 1997-07-28 1998-07-14 Irvine Biomedical, Inc. Lead extraction system and methods thereof
US5876431A (en) 1997-07-30 1999-03-02 Sulzer Intermedics Inc. Small cable endocardial lead with exposed guide tube
US5851227A (en) 1997-07-30 1998-12-22 Sulzer Intermedics Inc. Cardiac pacemaker cable lead
US6409674B1 (en) 1998-09-24 2002-06-25 Data Sciences International, Inc. Implantable sensor with wireless communication
US20060064135A1 (en) * 1997-10-14 2006-03-23 Transoma Medical, Inc. Implantable pressure sensor with pacing capability
AU1093099A (en) 1997-10-17 1999-05-10 Penn State Research Foundation; The Muscle stimulating device and method for diagnosing and treating a breathin g disorder
US7031775B2 (en) 1997-11-07 2006-04-18 Medtronic, Inc. Method and system for myocardial infarction repair
US6070100A (en) * 1997-12-15 2000-05-30 Medtronic Inc. Pacing system for optimizing cardiac output and determining heart condition
US6089833A (en) 1998-02-03 2000-07-18 Chrysler Corporation Drive pulley for improved service of engine mounted accessories
US6132456A (en) 1998-03-10 2000-10-17 Medtronic, Inc. Arrangement for implanting an endocardial cardiac lead
US6144880A (en) * 1998-05-08 2000-11-07 Cardiac Pacemakers, Inc. Cardiac pacing using adjustable atrio-ventricular delays
CA2331316A1 (en) 1998-05-08 1999-11-18 Andrew P. Kramer Cardiac pacing using adjustable atrio-ventricular delays
US6537248B2 (en) * 1998-07-07 2003-03-25 Medtronic, Inc. Helical needle apparatus for creating a virtual electrode used for the ablation of tissue
US6141588A (en) 1998-07-24 2000-10-31 Intermedics Inc. Cardiac simulation system having multiple stimulators for anti-arrhythmia therapy
AU5394099A (en) 1998-08-07 2000-02-28 Infinite Biomedical Technologies, Incorporated Implantable myocardial ischemia detection, indication and action technology
US6240316B1 (en) * 1998-08-14 2001-05-29 Advanced Bionics Corporation Implantable microstimulation system for treatment of sleep apnea
US6385472B1 (en) 1999-09-10 2002-05-07 Stereotaxis, Inc. Magnetically navigable telescoping catheter and method of navigating telescoping catheter
US6035239A (en) 1998-11-10 2000-03-07 Intermedics Inc. Cardiac lead with reduced inner crimp sleeve
US7313444B2 (en) * 1998-11-20 2007-12-25 Pacesetter, Inc. Self-anchoring coronary sinus lead
WO2000030534A1 (en) 1998-11-25 2000-06-02 Ball Semiconductor, Inc. Spherically-shaped biomedical ic
US6336937B1 (en) * 1998-12-09 2002-01-08 Gore Enterprise Holdings, Inc. Multi-stage expandable stent-graft
US6363938B2 (en) * 1998-12-22 2002-04-02 Angiotrax, Inc. Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth
US6161029A (en) 1999-03-08 2000-12-12 Medtronic, Inc. Apparatus and method for fixing electrodes in a blood vessel
US6366937B1 (en) 1999-03-11 2002-04-02 Hitachi America Ltd. System and method for performing a fast fourier transform using a matrix-vector multiply instruction
US7020530B1 (en) 1999-03-30 2006-03-28 The Uab Research Foundation Method and apparatus for passive cardiac stimulation
US6123724A (en) 1999-04-14 2000-09-26 Denker; Stephen Heart assist method and apparatus employing magnetic repulsion force
US6266567B1 (en) 1999-06-01 2001-07-24 Ball Semiconductor, Inc. Implantable epicardial electrode
US6516227B1 (en) 1999-07-27 2003-02-04 Advanced Bionics Corporation Rechargeable spinal cord stimulator system
EP1106202A3 (en) * 1999-11-30 2004-03-31 BIOTRONIK Mess- und Therapiegeräte GmbH & Co Ingenieurbüro Berlin Electrode for intravascular stimulation, cardioversion and /or defibrillation
US6582441B1 (en) 2000-02-24 2003-06-24 Advanced Bionics Corporation Surgical insertion tool
US6370434B1 (en) * 2000-02-28 2002-04-09 Cardiac Pacemakers, Inc. Cardiac lead and method for lead implantation
DE10011572A1 (en) * 2000-03-02 2001-09-06 Biotronik Mess & Therapieg Electrode arrangement
US6441747B1 (en) 2000-04-18 2002-08-27 Motorola, Inc. Wireless system protocol for telemetry monitoring
US6510345B1 (en) * 2000-04-24 2003-01-21 Medtronic, Inc. System and method of bridging a transreceiver coil of an implantable medical device during non-communication periods
US6442413B1 (en) 2000-05-15 2002-08-27 James H. Silver Implantable sensor
DE60140025D1 (en) 2000-06-19 2009-11-12 Medtronic Inc Implantable medical device with an external recharging coil
FR2810250B1 (en) 2000-06-20 2002-08-02 Rossignol Sa SNOW SNOWBOARD WITH UPPER REINFORCEMENT
US6584362B1 (en) 2000-08-30 2003-06-24 Cardiac Pacemakers, Inc. Leads for pacing and/or sensing the heart from within the coronary veins
WO2002032499A1 (en) 2000-09-14 2002-04-25 Alfred E. Mann Institute For Biomedical Engineering At The University Of Southern California Method and apparatus to treat disorders of gastrointestinal peristalsis
US6647292B1 (en) 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6988003B2 (en) 2000-09-18 2006-01-17 Cameron Health, Inc. Implantable cardioverter-defibrillator having two spaced apart shocking electrodes on housing
US7283874B2 (en) 2000-10-16 2007-10-16 Remon Medical Technologies Ltd. Acoustically powered implantable stimulating device
DE10055686A1 (en) 2000-11-03 2002-05-08 Biotronik Mess & Therapieg Device for influencing cell proliferation mechanisms in vessels of the human or animal body
US6611710B2 (en) 2000-11-29 2003-08-26 Pacesetter, Inc. Double threaded stylet for extraction of leads with a threaded electrode
US6574510B2 (en) 2000-11-30 2003-06-03 Cardiac Pacemakers, Inc. Telemetry apparatus and method for an implantable medical device
US6783499B2 (en) 2000-12-18 2004-08-31 Biosense, Inc. Anchoring mechanism for implantable telemetric medical sensor
US6890295B2 (en) 2002-10-31 2005-05-10 Medtronic, Inc. Anatomical space access tools and methods
US6445953B1 (en) 2001-01-16 2002-09-03 Kenergy, Inc. Wireless cardiac pacing system with vascular electrode-stents
US20020123785A1 (en) 2001-03-02 2002-09-05 Cardiac Pacemakers, Inc. Cardiac lead permitting easy extraction
US6535764B2 (en) 2001-05-01 2003-03-18 Intrapace, Inc. Gastric treatment and diagnosis device and method
US7209783B2 (en) * 2001-06-15 2007-04-24 Cardiac Pacemakers, Inc. Ablation stent for treating atrial fibrillation
US6675049B2 (en) 2001-07-17 2004-01-06 Medtronic, Inc. Method and apparatus for automatic implantable medical lead recognition and configuration
US6456256B1 (en) 2001-08-03 2002-09-24 Cardiac Pacemakers, Inc. Circumferential antenna for an implantable medical device
US7481759B2 (en) * 2001-08-03 2009-01-27 Cardiac Pacemakers, Inc. Systems and methods for treatment of coronary artery disease
US6718212B2 (en) * 2001-10-12 2004-04-06 Medtronic, Inc. Implantable medical electrical lead with light-activated adhesive fixation
US6736771B2 (en) 2002-01-02 2004-05-18 Advanced Bionics Corporation Wideband low-noise implantable microphone assembly
US8364278B2 (en) 2002-01-29 2013-01-29 Boston Scientific Neuromodulation Corporation Lead assembly for implantable microstimulator
US20090088813A1 (en) * 2004-03-12 2009-04-02 Brockway Brian P Cardiac Rhythm Management Device
US8321036B2 (en) 2002-02-15 2012-11-27 Data Sciences International, Inc. Cardiac rhythm management device
US7236821B2 (en) 2002-02-19 2007-06-26 Cardiac Pacemakers, Inc. Chronically-implanted device for sensing and therapy
AUPS101502A0 (en) 2002-03-11 2002-04-11 Neopraxis Pty Ltd Wireless fes system
US7236822B2 (en) 2002-03-22 2007-06-26 Leptos Biomedical, Inc. Wireless electric modulation of sympathetic nervous system
US7239912B2 (en) 2002-03-22 2007-07-03 Leptos Biomedical, Inc. Electric modulation of sympathetic nervous system
US20040147973A1 (en) 2002-06-27 2004-07-29 Hauser Robert G. Intra cardiac pacer and method
EP2462983A1 (en) 2002-06-28 2012-06-13 Boston Scientific Neuromodulation Corporation Microstimulator having self-contained power source and bi-directional telemetry system
WO2004012810A1 (en) 2002-08-05 2004-02-12 Japan As Represented By President Of National Cardiovascular Center Subminiature integrated heart pace maker and dispersed heart pacing system
US8303511B2 (en) 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
US7615010B1 (en) 2002-10-03 2009-11-10 Integrated Sensing Systems, Inc. System for monitoring the physiologic parameters of patients with congestive heart failure
US20040106954A1 (en) 2002-11-15 2004-06-03 Whitehurst Todd K. Treatment of congestive heart failure
US20040102830A1 (en) 2002-11-22 2004-05-27 Williams Terrell M. System for coupling an implanatable medical device to an epicardial site
JP2004173790A (en) 2002-11-25 2004-06-24 Terumo Corp Heart treatment equipment
TWI235523B (en) 2002-12-31 2005-07-01 Ind Tech Res Inst A radio transmitter and receiver of an implantable medical device
US20050025797A1 (en) * 2003-04-08 2005-02-03 Xingwu Wang Medical device with low magnetic susceptibility
US7016733B2 (en) 2003-04-23 2006-03-21 Medtronic, Inc. Telemetry antenna for an implantable medical device
NZ526115A (en) 2003-05-23 2006-10-27 Auckland Uniservices Ltd Methods and apparatus for detuning a pick-up of a contactless power supply
WO2005000398A2 (en) * 2003-06-04 2005-01-06 Synecor Intravascular electrophysiological system and methods
US7006864B2 (en) * 2003-06-17 2006-02-28 Ebr Systems, Inc. Methods and systems for vibrational treatment of cardiac arrhythmias
US7184830B2 (en) 2003-08-18 2007-02-27 Ebr Systems, Inc. Methods and systems for treating arrhythmias using a combination of vibrational and electrical energy
US7289853B1 (en) 2003-08-28 2007-10-30 David Campbell High frequency wireless pacemaker
US6917833B2 (en) * 2003-09-16 2005-07-12 Kenergy, Inc. Omnidirectional antenna for wireless communication with implanted medical devices
CA2540682A1 (en) * 2003-10-03 2005-04-14 Applied Medical Resources Corporation Bladeless optical obturator
US7003350B2 (en) * 2003-11-03 2006-02-21 Kenergy, Inc. Intravenous cardiac pacing system with wireless power supply
US7050849B2 (en) 2003-11-06 2006-05-23 Ebr Systems, Inc. Vibrational therapy device used for resynchronization pacing in a treatment for heart failure
US7197362B2 (en) 2003-12-11 2007-03-27 Cardiac Pacemakers, Inc. Cardiac lead having coated fixation arrangement
US20050149138A1 (en) 2003-12-24 2005-07-07 Xiaoyi Min System and method for determining optimal pacing sites based on myocardial activation times
US7186214B2 (en) 2004-02-12 2007-03-06 Medtronic, Inc. Instruments and methods for accessing an anatomic space
US20050182456A1 (en) 2004-02-18 2005-08-18 Ziobro John F. Automated cortical mapping
JP2005245215A (en) 2004-03-01 2005-09-15 Fu Sheng Industrial Co Ltd Method for producing reel seat for fishing rod
WO2005101660A1 (en) 2004-04-12 2005-10-27 Advanced Neuromodulation Systems, Inc. Voltage limited systems and methods
US8938300B2 (en) 2004-05-04 2015-01-20 University Of Rochester Leadless implantable intravascular electrophysiologic device for neurologic/cardiovascular sensing and stimulation
US8801746B1 (en) * 2004-05-04 2014-08-12 Covidien Lp System and method for delivering a left atrial appendage containment device
US8412348B2 (en) 2004-05-06 2013-04-02 Boston Scientific Neuromodulation Corporation Intravascular self-anchoring integrated tubular electrode body
US7162310B2 (en) 2004-05-10 2007-01-09 Pacesetter, Inc. Flat wire helix electrode used in screw-in cardiac stimulation leads
US7260431B2 (en) 2004-05-20 2007-08-21 Cardiac Pacemakers, Inc. Combined remodeling control therapy and anti-remodeling therapy by implantable cardiac device
JP2008500864A (en) 2004-06-01 2008-01-17 レモン メディカル テクノロジーズ リミテッド Cardiac function evaluation system
US20060020316A1 (en) 2004-06-03 2006-01-26 Medtronic, Inc. Implantable cardioversion and defibrillation system including intramural myocardial elecrtode
US7765001B2 (en) 2005-08-31 2010-07-27 Ebr Systems, Inc. Methods and systems for heart failure prevention and treatments using ultrasound and leadless implantable devices
US7747333B2 (en) 2004-08-16 2010-06-29 Cardiac Pacemakers, Inc. Lead assembly and methods including a push tube
US7200437B1 (en) * 2004-10-13 2007-04-03 Pacesetter, Inc. Tissue contact for satellite cardiac pacemaker
US7532933B2 (en) 2004-10-20 2009-05-12 Boston Scientific Scimed, Inc. Leadless cardiac stimulation systems
CA2583404A1 (en) 2004-10-20 2006-04-27 Boston Scientific Limited Leadless cardiac stimulation systems
US7522962B1 (en) * 2004-12-03 2009-04-21 Remon Medical Technologies, Ltd Implantable medical device with integrated acoustic transducer
US7410497B2 (en) 2004-12-14 2008-08-12 Boston Scientific Scimed, Inc. Stimulation of cell growth at implant surfaces
AR047851A1 (en) 2004-12-20 2006-03-01 Giniger Alberto German A NEW MARCAPASOS THAT RESTORES OR PRESERVES THE PHYSIOLOGICAL ELECTRIC DRIVING OF THE HEART AND A METHOD OF APPLICATION
US7606621B2 (en) 2004-12-21 2009-10-20 Ebr Systems, Inc. Implantable transducer devices
EP1835964B1 (en) 2004-12-21 2016-03-09 EBR Systems, Inc. Leadless cardiac system for pacing and arrhythmia treatment
US7558631B2 (en) * 2004-12-21 2009-07-07 Ebr Systems, Inc. Leadless tissue stimulation systems and methods
US20060173505A1 (en) 2005-01-28 2006-08-03 Salo Rodney W Controlled delivery of electrical pacing therapy for treating mitral regurgitation
US20060173504A1 (en) 2005-01-28 2006-08-03 Qingsheng Zhu Electrical pacing therapy for treating mitral regurgitation
US7532932B2 (en) 2005-03-08 2009-05-12 Kenergy, Inc. Implantable medical apparatus having an omnidirectional antenna for receiving radio frequency signals
US7634313B1 (en) 2005-04-11 2009-12-15 Pacesetter, Inc. Failsafe satellite pacemaker system
US7565195B1 (en) 2005-04-11 2009-07-21 Pacesetter, Inc. Failsafe satellite pacemaker system
DE102005020071A1 (en) 2005-04-22 2006-10-26 Biotronik Crm Patent Ag Pacemaker
NZ539770A (en) 2005-04-29 2007-10-26 Auckland Uniservices Ltd Inductively coupled power transfer system
NZ539771A (en) 2005-04-29 2007-10-26 Auckland Uniservices Ltd Tuning methods and apparatus for inductively coupled power transfer (ICPT) systems
JP5245215B2 (en) 2005-06-16 2013-07-24 株式会社竹屋 Amusement center membership management system
WO2007028035A2 (en) 2005-09-01 2007-03-08 Proteus Biomedical, Inc. Implantable zero-wire communications system
US7702392B2 (en) 2005-09-12 2010-04-20 Ebr Systems, Inc. Methods and apparatus for determining cardiac stimulation sites using hemodynamic data
US7749265B2 (en) * 2005-10-05 2010-07-06 Kenergy, Inc. Radio frequency antenna for a wireless intravascular medical device
US9168383B2 (en) 2005-10-14 2015-10-27 Pacesetter, Inc. Leadless cardiac pacemaker with conducted communication
US9358400B2 (en) 2005-10-14 2016-06-07 Pacesetter, Inc. Leadless cardiac pacemaker
WO2007067231A1 (en) * 2005-12-09 2007-06-14 Boston Scientific Scimed, Inc. Cardiac stimulation system
US8050774B2 (en) 2005-12-22 2011-11-01 Boston Scientific Scimed, Inc. Electrode apparatus, systems and methods
US8160722B2 (en) 2006-02-28 2012-04-17 Medtronic, Inc. Subcutaneous lead fixation mechanisms
EP2008321B1 (en) * 2006-03-24 2014-12-03 Medtronic, Inc. Implantable medical device and lithium battery
US7937161B2 (en) 2006-03-31 2011-05-03 Boston Scientific Scimed, Inc. Cardiac stimulation electrodes, delivery devices, and implantation configurations
US20070276444A1 (en) 2006-05-24 2007-11-29 Daniel Gelbart Self-powered leadless pacemaker
US8116862B2 (en) * 2006-06-08 2012-02-14 Greatbatch Ltd. Tank filters placed in series with the lead wires or circuits of active medical devices to enhance MRI compatibility
US7899541B2 (en) 2006-06-20 2011-03-01 Ebr Systems, Inc. Systems and methods for implantable leadless gastrointestinal tissue stimulation
US7894904B2 (en) 2006-06-20 2011-02-22 Ebr Systems, Inc. Systems and methods for implantable leadless brain stimulation
US20070293904A1 (en) 2006-06-20 2007-12-20 Daniel Gelbart Self-powered resonant leadless pacemaker
US7899542B2 (en) 2006-06-20 2011-03-01 Ebr Systems, Inc. Systems and methods for implantable leadless spine stimulation
US7894907B2 (en) 2006-06-20 2011-02-22 Ebr Systems, Inc. Systems and methods for implantable leadless nerve stimulation
US7894910B2 (en) 2006-06-20 2011-02-22 Ebr Systems, Inc. Systems and methods for implantable leadless cochlear stimulation
US7877142B2 (en) * 2006-07-05 2011-01-25 Micardia Corporation Methods and systems for cardiac remodeling via resynchronization
US8290600B2 (en) 2006-07-21 2012-10-16 Boston Scientific Scimed, Inc. Electrical stimulation of body tissue using interconnected electrode assemblies
US7840281B2 (en) 2006-07-21 2010-11-23 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US20080039904A1 (en) * 2006-08-08 2008-02-14 Cherik Bulkes Intravascular implant system
US7643879B2 (en) 2006-08-24 2010-01-05 Cardiac Pacemakers, Inc. Integrated cardiac rhythm management system with heart valve
US8644934B2 (en) * 2006-09-13 2014-02-04 Boston Scientific Scimed Inc. Cardiac stimulation using leadless electrode assemblies
US20080077184A1 (en) * 2006-09-27 2008-03-27 Stephen Denker Intravascular Stimulation System With Wireless Power Supply
US7899537B1 (en) * 2006-10-27 2011-03-01 Pacesetter, Inc. Pericardial cardioverter defibrillator
DE102006055340A1 (en) 2006-11-23 2008-05-29 Siemens Ag Explosion-proof module construction for power components, in particular power semiconductor components and its manufacture
US7792588B2 (en) * 2007-01-26 2010-09-07 Medtronic, Inc. Radio frequency transponder based implantable medical system
CN101396582B (en) * 2007-02-16 2012-05-30 圣美申医疗科技(上海)有限公司 No-electrode ultrathin minitype multifunctional heart rhythm regulation and control device
US8103359B2 (en) 2007-05-17 2012-01-24 Cardiac Pacemakers, Inc. Systems and methods for fixating transvenously implanted medical devices
US20090082828A1 (en) * 2007-09-20 2009-03-26 Alan Ostroff Leadless Cardiac Pacemaker with Secondary Fixation Capability
US8019419B1 (en) 2007-09-25 2011-09-13 Dorin Panescu Methods and apparatus for leadless, battery-less, wireless stimulation of tissue
US20090082827A1 (en) * 2007-09-26 2009-03-26 Cardiac Pacemakers, Inc. Hinged anchors for wireless pacing electrodes
US7877136B1 (en) * 2007-09-28 2011-01-25 Boston Scientific Neuromodulation Corporation Enhancement of neural signal transmission through damaged neural tissue via hyperpolarizing electrical stimulation current
US8165694B2 (en) * 2008-01-29 2012-04-24 Boston Scientific Neuromodulation Corporation Thermal management of implantable medical devices
WO2009099550A1 (en) 2008-02-07 2009-08-13 Cardiac Pacemakers, Inc. Wireless tissue electrostimulation
EP2265166B1 (en) 2008-03-25 2020-08-05 EBR Systems, Inc. Temporary electrode connection for wireless pacing systems
US20090275998A1 (en) 2008-04-30 2009-11-05 Medtronic, Inc. Extra-cardiac implantable device with fusion pacing capability
US8527068B2 (en) 2009-02-02 2013-09-03 Nanostim, Inc. Leadless cardiac pacemaker with secondary fixation capability
US20110077708A1 (en) * 2009-09-28 2011-03-31 Alan Ostroff MRI Compatible Leadless Cardiac Pacemaker
US8478431B2 (en) 2010-04-13 2013-07-02 Medtronic, Inc. Slidable fixation device for securing a medical implant
US8532790B2 (en) 2010-04-13 2013-09-10 Medtronic, Inc. Slidable fixation device for securing a medical implant
US20110270339A1 (en) 2010-04-30 2011-11-03 Medtronic Vascular, Inc. Two-Stage Delivery Systems and Methods for Fixing a Leadless Implant to Tissue
US20110270340A1 (en) 2010-04-30 2011-11-03 Medtronic Vascular,Inc. Two-Stage Delivery Systems and Methods for Fixing a Leadless Implant to Tissue
EP2433675B1 (en) * 2010-09-24 2013-01-09 Sorin CRM SAS Active implantable medical device including a means for wireless communication via electric pulses conducted by the interstitial tissue of the body
EP2627403A4 (en) * 2010-10-12 2014-03-26 Nanostim Inc Temperature sensor for a leadless cardiac pacemaker
JP2013540022A (en) 2010-10-13 2013-10-31 ナノスティム・インコーポレイテッド Leadless cardiac pacemaker with screw anti-rotation element
US20120095539A1 (en) * 2010-10-13 2012-04-19 Alexander Khairkhahan Delivery Catheter Systems and Methods
US20120095521A1 (en) * 2010-10-19 2012-04-19 Medtronic, Inc. Detection of heart rhythm using an accelerometer
US8666505B2 (en) * 2010-10-26 2014-03-04 Medtronic, Inc. Wafer-scale package including power source
US8825170B2 (en) 2010-10-29 2014-09-02 Medtronic, Inc. Low-power system clock calibration based on a high-accuracy reference clock
WO2012082755A1 (en) 2010-12-13 2012-06-21 Nanostim, Inc. Pacemaker retrieval systems and methods
EP2654889B1 (en) 2010-12-20 2017-03-01 Pacesetter, Inc. Leadless pacemaker with radial fixation mechanism
US10112045B2 (en) 2010-12-29 2018-10-30 Medtronic, Inc. Implantable medical device fixation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995010226A1 (en) * 1993-10-14 1995-04-20 Ep Technologies, Inc. Locating and ablating pathways in the heart
EP0758542A1 (en) * 1995-08-16 1997-02-19 Ats Medical, Inc. Heart valve prosthesis incorporating electronic monitoring and/or pacing circuitry
WO1999064104A1 (en) * 1998-06-12 1999-12-16 St. Jude Medical Ab Inflatable electrode for temporary pacing
WO2001000114A1 (en) * 1999-06-25 2001-01-04 Vahid Saadat Apparatus and methods for treating tissue
US20060085041A1 (en) * 2004-10-20 2006-04-20 Hastings Roger N Leadless cardiac stimulation systems
US20070106357A1 (en) * 2005-11-04 2007-05-10 Stephen Denker Intravascular Electronics Carrier Electrode for a Transvascular Tissue Stimulation System

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8478408B2 (en) 2004-10-20 2013-07-02 Boston Scientific Scimed Inc. Leadless cardiac stimulation systems
US9072911B2 (en) 2004-10-20 2015-07-07 Boston Scientific Scimed, Inc. Leadless cardiac stimulation systems
US10493288B2 (en) 2004-10-20 2019-12-03 Boston Scientific Scimed Inc. Leadless cardiac stimulation systems
US9925386B2 (en) 2004-10-20 2018-03-27 Cardiac Pacemakers, Inc. Leadless cardiac stimulation systems
US11154247B2 (en) 2005-12-09 2021-10-26 Boston Scientific Scimed, Inc. Cardiac stimulation system
US11766219B2 (en) 2005-12-09 2023-09-26 Boston Scientific Scimed, Inc. Cardiac stimulation system
US10022538B2 (en) 2005-12-09 2018-07-17 Boston Scientific Scimed, Inc. Cardiac stimulation system
US8050774B2 (en) 2005-12-22 2011-11-01 Boston Scientific Scimed, Inc. Electrode apparatus, systems and methods
US7937161B2 (en) 2006-03-31 2011-05-03 Boston Scientific Scimed, Inc. Cardiac stimulation electrodes, delivery devices, and implantation configurations
US11338130B2 (en) 2006-07-21 2022-05-24 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US8185213B2 (en) 2006-07-21 2012-05-22 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US10426952B2 (en) 2006-07-21 2019-10-01 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US9308374B2 (en) 2006-07-21 2016-04-12 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US9662487B2 (en) 2006-07-21 2017-05-30 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US7840281B2 (en) 2006-07-21 2010-11-23 Boston Scientific Scimed, Inc. Delivery of cardiac stimulation devices
US8644934B2 (en) 2006-09-13 2014-02-04 Boston Scientific Scimed Inc. Cardiac stimulation using leadless electrode assemblies
US9956401B2 (en) 2006-09-13 2018-05-01 Boston Scientific Scimed, Inc. Cardiac stimulation using intravascularly-deliverable electrode assemblies
US9795797B2 (en) 2008-02-07 2017-10-24 Cardiac Pacemakers, Inc. Wireless tissue electrostimulation
US10307604B2 (en) 2008-02-07 2019-06-04 Cardiac Pacemakers, Inc. Wireless tissue electrostimulation
US9393405B2 (en) 2008-02-07 2016-07-19 Cardiac Pacemakers, Inc. Wireless tissue electrostimulation
US8204605B2 (en) 2008-02-07 2012-06-19 Cardiac Pacemakers, Inc. Multi-site atrial electrostimulation
US8738147B2 (en) 2008-02-07 2014-05-27 Cardiac Pacemakers, Inc. Wireless tissue electrostimulation
US10456553B2 (en) 2012-09-11 2019-10-29 Native Cardio, Inc. Device and methods for targeted tissue drug delivery
KR20150080491A (en) * 2012-09-11 2015-07-09 네이티브 카디오카슐러 엘엘시 Device and methods for targeted tissue drug delivery
CN107837453A (en) * 2012-09-11 2018-03-27 本土心血管公司 Apparatus and method for being administered to target tissue
KR102223218B1 (en) 2012-09-11 2021-03-04 네이티브 카디오카슐러 엘엘시 Device and methods for targeted tissue drug delivery
US10118014B2 (en) 2012-09-11 2018-11-06 Native Cardio, Inc. Device and methods for targeted tissue drug delivery
US11224718B2 (en) 2012-09-11 2022-01-18 Native Cardio, Inc. Device and methods for targeted tissue drug delivery
WO2014043039A1 (en) * 2012-09-11 2014-03-20 Native Cardiocascular Llc Device and methods for targeted tissue drug delivery
CN105142719A (en) * 2012-09-11 2015-12-09 本土心血管公司 Device and methods for targeted tissue drug delivery
EP2862594A1 (en) * 2013-10-17 2015-04-22 BIOTRONIK SE & Co. KG Active, reversible fixing of CRT electrodes
US10583301B2 (en) 2016-11-08 2020-03-10 Cardiac Pacemakers, Inc. Implantable medical device for atrial deployment

Also Published As

Publication number Publication date
US8738147B2 (en) 2014-05-27
US8204605B2 (en) 2012-06-19
US20090204170A1 (en) 2009-08-13
WO2009099550A1 (en) 2009-08-13
US20140236172A1 (en) 2014-08-21
US20160310750A1 (en) 2016-10-27
JP2011510787A (en) 2011-04-07
US9393405B2 (en) 2016-07-19
EP2254663B1 (en) 2012-08-01
US9795797B2 (en) 2017-10-24
EP2254663A1 (en) 2010-12-01
JP5153892B2 (en) 2013-02-27
US20090234407A1 (en) 2009-09-17
US20190255336A1 (en) 2019-08-22
US10307604B2 (en) 2019-06-04
US20170259070A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
US8204605B2 (en) Multi-site atrial electrostimulation
US10252063B2 (en) Leadless intra-cardiac medical device with built-in telemetry system
JP4995090B2 (en) Lead-free cardiac stimulation system
US9592399B2 (en) Deployable multi-electrode leadless electrostimulator
US8050774B2 (en) Electrode apparatus, systems and methods
JP5074926B2 (en) Lead-free cardiac stimulation system
JP2004508149A (en) Subcutaneously implantable defibrillator and optional pacemaker
CA2869743A1 (en) Minimally invasive epicardial pacemaker
CN114340724A (en) Cardiac stimulation system
WO2021058555A1 (en) A system for holding an active implant in an atrial appendage of a heart and methods for implanting an active implant
Santos et al. Atrial defibrillation using low tilt pulses delivered by transcutaneous RF coupling

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09708174

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09708174

Country of ref document: EP

Kind code of ref document: A1